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Abstract 
Fused Deposition Modelling (FDM) is a variant of 3D Printing (3DP) that relies on the 
melt extrusion of thermoplastic polymers for the fabrication of objects. Using FDM, 
objects with customised geometries, mass, shapes, and dimensions can be printed on-
demand. This customisability makes FDM a robust method for creating patient-tailored, 
personalised dosage forms. Therefore, the past few years have seen an increase in research 
demonstrating the use of FDM to produce solid dosage forms. Various research efforts 
have demonstrated the capacity of FDM to create dosage forms with customised 
geometries, tailored release profiles, and polypills containing multiple drugs. However, 
there remains no commercially available products are produced by FDM. This may be 
due to reported works describing the use of FDM as a pharmaceutical manufacturing 
process often employ a trial-and-error approach to arrive at a formulation, with little work 
demonstrating a thorough understanding of the FDM process and the involved parameter 
interactions as a whole. The work presented herein describes an investigation into the 
parameters involved in FDM, and their impact on the perceived quality parameters of 3D 
printed solid dosage forms, which should help to guide towards a more rational approach 
towards FDM printable dosage forms.  
 
The work conducted herein investigated material properties, and FDM printing speed, 
printing temperature, and infill density, and their impact on perceived quality attributes 
of the printed dosage forms. Optimising the mechanical properties of the filament was 
found to be the rate limiting in creating a printable formulation. Chapter 3 describes a 
method developed to predetermine the mechanical suitability of a filament for FDM. 
Chapter 4 describes an investigation into the critical quality parameters of FDM, in which 
printing speed was found to have greater impact on the quality of printed dosage forms 
than printing temperature. Furthermore, a distortion effect related to material melt flow 
was observed and described, which is dubbed the First Layer Effect. Chapter 5 
demonstrated how the use of the infill process parameter  can be used to manipulate the 
drug release rate from a 3D printed dosage form and tune the formulation to a range of 
release characteristics ranging from an immediate release formulation to a sustained 
release and even a delayed release formulation without the need to alter the constituents 
of the printed dosage form.   
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1.1. 3D printing for oral solid dosage forms, the solution to Personalised 
Medicine?  
1.1.1. The personalised medicine challenge: 
In recent years, it has been observed that an increasing number of marketed drugs, drugs 
under development, and New Chemical Entities (NCEs) being screened for 
pharmacological activity are more likely to be hydrophobic molecules, possessing poor 
aqueous solubility (Figure 1-1). This increase in the number of poorly water-soluble drug 
substances is believed to be correlated with a trend in pharmacotherapy to favour 
molecules that exhibit higher potency. Potency which is mediated, at least in part, by 
hydrophobic interactions between the molecule and the corresponding receptors in the 
body (1). This creates a problem for formulation scientists; most NCEs and drugs under 
development are likely to be formulated as oral solid dosage forms, which dictate that the 
drug substance must possess at least a minimum threshold of aqueous solubility for the 
formulation to be adequately bioavailable (2,3).  
 
 
Figure 1-1: comparison of the distribution of the solubility of the top 200 oral drugs around the 
world. Figure obtained from Williams et al. (1). 
 
Furthermore, the advent of therapeutic regimens involving potent pharmacotherapeutic 
drugs led to an increased understanding of the individualised needs of different patients. 
The “one-size-fits-all” approach to pharmacotherapy has proven to be less than suitable 
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for therapy monitoring and prognosis assessment. Which in turn led to the birth of the 
field of personalised medicine, which is the premise that different patients will always 
have genetic differences (and by extension, metabolic differences) that require different 
doses of the same drug substance to achieve an equivalent therapeutic effect. This, in turn, 
bottlenecks formulation development; most pharmaceutical manufacturing techniques 
have been adapted and optimized for quick and consistent production of large quantities 
of static doses of drug substances. Therefore, formulating potent drug substances while 
allowing for dosing personalization requires revamping of techniques and manufacturing 
processes used in the pharmaceutical industry (4,5). 
 
Yet another issue that needs to be addressed when discussing personalised medicine is the 
increasing number of polypharmacy patients (6). A polypharmacy patient is defined as a 
patient undergoing a therapeutic regimen requiring 5+ tablets to be administered daily, a 
phenomenon that is becoming increasingly prevalent, particularly in geriatric patients (7–
9). Being on a polypharmacy regimen is a known cause of poor patient compliance with 
the therapeutic regimen, which negatively affects disease prognosis and could lead to life-
threatening complications (6).   
 
There have been a few efforts aimed at developing dosage forms that allow for dosing 
flexibility and personalisation, such techniques include the formulation of drugs into 
liquid dosage forms (in which the volume corresponding to the desired dose is measured 
and administered to the patient) (10), fragmented solid dosage forms (like granules, 
pellets, or mini-tablets(, in which a single unit (i.e. a single granule) contains a fraction 
of the dose, with the desired dose being achieved by counting or weighing the number of 
units required to achieve the prescribed dose. Scored tablets (which can be broken or cut 
to achieve fractions of the larger dose contained within an entire tablet) have also been 
investigated as a method to allow dose personalisation (4). Fixed-dose combination 
formulations have been conceived and are marketed as a method to circumvent the 
inconvenient number of tablets a polypharmacy patient has to take daily, but as the name 
suggests, they are “fixed dose” combinations and allow very little in terms of dosing 
personalisation (11). Therefore, it comes as no surprise that those techniques have, 
however, proven mostly inadequate, particularly in therapeutic regimens involving very 
potent drugs, due to either human error (patients on therapeutic drug regimens involving 
potent drugs are more likely to be geriatric patients (7,9,12) who are less capable of 
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accurately measuring the required dose), or instrument error due to unstandardized 
measurement apparatus (i.e. a tablespoon, a teaspoon, half a tablet) (4,10). 
 
One dosing personalisation technique that has generated considerable interest in the past 
few years is 3D printing (3DP) (13). 3DP was pioneered in the late 20th century as a rapid 
prototyping, high-throughput fabrication method for engineering applications. However, 
the past few years have seen a rise in the number of affordable “desktop” 3D printers 
aimed at the general public. With the technique becoming less specialised for niche 
applications, and more suitable (both in terms of cost and complexity) for hobbyists. 
Which led to the technique being explored for applications in a number of different 
industries (14). The technique has since found applications in the healthcare industry, 
being used as means to fabricate medical devices, artificial limbs, pharmaceutical dosage 
forms, and even live human tissue (13,15–17). The use of 3DP as a method for the 
manufacture of pharmaceutical dosage forms is discussed in section 1.2 below.   
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1.2 Pharmaceutical 3D printing: current advancements and trends  
3DP has generated a lot of research interest within the pharmaceutical industry, mainly 
due to it seemingly holding the key to solving the challenge the industry is facing in terms 
of personalised medicine (15,18,19). It has been postulated numerous times that, due to 
the sequence of events through which 3DP fabricates an object, it is possible to 
manufacture dosage forms consisting of multiple drugs in hybrid dosings, adapted to the 
needs of a particular patient, by embedding different drugs in different layers of the same 
unit dosage form (20). The prospects promised by 3DP were further cemented in 2015 
when the United States Food and Drug Administration (US FDA) approved for 
commercialisation the first 3D printed pharmaceutical product, Spritam®, manufactured 
by pharmaceutical company Aprecia Pharmaceuticals (21). Although Spritam® is 
manufactured via 3DP, it does not utilise the full capabilities made possible by 3DP. 
Spirtam® is a mass-manufactured dosage form that is produced only as a single, 1000 mg 
dose of a single drug, levitracetam, and does not utilise the capabilities offered by 3DP 
for dose personalisation. However, the FDA authorisation of this 3D printed drug does 
show prospects in the possibility of general acceptance of marketing dosage forms 
manufactured by 3DP. 
 
The term “3DP” does not refer to a particular technology. It is rather an umbrella term 
that is used to refer to a number of different techniques that fabricate objects by additive 
manufacturing (AM). AM is a fabrication process in which the object is built up 
sequentially by the superimposition of layers of material atop one another (Figure 1-2). 
The main difference between the different variants of 3DP is the materials they utilise, 
and their material deposition mechanism (5,13). Variants of 3DP include Powder-Based 
Printing (PBP), Stereolithography (STL), Semi-Solid Extrusion (SSE), Selective Laser 
Sintering (SLS), and Fused Deposition Modelling (FDM) (22–26). Of all the variants of 
3DP, PBP has been the most pharmaceutically successful, being, to date, the only variant 
of the technology to successfully bring a product to the market, with the product Spritam® 
(1000 mg levitracetam) becoming the first 3D printed drug to gain FDA approval (21). 




Figure 1-2: Layer superimposition to form the 3D object during 3DP 
 
1.2.1. Powder-bed 3D printing: 
PBP is a variant of 3DP technology that utilizes the controlled distribution of thin layers 
of powders. During a PBP printing run, a layer of powder is spread on the build plate, the 
layer is then glued together by the action of droplets of binder solution that are sprayed 
on it, followed by addition of a second layer of powder and so on. The process is 
continued layer-by-layer until completion of the build (13,27). 
 
 
Figure 1-3: Powder bed 3DP. Figure obtained from Alhnan et al. (13). 
 
The use of PBP for the fabrication of pharmaceutical dosage forms has been widely 
described, with the technique being investigated to fabricate tablets with modified release 
profiles (15). Yu et al. used PBP to fabricate fast-disintegrating tablets of paracetamol 
(28), Pryce-Lewis et al. was awarded a patent for his design of powder-bed printed, 
cylindrical drug delivery systems (29). And, as previously mentioned, Spritam®, an 
immediate-release formulation of levitracetam, became the first 3D printed drug to gain 
US FDA approval in August 2015 (21). Spritam® is manufactured via PBP, it employs a 
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technology that manufacturer Aprecia Pharmaceuticals has dubbed ZipDose® technology 
(30). The technology is claimed to provide very rapid disintegration, coupled with high 
drug loading whilst providing efficient taste masking (31).  
 
The main drawbacks associated with PBP are the friability and high porosity of the 
finished products, as well as the low printing resolution, and the post-printing processing 
required to achieve the finalized product (13).  
 
Despite the fact that PBP is generally considered a variant of 3DP, it is worth noting that, 
from a materials perspective, PBP offers little variation from wet granulation techniques 
commonly used in the pharmaceutical industry; in wet granulation, powders are blended 
and formed into granules by the addition of a binder solution and are then compressed to 
form a tablet (32). In PBP, the same “powder held by a binder solution” logic is used, 
albeit with a different processing route. Which suggests that the technique may suffer 
from similar challenges to those faced by traditional, punch-pressed tablets; such as loss 
of mechanical strength over the shelf life of the product, tendency to friability, and need 
for coating to manipulate drug release.  
 
1.2.2. Stereolithographic 3D printing: 
STL is a variant of 3DP technology. Fabrication is done via controlled exposure of 
photopolymeric resins to UV radiation, causing curing of the resins to form the solid 
object. In STL, lens-focused UV radiation is deflected by a rotating mirror onto the top-
most layer of the photosensitive resin which rests on a build plate. The UV radiation 
causes curing and hardening of the material, the build plate is then lowered along the Z-
axis by a set amount to allow the addition of a second layer on top of it (Figure 1-4), with 
the movement of the mirror and the plate controlled by computer software (23). Polymers 
which have been investigated for use in STL include low molecular weight methacrylates, 
as well as mono- and macro- polymeric epoxy resins. Those polymers often form rigid, 




Figure 1-4: Printing mechanism used in STL. Figure obtained from Alhnan et al. (13) 
 
There have been attempts to utilise STL as a method for manufacturing pharmaceutical 
solid dosage forms. Robles-Martinez et al. used STL to fabricate six-layered, stratified 
polypills, with each layer hosting a drug (prednisolone, chloramphenicol, caffeine, 
paracetamol, aspirin, and naproxen) (33). The printing was conducted using a stop-start 
method in which the printer needs to be paused after each drug layer was printed, to swap 
the resin in the printer for one containing the next drug. Healey et al. used STL 3DP to 
produce caplets containing either paracetamol or aspirin (34).   
 
Despite its high printing resolution (layer thickness ≈ 0.2 µm), STL is generally 
considered to be a poor candidate for pharmaceutical adaptation due to its several 
disadvantages; most photo-curable resins suitable for STL are carcinogenic, their 
photosensitivity suggests that they are most likely to be unstable and susceptible to photo-
degradation, and the use of UV radiation during manufacturing can degrade some of the 
drugs being printed (13). Products fabricated via STL often require additional curing 
following printing which makes it a less time-efficient process in comparison to some of 
its counterparts (23). Furthermore, because the tablet being printed is submerged in the 
resin from which it is cured. Drug migration to and from the resin may be a concern. This 
phenomenon was particularly notable in the experiment Robles-Martinez et al. mentioned 
prior (33), in which almost every layer in the printed tablets was contaminated with at 
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least one drug which was meant to reside in a different layer within the matrix of the 
tablet.  
 
1.2.3. Selective Laser Sintering: 
SLS can be considered the ambient variant of PBP. SLS printing uses a powder bed as 
raw materials for the build, the powder is fused via the use of a high-intensity laser which 
serves to liquefy and fuse the powder particles, resulting in the fusion of the powder into 
a solid layer (13).  
 
Figure 1-5: Selective laser sintering. Figure obtained from Alhnan et. al (13). 
 
The use of SLS for the fabrication of pharmaceutical dosage forms has not been explored, 
which could be attributable to either the high-intensity laser used in the process, which 
has the potential to degrade most drugs or to the fact that materials that are laser-curable 
are often carcinogenic and are suitable for drug delivery applications (13).  
 
1.2.4. Semi-solid Extrusion: 
SSE printing involves the layer-wise extrusion of semi-solid pastes through a syringe (13). 
The pastes used in said formulations are often mixtures of drug/polymer/solvent systems 
whose viscosity was optimised to be extrudable through the printer syringe (24).  
 
Khaled et al. used SSE to fabricate a 5-in-1, hybrid release profiles polypill, consisting of 
an immediate-release compartment housing aspirin and hydrochlorothiazide, and a 
sustained release compartment housing pravastatin, ramipril and atenolol (35). Khaled et 
al. also used SSE to produce guaifenesin-loaded HPMC bi-layer tablets (24). Kyobula et 
al. used SSE to print fenofibrate-loaded beeswax tablets (36) 
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The main drawback of SSE lies in semi-solid nature of the starting materials, which shrink 
upon drying, compromising the geometrical integrity of the fabricated tablet. Furthermore, 
the fabricated structures are very likely to collapse if a layer did not harden sufficiently 
before the addition of the next (13). There have been attempts to circumvent this 
drawback, by using an SSE – STL hybrid printing technique in which the semi-solid gels 
printed are made from curable resins, which are cured by UV light immediately upon 
printing (37).  
 
1.2.5. Fused Deposition Modelling: 
FDM is perhaps the most commercially available variant of 3DP (5). The availability of 
low-cost, FDM-based desktop 3D printers has caused a boost in the interest of using 
utilizing FDM (16). For Pharmaceutical 3D Printing (P3P), FDM is especially more 
attractive than other AM techniques. FDM is, in the most abstracted form, a melt 
extrusion technique, which makes it readily utilisable for polymeric drug delivery 
applications, namely amorphous solid dispersions (ASDs) (2,38).  
 
In a typical FDM printing run, a thermoplastic polymer (which had previously been 
shaped into a thin strand called a filament), is fed into the printer by the action of two 
counter-rotating rollers. The feeding rollers carry the filament to a heating zone where the 
filament heated to a temperature beyond its melting point to form a melt, which is then 
deposited as a layer on the build plate through a nozzle. For the type of printer used herein, 
the maximum operational temperature the print head may be used at is 250 °C (39). The 
mechanical assembly consisting of the feeding rollers, heating zone, and the nozzle are 
collectively referred to as the printing head. After the melt exits the printing head, it is 
deposited onto the build plate to form a layer, this is then followed by the previously 
described downwards movement of the build plate to allow for a second layer to be 





Figure 1-6: An illustration of FDM. 
 
Out of all the variants of 3DP described in prior sections, FDM is seemingly the most 
attractive for pharmaceutical applications, with various research efforts demonstrating its 
feasibility; Goyanes et al. used commercial PVA filaments loaded with fluorescein as a 
model drug to demonstrate the feasibility of the technique for printing tablets (16), 
Goyanes also used FDM to print commercial PVA filaments loaded with 4-, and 5-
aminosalicylate (4-ASA and 5-ASA respectively) (26), Skowyra et al. used FDM to print 
prednisolone-loaded, commercial PVA filaments (18). This loading of commercial 
filaments is achieved by incubation of the filament in an organic solution of the drug 
substance. A method that, although feasible, is noted for its inability to achieve 
sufficiently high drug loading percentages (Table 1-1). (9).  
 
Table 1-1: the poor loading percentages of printed dosage forms prepared by incubation of 
commercial filaments 
Drug Polymer Loading percentage  Reference 
4-ASA PVA 0.236% w/w (26) 
5-ASA PVA 0.063% w/w (28) 
Fluorescein PVA 0.29% w/w (16) 
Prednisolone PVA 1.9% w/w (18) 
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Pietrzak et al. used Hot-Melt Extrusion (HME) to prepare filaments of solid dispersions 
of theophylline, loaded in hydroxypropyl cellulose (HPC), Eudragit® RS PO, Eudragit® 
RL PO, and Eudragit® EPO, demonstrating that, when used in conjunction with HME, 
FDM has the potential to produce formulations possessing adequate drug loading, and 
greatly expanding the number of materials that may be used for P3P applications (44).  
  
Alhijjaj et al. described the fabrication of a 5-component matrix containing either 
Eudragit® EPO, Soluplus®, or PVA, plasticised with polysorbate (Tween®) 80, 
polyethylene oxide (PEO) N10, and polyethylene glycol (PEG) 4000 with felodipine as 
a model drug and the fifth component of the matrix. Alhijjaj noted that the unavailability 
of pharmaceutically relevant materials suitable for P3P applications is the primary 
challenge against the development of commercially scaled FDM printing processes in the 
pharmaceutical industry (43).  
 
A second challenge that stands in the way of successful commercialisation of P3P lies in 
the barrier posed by regulatory bodies (20). Regulatory bodies, such as the FDA and the 
Medicines and Healthcare Products Regulatory Agency (MHRA) require the 
demonstration consistency and reliability during manufacturing; the tried-and-tested 
methods that have been employed in the pharmaceutical industry for decades are 
considered to be more trusted, and by extension, safer than a newcomer technology like 
3DP (45). However, the introduction of process exploratory paradigms such as 
pharmaceutical Quality Risk Management (QRM) and Quality by Design (QbD) by the 
US FDA provided pharmaceutical manufacturers with a margin of freedom to explore 
innovative approaches to drug formulation and development, provided that they 
demonstrated satisfactory understanding of the Critical Process Parameters (CPPs) that 
govern a particular industrial process (46).  
 
Huang et al. grouped the CPPs relating to FDM into either one of three categories: 
machine-specific parameters, operation-specific parameters, and material-specific 






Table 1-2: Critical Process Parameters relating to FDM as reported by Huang et al. Table 
recreated from Huang et al. (47). 




























While the CPPs outlined by Huang et al. are limited to physical parameters, some 
literature suggests that slicing algorithms play a significant role in the overall quality of 
the printed object (48,49). Slicing is the process by which the computer-generated 3D 
model is translated into movement instructions for the printer motors. It should be noted, 
however, that the classification is described from the perspective of FDM as an 
engineering tool, and does not account for special requirements that are undoubtedly 
necessary for robust pharmaceutical adaptations. When characterising the FDM printed 
objects, the non-pharmaceutical literature is largely concerned with the surface roughness 
and tensile strength of the fabricated objects (40,50–53). In pharmaceutical applications, 
where the FDM printed objects are intended to be used as solid dosage forms, achieving 
precise and highly reproducible dimensions and weight is critical. Thusly, the CPPs for 




Figure 1-7: Summary of the interactions between the materials properties and the machine and 
process parameters in an FDM 3D printing process. 
 
To date, FDM has been constrained to being explored only by repurposing commercial, 
hobbyist application 3D (16,18,26,43,44,54–57). Such commercial application printers 
do not allow the user to control some of the machine parameters described prior; 
parameters such as nozzle diameter, filament diameter, roller speed, feeding rate, flow 
rate, road width, head speed, infill pattern, and part orientation are pre-installed into the 
hardware and/or firmware of the printer, preventing the user from controlling said 
parameters freely, and at best offering the user the choice between a number of pre-
programmed presets relating to the aforementioned parameters (39).  
 
The main disadvantage of FDM lies in the fact that it is liable to induce thermal 
degradation of the pharmaceutical product due to the process requiring elevated 
processing temperatures. However, it is worth noting that thermal processing techniques 
like HME have been extensively used in the context of pharmaceutical manufacturing, 
and the relevant literature contains a wealth of information regarding the mitigation 
against the risks of thermal degradation (58–61). Furthermore, simple methods like 
Thermogravimetric Analysis (TGA) are capable of providing detailed information about 
the thermal stability of APIs and excipients being processed, and can be used to gain an 
understanding of the degradation temperature and residence time that a drug/excipient 
may be exposed before becoming liable to thermally decompose (62,63). 
 
In the present work, FDM was used in conjunction with HME to fabricate drug-loaded 
filaments for 3DP.  
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1.2.6. 3D printing terminology: 
As previously mentioned, 3DP is an umbrella term describing the mechanism by which 
the objects are fabricated. In the object-oriented engineering applications for which 3DP 
was conceived, this may be appropriate as the technology is used to produce parts that 
provide mechanical and geometrical functionality, regardless of the materials from which 
they are constructed (51,52,64), with some manufacturers offering the different variants 
of 3DP as alternative means to produce the same object (65). In the material-centric 
pharmaceutical applications, this equivalency is not applicable. The use of different 
materials to fabricate the same geometrical object will yield dosage forms that perform 
differently and are specialised to particular applications depending on the formulation 
constituents (i.e. different polymers produce different, pH-dependent drug release profiles 
(66)). For example, PBP utilizes powders and binder solutions, making it almost identical 
in formulation constituents to traditional tabletting techniques, and unrelated (from a 
materials perspective) to the continuous polymeric matrices used in FDM. Due to those 
differences, it is in the view of this writing that grouping all the different types of AM 
techniques under the umbrella term of “3DP” may lead to some ambiguity. FDM is 




1.3.  Phases of the solid state: crystalline and amorphous solids, and amorphous 
solid dispersions 
FDM, as previously mentioned, necessarily requires a polymeric matrix to be the primary 
formative material for the fabricated object (13,43,54,64,67). When preparing filaments 
for FDM, formulating the filament as an ASD, in which the drug is dispersed in the 
polymeric matrix, is often desirable to create sufficiently bioavailable dosage forms. The 
upcoming sections discuss some of the underlying theory regarding ASDs and their ability 
to increase the bioavailability of poorly soluble drugs.  
 
The use of polymeric matrices as vehicles for drug delivery applications is a well-
established method for improving the bioavailability of poorly water-soluble drugs 
(38,54,59,60,63,68–80). This is often achieved by molecularly dispersing the API to be 
formulated within the matrix of the chosen carrier polymer to form an amorphous solid 
dispersion (2,59,81,82).  
 
1.3.1. Crystalline versus amorphous: short, and long-range molecular order and its 
impact on dissolution properties: 
Solid materials exist as either crystalline, semi-crystalline, or completely amorphous 
materials. The terms “crystalline” and “amorphous” are two terms used to describe the 
organisation of the packing of molecules within the solid lattice. The main difference 
between the two lies in their molecular packing; crystalline solids tend to have precisely 
packed molecules based on a regularly shaped repeating unit, forming a continuous, long-
range order of molecules, while amorphous solids generally have short-range, 
discontinuous domains (Figure 1-8), with no regularly repeating patterns (38,83). 
Furthermore, crystalline materials are known to exhibit polymorphism (83–86), a 
phenomenon that arises when molecules of the same material can arrange themselves in 
different arrangements (Figure 1-9), yielding chemically identical, yet physically 
distinguishable crystalline forms. The existence of what is known as “polyamorphous” 
solids is a debated idea (38). However, the pharmaceutical relevance of polyamorphous 
phases is yet to be described (38) 
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Figure 1-8: A representation of the molecular packing of an amorphous solid structure (right) 
vs. a crystalline solid structure (left). 
 
The physical phenomenon of melting, otherwise known as fusion, is the endothermic 
destruction of the crystal lattice of a solid, resulting in the thermodynamic event that is 
the phase transition from solid to liquid. The melting temperature (Tm) of a crystal is a 
defining physical characteristic of that particular crystal (83,87). Amorphous materials, 
on the other hand, do not exhibit melting in the strict definition; on exposure to heat, 
amorphous materials will exhibit either an increase or a decrease in heat capacity (relative 
to the direction of the heat gradient) once the applied temperature crosses the threshold 
of the glass transition (Tg). This transition is a kinetic event that may be shifted or even 
bypassed by varying the rate of change in the heating gradient (38,88). 
 
  
Figure 1-9: Polymorphs of paracetamol. Left: monoclinic (Form I) form. Right: Orthorhombic 
(Form II) form. (89) 
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Amorphous solids are particularly of interest in the pharmaceutical industry due to their 
ability to enhance the dissolution of poorly water-soluble drugs (80). It has been 
postulated that receptor affinity (and by extension, the efficacy) of pharmacologically 
active molecules is directly correlated with their capacity to exhibit lipophilic interactions 
with the target receptors (3), which could be the reason why most drugs fall into class II 
in the biopharmaceutical classification system (BCS) (Figure 1-10) (1). Enhancing the 
aqueous solubility of BCS class II drugs is often regarded as the deterministic factor in 
their successful formulation (90).  
 
 
Figure 1-10: Biopharmaceutical classification system classes. Figure recreated from Wu & 
Benet (3). 
 
The preparation of amorphous solids is generally carried out by suddenly and very rapidly 
forcing the material into the solid state, which does not allow enough time for the 
molecules to arrange themselves and establish the more thermodynamically stable long-
range ordered domains, resulting in solid whose molecules are arranged in discontinuous, 
short-range domains possessing higher free energy than its crystalline counterpart 
(38,91,92). Systems possessing higher free energy spontaneously tend towards relaxation, 
whether by recrystallisation or via dissolution. A common metaphor for amorphous solids 
is the compressed spring; a compressed spring has a large amount of stored potential 
energy that, once the opportunity allows for the spring to relax, it will spontaneously jump 
back into the uncompressed state. Similarly, when provided with the opportunity to 
escape the strained, thermodynamically unstable amorphous conformation (i.e. when 
placed in an aqueous medium, allowing it to dissolve), an amorphous solid will 
spontaneously jump to the more thermodynamically favourable dissolved state (56). In 
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lay terms, a molecule would prefer “escaping” to the dissolved state than remaining in 
the high-strain amorphous state.   
 
This phenomenon may be more formally described by the change in Solution Free Energy 
(∆𝐺𝑠) equation:  
 
∆𝐺𝑠 = 𝐺𝑃 + 𝐺𝐶 + 𝐺𝑆𝑜𝑙    (Equation 1-1) 
 
where GP is the Packing Free Energy; the net free energy on the disruption of the packing 
of the lattice of the solute to liberate a single molecule. GC is the Captivation Free Energy, 
the net free energy change when solvent molecules expand to create a cavity which can 
accommodate the liberated solute molecule, and GSol is the Solvation Free Energy; the net 
free energy change due to the spontaneous formation of solvent-solute interactions. For 
dissolution to occur, ∆𝐺𝑠 < 0. Which implies that the 𝐺𝑆𝑜𝑙  < (𝐺𝑃 +  𝐺𝐶). In other words, 
dissolution is thermodynamically favoured when the energy released due to the formation 
of solvent-solute interactions (𝐺𝑆𝑜𝑙) is larger than the energy consumed disrupting the 
solvent (change in 𝐺𝑆) and solute (change in 𝐺𝑃) molecules to accommodate dissolution.  
 
Since crystalline solids are, by definition, highly stable conformations due to the 
organised packing of molecules within the crystal lattice, their 𝐺𝑃 often tends to be much 
larger than the net sum of 𝐺𝐶
  and 𝐺𝑆𝑜𝑙 . Making dissolution less thermodynamically 
favoured than maintaining the stable conformation of the crystalline phase. On the other 
hand, amorphous conformations are thermodynamically unstable, and therefore highly 
strained structures (38) and possess more stored potential energy, and thus have a lower 
𝐺𝑃 figure and are less thermodynamically stable. Due to their decreased thermodynamic 
stability, amorphous solids spontaneously favour the dissolved state over their strained 
amorphous conformation.  
 
The main challenge in the formulation of amorphous solids lies in their physical 
instability; they are very likely to recrystallise throughout the shelf life of the drug due to 
the formation of nuclei which serve as the basis for the formation of crystals (83). 
However, incorporation of amorphous solids into polymeric matrices to form solid 
dispersions has been demonstrated to inhibit nucleation and improve the physical stability 
of amorphous solids (2,72,93).  
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1.3.2. Solid Dispersions: 
In its simplest definition, a solid dispersion is a binary system in which one material is 
molecularly dispersed within the matrix of another (1,59,92). Systems consisting of a 
drug (regardless of solid state) with a matrix consisting of either a sugar, emulsifier, small 
molecule, or a polymer (regardless of whether a glass or an eutectic mixture was formed) 
have all been traditionally described as solid dispersions (92,94). In recent years, the 
convention in the pharmaceutical literature has become to use the term solid dispersion 
to describe a system in which an API is molecularly dispersed within the matrix of a 
polymer (59,74,92). Such systems are also often dubbed solid solutions (69), this term is 
likely arising from the common solute/solvent metaphor used to describe the dispersed 
API and the polymeric matrix respectively. This metaphor extends past terminology, as 
the use of theoretical solubility models has been reported as a method to approximate 
drug-polymer compatibility (70,78,95,96). 
 
As previously discussed, the rationale behind formulating a pharmaceutical product as a 
solid dispersion stems from the need to enhance its oral bioavailability by increasing the 
apparent aqueous solubility of the drug (1,59). For solid dispersions to successfully 
improve the bioavailability of BCS-Class II drugs, the drug should remain molecularly 
dispersed and not crystallise out of the polymeric matrix throughout the entire shelf-life 
of the dosage form (1,70,97). Those stability requirements require that the drug be 
miscible with the polymer during production, and must remain thermodynamically stable 
(or possibly kinetically stable, if the rate of the recrystallisation process is sufficiently 
slow) throughout the shelf-life of the product (38,71,74,97–103).  
 
Miscibility of two components in a thermodynamically closed system, when expressed 
as a function of the net energy change induced by their interactions during mixing, can 
be expressed in terms of the change in the Gibbs Free Energy of the system (96,104,105):  
 
∆𝐺𝑚𝑖𝑥 =  ∆𝐻𝑚𝑖𝑥 −  𝑇 ∗ ∆𝑆𝑚𝑖𝑥   (Equation 1-2) 
 
Where ∆Gmix is the change Gibbs Free Energy of the system, while ∆Hmix and ∆Smix are 
the change in enthalpy of mixing (net energy liberated or absorbed during mixing) and 
change in entropy (disorder) at temperature T, respectively. Two components are said to 
be miscible if ΔGmix is negative (∆Hmix < 𝑇∆Smix). In other words, miscibility is favoured 
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at temperature T when the degree of disorder of the system is greater than the net energy 
change brought about by mixing the two components of the system.  
 
The present worked used HME to prepare ASDs of paracetamol dispersed in HPMCAS 
(Chapter 3, Chapter 5), and three different formulations of acetylsalicylic acid dispersed 
in PCL (Chapter 4). HME is a commonly used method for preparing ASDs 
(72,93,103,106,107). During the HME process, the drug and polymer are heated to the 
molten state. At that elevated temperature, the drug becomes more readily miscible with 
the polymer. The increased polymer chain mobility and the elevated temperature increase 
the degree of disorder in the system (T∆Smix), if the increase in the entropy of mixing is 
sufficient to exceed ∆Hmix, the drug and polymer become miscible inside the extruder, 
forming a homogenous melt.  
 
Once retrieved and allowed to cool back to a solid, the drug-polymer mixture must remain 
sufficiently stable and homogenous. Instability of solid dispersions manifests as 
recrystallisation of the drug, causing it to phase-separate from the matrix, and is attributed 
to inadequate drug-polymer interactions (81,92,99). A number of theoretical methods for 
predicting drug-polymer miscibility exist (78). Experimentally, observing the formation 
of drug-polymer interactions can be done by detecting the formation of hydrogen bonds 
or dipole-dipole interactions between the polymer and drug (69–71,77,101,108–112). 
One may consider this practical approach an extension of Hansen’s theory of solubility, 
what is known as the “like dissolves like” principle; the principle that a solvent may 
dissolve a solute if the solvent-solute molecules interact in a manner similar to how the 
molecules of each interact with themselves. ASDs that remain stable in the absence of 
any distinct drug-polymer interactions are said to be kinetically stable (78,113,114).  
 
In the present work, the paracetamol ASDs were found to be stable, as no crystals of 
paracetamol were observed in the finished formulation. However, two of the 
acetylsalicylic acid formulations were found to be unstable, with phase separate drug 
crystals being detectable in both formulations. When characterised by infrared 
spectroscopy, the paracetamol-HPMCAS ASD was observed to be kinetically stable, as 
no distinct HPMCAS-paracetamol interactions were observed (Section 3.3.1.). Of the 
three acetylsalicylic acid formulations, the formation of hydrogen bonds was observed 
between the drug and the polymer only in the one formulation found to maintain a stable 
ASD.   
38 
1.4. Aims and objectives 
As previously discussed in section 1.2.5., the CPPs governing P3P are still not very well 
understood. Furthermore, the absence of regulation means that there is no agreed upon 
standard 3D printer. Variations between different brands of 3D printers will inadvertently 
introduce brand-specific oddities, making consistent reproduction of 3D printed dosage 
forms more challenging, thus adding another barrier towards commercialization.  
 
Despite this lack of standardization, Hsiao et al. noted that the Makerbot® Replicator 3D 
Printer has  “spearheaded” the P3P movement (56). Observing the convention in the 
literature, it indeed appears as though the Makerbot® Replicator 2 has become a de facto 
standard of P3P (16,18,26,43,44,54,55,57). A particular brand being conventionally 
popular for P3P applications does not automatically indicate its suitability for such 
applications; the Makerbot® Replicator 2 was not designed to be a Good Manufacturing 
Practices (GMP) compliant machine. However, its popularity among pharmaceutical 
scientists means that it can serve as a metaphorical “yardstick”, by which we can 
investigate the capabilities and limitations of P3P, and possibly describe some of the 
design requirements of a GMP-compliant 3D printer by observing the shortcomings of 
the current “de facto standard” printer.  
 
The work presented herein attempted to serve as an investigation of the capabilities and 
limitations of the current form of P3P via a systematic investigation of some of the 
accessible CPPs outlined in Figure 1-7. The parameters investigated were:  
 Mechanical properties of filaments and their impact on the feedability of a 
filament.  
 Process parameters (printing speed and printing temperature) and their impact on 
the weight and dimensions of the 3D printed objects, and the reproducibility of 
printing at different process conditions.  









Chapter 2  








2.1.1.  Acrylonitrile Butadiene Styrene and High-Impact Polystyrene: 
Acrylonitrile Butadiene Styrene (ABS) and High-Impact Polystyrene (HIPS) are 
amorphous, thermoplastic polymers (115) that are synthesised via the incorporation of 
butadiene rubbers into either styrene-acrylonitrile (in the case of ABS) or polystyrene (in 
the case of HIPS) (116,117). ABS and HIPS possess various attractive properties which 
makes them a staple of the plastic industry; both polymers are readily mouldable, 
possesses high chemical resistance, and high impact strength (12, 13, 14). ABS and HIPS 
are commonly used in various manufacturing industries including toys, automotive, 
protective gear, electronics, and piping (116–118). In recent years, the two polymers have 
been used to produce filaments for FDM 3DP. ABS is regarded as the “de facto standard” 
FDM printing filament (14), with various 3D printer manufacturers offering ABS 
filaments as the standard filament for FDM printing. HIPS is commonly used in FDM as 
a support material due to its ability to be selectively dissolved by limonene without 
affecting the ABS (119).  
 
Figure 2-1: Chemical structure of ABS (left) and HIPS (right). Figures retrieved from Okada et 
al. (120) and Polymer Science Learning Center (121) respectively.  
 
ABS and HIPS were used in this work as reference materials for mechanical properties 
after which in-house made filaments were modelled. ABS was also used as a purge 
material to clean the 3D printer nozzle. ABS, and HIPS (MakerBot® Dissolvable 
Filament) used in this study was purchased as pre-extruded filaments from MakerBot® 
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Industries (Makerbot Industries LLC., New York, United States). Both materials were of 
an undeclared grade.   
 
2.1.2. Polyvinyl alcohol:  
Polyvinyl alcohol (PVA) is a synthetic, semi-crystalline, water-soluble polymer. PVA is 
available in different grades, from partially hydrolysed to completely hydrolysed grade. 
With a Tm ranging between 180 °C – 228 °C depending on the degree of hydrolysis 
(63,122,123).  PVA is commonly used to manufacture resins, lacquers, and textiles. It is 
also commonly used as a pharmaceutical coating material, a matrix former for the 
fabrication of solid dispersions, and as a food additive (54,63,74,76). PVA is also widely 
available in the form of commercial filaments for 3DP applications. Being one of very 
few pharmaceutically-relevant, 3DP-suitable polymers, commercially available filaments 
of PVA are very commonly used for P3P, with the drug being loaded either by 




Figure 2-2: Chemical structure of a PVA monomer. Figure recreated from The Handbook of 
Pharmaceutical Excipients (123) 
 
PVA used in this work was purchased as either pre-extruded commercial filaments from 
XYZprinting.com (XYZprinting Inc., California, United States) or as Mowiflex® C-17 
pellets, which are melt-extrudable pellets that yield filaments possessing suitable 
mechanical properties for 3DP (129). Mowiflex® pellets are pre-formulated pellets 
containing PVA and an undeclared plasticiser. Mowiflex® pellets used in this study were 
obtained as gratis from Kurary (Kurary GmbH, Frankfurt, Germany.  
 
2.1.3. Polycaprolactone: 
Polycaprolactone (PCL) is a semi-crystalline, hydrophobic, and biocompatible polyester. 




PCL is commonly used in parenteral formulations (123), and for fabricating implantable 
biomaterials and scaffolds (25,130,131). In recent years, PCL has also found use as a 
filament for 3DP applications (132).  
 
Figure 2-3: Structure of a PCL monomer. Figure retrieved from Deshmukh et al. (133) 
 
Two variants of PCL were used in this work; PCL commercial filaments were purchased 
from MakerBot® Industries (Makerbot Industries LLC., New York, United States). PCL 
pure powder (CAPA™, Lot #: 130115) was purchased from Perstorp Chemicals (Perstorp 
Chemicals GmbH, Arnsberg, Germany).  
 
2.1.4. Polyethylene Glycol/Polyethylene Oxide:  
Polyethylene glycol (PEG), or polyethylene oxide (PEO) are two terms used to refer to 
the synthetic, semi-crystalline polyether of ethylene oxide (134). While the terms PEG 
and PEO describe a polymer comprising of the same repeating ethylene oxide subunit, 
they cannot be used interchangeably; the term PEG is used to refer to poly-[ethylene 
oxide] polymers whose molecular weight does not exceed 100,000, with the term PEO 
being reserved for poly-[ethylene oxide] polymers whose molecular weight exceeds 
100,000 (135). PEO and PEG typically possess a Tm of 60 °C (Figure 3-4) and a Tg of -





Figure 2-4: Chemical structure of a PEG/PEO monomer. Figure obtained from the Handbook 
of Pharmaceutical Excipients (123) 
 
PEG/PEO is very widely used in the pharmaceutical industry in topical, injectable, and 
oral dosage forms (123), and as a plasticiser for HME (19). Grades of PEG possessing a 
molecular weight between 3350 and 6000 are used clinically as a laxative, in which case 
they are commonly referred to by the international non-proprietary name (INN) macrogol 
(136). PEO grades of the polyether have been used to produce filaments for 3DP (54), 
making it one of the few pharmaceutically relevant polymers which are suitable for 3DP. 
PEG (molecular weight: 4000. Lot #: BCBP6905V) was obtained from Sigma Aldrich, 
(Sigma Aldrich, Salisbury, United Kingdom) and was used as a plasticiser for preparing 
filaments by HME. PEO (molecular weight: 100,000. Lot #: DT367148) used in this study 
was obtained as gratis from Colorcon (Colorcon Ltd., Dartford, United Kingdom) and 
was used both as a plasticiser for HME, and to create a reference filament for the 
mechanical properties screening.  
 
2.1.5. Polysorbate 80:  
Polysorbate (Tween) 80 is a fatty acid ester of a sorbitol-ethylene oxide copolymer. Tween 
80 is a hydrophilic, non-ionic surfactant and is commonly used as an emulsifier, and as a 
solubilising agent in topical, oral, and parenteral pharmaceutical preparations (123). 
Tween 80 has also been used as a plasticiser in HME (43,137). Tween 80 used in this 
study was purchased from Acros Organics (Acros Organics, Geel, Belgium. Lot #: 
BCBQ4189V).  
 
2.1.6. Hypromellose acetate succinate:  
Hypromellose acetate succinate (HPMCAS) is an amorphous, semi-synthetic cellulose 
derivative. The Tg of HPMCAS is 120 °C (Figure 3-4), depending on the grade. Its 
solubility is pH-dependant, with the three available grades all dissolving above pH 5.5 





Figure 2-5: Chemical structure of HPMCAS. Figure adapted from Shin Etsu (138). 
 
Due to its film forming properties and its pH-dependant solubility, HPMCAS was 
traditionally used as an enteric coating material to infer either pH-dependant or sustained 
release properties onto a tablet. HPMCAS since been employed in the manufacture of 
solid dispersions, both by HME and by spray drying (1,69,77,82,92,111).  
 
HPMCAS (Low-Fine grade: LF. Lot #: 60410001) used in this work was obtained as 
gratis from Shin Etsu (Shin Etsu Inc., Tokyo, Japan). 
 
2.1.7. Eudragit® EPO: 
Eudragit EPO is an amorphous, synthetic polymethacrylate copolymer that is commonly 
used as a film coating material in the pharmaceutical industry. It has a Tg of 45 °C (Figure 
3-3) (43,112). Eudragit EPO is soluble below pH 5 and swells to form a permeable matrix 
above pH 5 (123,139). Eudragit EPO has also been used to prepare nanoparticles (140), 





Figure 2-6: Chemical structure of Eudragit EPO. Figure obtained from Evonik Industries 
(139). 
 
Eudragit EPO used in this work was obtained as gratis from Evonik Industries (Evonik, 
Darmstadt, Germany. Lot #: G170331544). 
 
2.1.8. Soluplus®:  
Soluplus is a polyethylene-glycol–polyvinyl caprolactam–polyvinyl acetate graft 
copolymer that was purposely designed by BASF® for HME applications (141). It is a 
self-plasticised amphiphilic polymer possessing a relatively low Tg of ≈70 ºC (Figure 3-
3), making it ideal for HME applications (95), and is commonly used to prepare solid 





Figure 2-7: Chemical structure of Soluplus. Figure obtained from BASF Inc (141).  
 
Soluplus used in this study was obtained as gratis from BASF® (BASF inc., 
Ludwigshafen, Germany. Lot #: 84414368E0). 
 
2.1.9. Copovidone®:  
Copovidone, also known as polyvinylpyrrolidone-vinyl acetate (PVPVA), is an 
amorphous, synthetic copolymer that is commonly used in the pharmaceutical industry. 
It has a Tg of ≈110 ºC (111). Copovidone is commonly used as a binder for wet 
granulation, and as a coating material for controlled release tablet coating (123). It has 
also found use as a matrix former in the formulation of amorphous solid dispersions 
(1,59,73,92,97). Copovidone (grade 64) used in this study was obtained as gratis from 
BASF® (BASF inc., Ludwigshafen, Germany. Lot #: 23408975L0). 
 
2.1.10. Hydroxypropyl cellulose: 
Hydroxypropyl cellulose (HPC) is a semi-synthetic, poly(hydroxypropyl) ether of 
cellulose. HPC is commonly used in the pharmaceutical industry as a coating material, 
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tablet binder, viscosity-adjusting agent, and as a matrix former in the formulation of 
amorphous solid dispersions. HPC also use in 3DP due to its mechanically suitable 
properties for printing (44,54,123,142).  
 
HPC used in this work was Klucel® EF grade and was obtained as gratis from Ashland 
(Ashland Industries Europe GmbH, Schaffhausen, Switzerland. Lot #: 53013). 
 
2.1.11. Paracetamol:  
Paracetamol (also known as acetaminophen), is an active pharmaceutical ingredient (API) 
that is commonly used as an analgesic and antipyretic (143). It is polymorphic, with the 
stable form (monoclinic form) having a melting point of 169 °C (144). It is very slightly 
soluble in cold water (1 to 5 mg/mL at 22 °C) but soluble in hot water (145).  
 
 
Figure 2-8: Chemical Structure of paracetamol. Figure adapted from Ivanova (146) 
 
Pharmaceutical grade paracetamol (>99.0% pure) was used in this study was purchased 
from Sigma Aldrich (Sigma Aldrich Ltd., Dorset, United Kingdom. Lot #: SLBC6391V) 
and was used as a model drug. 
 
2.1.12. Acetylsalicylic acid: 
Acetylsalicylic acid (also known as aspirin) is an API that is commonly used as an 
analgesic, antipyretic, anti-inflammatory, and antiplatelet (147,148). Acetylsalicylic acid 
is polymorphic (149) with the stable form possessing a melting point of 135 °C. Aspirin 





Figure 2-9: Chemical structure of acetylsalicylic acid. Figure recreated from Varughese et al. 
(149) 
 
Pharmaceutical grade aspirin (>99.0% pure) used in this study was purchased from Sigma 
Aldrich (Sigma Aldrich Ltd., Dorset, United Kingdom. Lot #:081M0194V) and was used 
as a model drug. 
 
2.1.13. Sodium bicarbonate: 
Sodium bicarbonate (NaHCO3) is a commonly used excipient pharmaceutical 
formulations. Under acidic conditions, NaHCO3 reacts vigorously with water, producing 
carbon dioxide. Due to its vigorous reaction with water in which carbon dioxide is 






2.2.1. Hot-Melt Extrusion: 
Hot-Melt Extrusion (HME) is a process by which materials (in the molten state) are forced 
through a barrel by the action of conveyer screws into a die cavity to obtain a final product 
comprising a matrix of uniform shape and density. During the process, a polymer and the 
API are fed into the extruder by a gravimetric hopper, the materials are then received by 
two, co-rotating screws which serve to convey the materials into the various regions 
within the extruder. They are first carried into the melting zone where they are melted by 
the action of the heat conduction of the barrel and the mechanical shear from the screws, 
the molten materials are then carried by the screws to the mixing region where mixing 
elements homogenise the molten drug and polymer together to create a uniform 
dispersion, the mixture is then pumped through a die where the melt is cooled and 
collected for further processing (103,151).  
 
The technique was originally pioneered for the plastic industry, but it has been ported into 
the pharmaceutical industry, having demonstrated its robustness as a technique to 
manufacture solid dispersions (1,2,82), and more recently as a method to prepare drug-
loaded filaments for FDM (43,44,54).  
 
 
Figure 2-10: Basic anatomy of a hot melt extruder, Figure obtained from Particle Sciences 
(106).  
 
It should be noted that depending on certain parameters (such as temperature, screw 
configuration, and the physicochemical properties of the processed materials) during the 
extrusion process, the produced extrudates can be in a range of different physical states, 
from amorphous to semi-crystalline and crystalline. However, the greatest utilization of 
HME has been for the fabrication of amorphous solid dispersions. In the manufacture of 
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ASDs, HME offers several advantages over other commonly used methods; other 
methods used to prepare ASDs like spray drying, and freeze drying mandate that both the 
drug and polymer be soluble in a common solvent (2,38,75). HME, on the other hand, is 
an ambient process, requiring no solvent use, which makes HME a more robust process 
that allows for greater flexibility in making solid dispersions as it cuts down on the time 
needed to identify and prepare a solvent (or solvent mixture) and prepare the 
drug/polymer solution (59,125,151,152). Furthermore, HME is a continuous 
manufacturing process, which makes it a more readily scalable process than both spray 
drying and freeze drying, which allows for easier incorporation of online Process 
Analytical Technologies into the production pipeline (60,77,153).  
 
All formulations produced in this study were produced using a Haake Minilab II benchtop 
melt extruder (Thermo Fisher Scientific, Karlsruhe, Germany) equipped with a 1.75mm 
circular die. 
 
2.2.2. Material Characterisation Methods: 
2.2.2.1. Differential Scanning Calorimetry 
Differential Scanning Calorimetry (DSC) is a thermal materials characterisation 
technique.  DSC is regarded as a quintessential thermal characterisation technique in the 
pharmaceutical industry, due to its ability to provide highly detailed information about 
the physicothermal properties of a material whilst consuming minute amounts of material 
(up to a few milligrams) per scan (113). 
 
Two variants of DSC exist, heat flux DSC, and power-compensated DSC. In heat-flux 
DSC, two pans (one containing the sample to be tested and the other a blank reference 
pan) are placed in the same furnace. The furnace is heated as per the user-submitted 
heating sequence. The temperature difference between the sample pan and the reference 
pan is measured and converted to energy. In power compensated DSC, the two pans 
(sample and reference) are placed in separate furnaces, with the machine measuring the 
energy required to maintain the two pans at the same temperature (154). This study used 





Figure 2-11: A graphical representation of a heat flux DSC. S: sample pan, R: reference pan. 
Figure adapted from Clas et al. (113) 
 
DSC is used to detect changes in material properties with respect to temperature change. 
Thermal transitions visible by DSC include melting (fusion), recrystallisation, solvent 
evaporation, β-transitions, glass relaxations, and glass transitions (63,113,154). 
 
As previously discussed in section 1.3.1., observing the nature of thermal transitions is a 
common method to distinguish between crystalline and amorphous solids. Crystalline 
solids exhibit sharp and precise melting points (Tm), amorphous solids, however, do not 
melt on heating, but rather exhibit an increase in their molecular mobility after crossing 
a particular temperature threshold called the glass transition temperature (Tg). This 
characteristic difference between the thermal behaviours of the two solid phases allows 
for them to be easily distinguished via DSC. Furthermore, since the general goal of 
formulating pharmaceutical substances into solid dispersions is to remove the crystallinity 
of the drug substance, DSC is very commonly used in characterising solid dispersions; 
the presence of peaks corresponding to the melting of the drug indicates failure to 
formulate a stable solid dispersion, while the absence of a peak corresponding to the Tm 
of the drug is indicative of the formation of a solid dispersion (38,69,76–78,82,137,155).  
 
This study used both a Q20 DSC and a 2500 Discovery DSC, both of which were 
manufactured by TA Instruments (TA Instruments, Newcastle, USA). All pans used in this 




2.2.2.2. Thermogravimetric Analysis 
Thermogravimetric analysis (TGA) is a thermal characterisation technique. TGA is used 
to measure changes in the mass of a sample relative to the change in temperature. 
Temperature-dependent events which result in a change in the mass of the sample such as 
solvent loss or degradation can be easily observed and quantified using TGA (154). 
 
A TGA machine consists of a hook that is used to gravimetrically suspend the sample pan 
in an environmentally isolated furnace. Inside the furnace, the sample may be exposed to 
a temperature ramp, or held isothermally at a set temperature, with the machine recording 
the change in mass relative to temperature or time (154).   
 
The TGA used in this study was a TA Instruments 5500 Discovery TGA (TA Instruments, 
Newcastle, USA). 
 
2.2.2.3. Attenuated Total Reflectance – Fourier Transform Infrared 
Spectroscopy 
Infrared spectroscopy is a vibrational spectroscopic technique used to detect vibrations of 
bonds (i.e. bending or stretching of a bond) within a molecule. The base principle of 
infrared spectroscopy relies on the fact that if the wavelength of a particular infrared beam 
(i.e. 5714 nm/1750 cm-1) matches the frequency of a particular oscillation of a bond (i.e. 
the stretching oscillation of the C=O bond), the infrared beam will be absorbed by that 
particular bond. Infrared spectroscopy is conventionally used to refer to IR spectroscopy 
conducted in the mid-infrared region (2500 nm – 25000 nm. Equivalent to 4000 cm-1 – 
400 cm-1), with modern spectrometers applying a Fourier transform to yield an FTIR 
spectrum (63,105).  
 
Attenuated total reflectance (ATR) is an infrared sampling technique developed by 
Fahrenfort (156).  ATR-FTIR spectroscopy offers many advantages over conventional, 
transmittance infrared spectroscopy; ATR-FTIR is quick and requires little to no sample 
preparation, and does not carry with it the risk of altering the properties of the sample 
which may happen during milling or pressing the sample as is the case with conventional, 
transmittance infrared spectroscopy (156). 
 
At the heart of an ATR accessory is a crystal of high reflective index and no infrared 
absorption (i.e. diamond). The spectrum that is obtained from ATR-FTIR is a result of 
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measuring the change in an infrared beam that is totally reflected inside the crystal when 
it comes in contact with the sample, penetrating it not more than a few micrometres (157). 
 
 
Figure 2-12: schematic representation of total internal reflectance in an ATR crystal. Figure 
recreated from Lee et al. (158) 
 
ATR-FTIR is commonly used in the pharmaceutical industry as a rapid method for 
material identification (159), solid state characterisation (84,85), and for determining the 
mechanism of drug-polymer interactions in solid dispersions (1,19,59,77,160).  
 
ATR-FTIR spectra presented in this work were measured using a Vertex 70 infrared 
spectrometer (Bruker Optics Ltd., Coventry, United Kingdom), equipped with Golden 
Gate ATR accessory (Specac Ltd., Orpington, United Kingdom) fitted with a diamond 
internal reflection element. 
 
2.2.2.4. Powder X-Ray Diffraction 
Powder X-Ray Diffraction (PXRD) is a structural characterisation technique. PXRD can 
be used to deduce information about solid state, polymorphism, crystal orientation, and 
degree of crystallinity within a sample (161).  
 
The working principle of PXRD relies on the fact that crystalline materials act as 
diffraction gratings for x-ray beams whose wavelengths match the spacing of the planes 
within a crystalline lattice. Lawrence Bragg defined the working principle of PXRD when 
he described the X-Ray scattering phenomenon in what is now known as Bragg’s law: 
supposing a crystalline lattice comprised of parallel planes of a constant parameter d, an 
incident X-Ray beam produces a Bragg peak if its reflections off the various planes 




PXRD is a particularly powerful tool for determining the solid state of a material 
(101,163). As previously discussed in section 1.3.1., amorphous materials lack the long-
range order that is characteristic of a crystal lattice. Therefore, no Bragg peak is produced 
when an amorphous material is exposed to PXRD, as the lack of long range order 
indicates the absence of parallel planes within the lattice, and therefore no constructive 
interference of the X-Ray (161).  
 
The X-Ray diffraction patterns of crystalline materials are often sharp precise peaks, 
while amorphous materials typically exhibit broad features often dubbed the “amorphous 
halo” (Figure 2-13) (82). Deconvolution of the broad features of the amorphous halo is 
not a simple process and is often needed to determine whether the features observed are 
due to the presence of an amorphous material or due to micro- or nanocrystalline materials, 
as PXRD is well-documented to be affected by the granule size of the materials being 
tested (164).  
 
 
Figure 2-13: A crystalline material (paracetamol form I; bottom) and an amorphous material 
(HPMCAS; top) as they appear under PXRD 
 
This study used a Thermo ARL Xtra X-ray diffractometer (Thermo Scientific, 
Switzerland) equipped with a copper X-ray Tube (k = 1.540562 Å) as a solid state 
characterisation tool. No baseline correction was applied to the diffraction patterns, as the 
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same machine was used to scan all samples and compare differences in the diffraction 
patterns.   
 
2.2.2.5. Scanning Electron Microscopy:  
Scanning electron microscopy (SEM) is a high-resolution microscopic characterisation 
technique commonly used to examine surfaces and microstructures of materials. During 
SEM imaging, an electron beam is used to scan the material. The electron beam is fired 
from the electron gun, which is then focused and demagnetised by a series of focusing 
lenses. The beam is then demagnetised and focused onto the sample being investigated 
(63).  
 
The SEM used in this study was a JSM 5900LV Field Emission Scanning Electron 
Microscope (Jeol Ltd, Japan) equipped with a tungsten hairpin electron gun. 
 
2.2.3. Texture Analysis: 
Texture analysis (TA) is a technique commonly used for studying the mechanical 
properties of materials (165). The technique is very commonly used in the food industry 
to extract information about the texture and mechanical properties of food  (166–168). 
The technique has also found use in the pharmaceutical industry, particularly to 
quantitatively measure the mechanical properties of hard gelatin capsules (169). 
 
A texture analyser consists of a mechanical moving arm that is equipped with a load cell. 
The arm is used to deform the sample to be tested. The load cell records the force response 
exerted by the sample as resistance to the deformation.  The output result is a curve 
showing the force (resistance exerted by the sample) against either time, or distance 
travelled by the mechanical arm. The produced force graph can be used to extract 
information about brittleness, compressibility, and yield strength (165).  
 
The work presented herein used a Stable Micro Systems TA.XT 2 Plus Texture Analyser 
(Stable Micro Systems, Godalming, United Kingdom). 
 
The operational parameters for all the methods described in this section are detailed in 





2.2.4. Principal Component Analysis: 
Principal Component Analysis (PCA) is a multivariate statistical analysis technique that 
is commonly used as a method to reduce the dimensionality of multivariate data (158,170). 
PCA is used to extract the most important information from a data set and project it on a 
set of new uncorrelated, orthogonal variables called Principal Components (PCs), 
retaining maximum variability of the data set (171). In a data set consisting of two 
variables Y1 and Y2, the first PC is extracted by plotting Y1 vs. Y2, discarding the axes, 
while retaining the data points relative to each other. The best fit axis maintaining 
maximum data variance is then calculated, resulting in the first PC. Subsequent PCs are 
then plotted with each subsequent PC perpendicular to the last, provided that maximum 
possible data variance is maintained. Finally, the data matrix is rotated such that the newly 
extracted first PC becomes the X-axis of the PC matrix (172). The rotated data matrix is 
described by its eigen-decomposition values (eigenvector and eigenvalue). The 
eigenvector is the vector in the matrix that maintains its direction following the matrix 
rotation, with the eigenvalue denoting the magnitude said eigenvector was multiplied by 
during the matrix rotation (172). The eigen-decomposition values of a covariance matrix 
of a data set is its PCA rotation (171). PCA is a popular data analysis technique that is 
commonly used across multiple disciplines to facilitate the analysis of multivariate data, 





Chapter 3  
Investigating the mechanical properties of melt-









The filament-based feeding mechanism employed by FDM printers utilises mechanical 
gearing arrangements to push the filament into the heating zone (Figure 3-1) (41). For the 
filament movement to be accurately controlled, it has to be held tightly (pinched) between 
the two rollers (175), leaving the filament effectively under pressure between the rollers 
and the nozzle during the feeding. In situations where the filament is brittle, this is likely 
to cause the filament to fracture, stopping the forward propulsion of the filament, causing 
a blockage in the printing head, as illustrated in Figure 3-1. Blockages in the printing head 
are very problematic; broken pieces of filaments inside the printing head can contaminate 
the machine, compromising the purity of any dosage forms one wishes to fabricate. 
Blockages in the printing head are also difficult to clean, often requiring disassembly of 
the entire printing head to be cleared. Therefore, there is a need for screening the 
mechanical suitability of the filament before attempting to feed the filament into a printer.  
 
 
Figure 3-1: Illustration of the different behaviour of filaments during feeding. Left: a filament 
that is too flexible to be fed. Centre: an ideal filament. Right: a filament that is too brittle to be 
fed 
 
Zhang et al. described a characterisation method utilising the 3-point bend test to 
determine the mechanical suitability of filaments prepared by HME for FDM (176). 
Zhang identified two parameters, filament stiffness (breaking strain) and filament 
brittleness (breaking distance) as the deterministic parameters in determining the 
mechanical suitability of the filaments for 3DP. While the method determined which 
filaments were too brittle to be printed, there was no clear correlation in the mechanical 
properties of the filaments which were deemed mechanically adequate for printing was 
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observed. Furthermore, Zhang required that a filament must coil inside the printing head 
over six times to be deemed too flexible to be printed. More recently, applying the 3-point 
bend test to the filament has been conducted solely to determine the brittleness of the 
filament to avoid fracture inside the print head (137,177,178). Ponsar et al. investigated 
whether Young’s Modulus may be used to extrapolate information about the feedability 
of filaments, but reported that differences in Young’s Modulus were“of little practical 
relevance” (177). Similarly, data reported by Borujeni et al. showed no correlation 
between Young’s Modulus and the feedability of the filaments (179).  
 
This study describes the development of a screening method for predicting the feedability 
of melt-extruded filaments for FDM. Unlike the 3-point bend test, the method presented 
herein uses a texture analyser to compress the filament parallel to the direction of feeding. 
Unlike the attempts utilising Young’s Modulus as a method to determine feedability, the 
entire compression force vs. probe travel distance curve was used. Since its publication 
(180), successful use of this method to determine feedability of filaments was reported 
by Gültekin et al., (181), as well as in another section presented in this work (Appendix 
1). 
 
In this study, a number of binary and ternary polymer blends were prepared as filaments 
via HME. Furthermore, a complex, quaternary formulation that has been reported by 
Alhijjaj et al. (43) to be feedable was also used studied as a higher complexity system. 
Filaments were prepared and attempted to be fed into an unmodified Makerbot® 
Replicator 2 3D printer to determine their feedability. A custom-made Texture Analyser 
rig (Figure 3-2) was used to test the filament response in a compress-and-release cycle, 
yielding a plot of force (exerted by the filament as resistance to deformation) vs. distance 
compressed. Such data was used to quantify the mechanical properties of the filaments 
and to determine whether it is possible to predict the feedability of a filament without 





Figure 3-2: The Texture Analysis rig used in this study 
 
Using the force/distance plots (hereinafter referred to as the flexibility profile) produced 
by commercial filaments as a control, correlation analysis and principal component 
analysis (PCA) were used to determine whether there exists a statistically significant 
correlation between the flexibility profiles of different filaments and their feedability and 
subsequently printability. This allows one to predetermine whether or not a produced 
filament is feedable, therefore printable. The relationship between the formulation 
composition and the feedability of the filament investigated in this study can bring new 
insights into the development of principles in the rationalisation of FDM printable 




3.2. Materials and Methods 
3.2.1. Materials: 
The materials used in this study were ABS, HIPS, PVA (both as a commercial filament, 
and as Mowiflex pellets), HPMCAS, Tween 80, PEO, Eudragit EPO, Soluplus, 
Copovidone, PEG, and paracetamol. The three commercial filaments (ABS, HIPS, and 
PVA) were used as purchased. Detailed descriptions of the materials and their sourcing 
can be found in Section 2.1. 
 
3.2.2. Preparation of in-house filaments: 
In-house filaments were prepared by HME and extruded through a 1.75 mm circular die.  
A list of prepared formulations and their key extrusion parameters can be found in Table 
3-1. All multi-component formulations were cycled in the extruder for 5 minutes at a 
screw speed of 100 RPM to ensure homogenous mixing (43). Following extrusion, the 
filaments with diameters of 1.75 mm ± 0.05 mm were collected for further testing.  
 
Table 3-1: Compositions and extrusion temperature of the studied filaments.  
Formulation Constituents Temperature 
Mowiflex Mowiflex® (contains PVA and an undeclared 
plasticizer at an undeclared concentration 
170 ºC 
HPMCAS HPMCAS (100% w/w) 170 ºC 
PEO PEO (100% w/w) 75 ºC 
Copovidone PVP/VA 64 (100% w/w) 140 ºC 
Soluplus Soluplus® (100% w/w) 120 ºC 
Eudragit 
EPO 
Eudragit® EPO (100% w/w) 120 ºC 
EUD Eudragit EPO (55.5% w/w) 
+ 11.1% w/w, 16.7% w/w, and 16.7% Tween 80, 
PEG, and PEO, respectively (43) 
100 ºC 
HD HPMCAS (90% w/w) and paracetamol (10% w/w) 150 ºC 
HP10 HPMCAS (90% w/w) and PEO (10% w/w) 150 ºC 
HP10D HPMCAS (81% w/w), PEO (9% w/w) and 
paracetamol (10% w/w) 
140 ºC 
HP20 HPMCAS (80% w/w) and PEO (20% w/w) 150 ºC 
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Formulation Constituents Temperature 
HP20D HPMCAS (72% w/w), PEO (18% w/w) and 
paracetamol (10% w/w) 
130 ºC 
HP30 HPMCAS (70% w/w) and PEO (30% w/w) 140 ºC 
HP30D HPMCAS (63% w/w), PEO (27% w/w)and 
paracetamol (10% w/w) 
120 ºC 
HP40 HPMCAS (60% w/w) and PEO (40% w/w) 130 ºC 
HP70 HPMCAS (30% w/w) and PEO (70% w/w) 100 ºC 
HP90 HPMCAS (10% w/w) and PEO (90% w/w) 85 ºC 
SP Soluplus® (90% w/w) and PEG (10% w/w) 110 ºC 
ST Soluplus® (80% w/w) and Tween® 80 (20% w/w) 100 ºC 
 
 
3.2.3. Filament Characterisation: 
3.2.3.1. Differential Scanning Calorimetry  
DSC was conducted using a Q20 differential scanning calorimeter. All in-house prepared 
filaments were tested using a heat-cool-reheat cycle with a temperature range of 20 ºC to 
185 ºC at 10 ºC/min. Physical mixes were scanned using a heat-cool-reheat program along 
the aforementioned temperature range. All samples were tested as fresh samples (where 
applicable) immediately after extrusion. All tests were done in triplicates.  
 
3.2.3.2. Attenuated Total Reflectance – Fourier Transform Infrared 
Spectroscopy  
FTIR spectroscopy was conducted using a resolution of 4 cm-1, 32 scans for each sample, 
within the range of wavenumbers from 4000–550 cm-1. Spectra analysis was conducted 
using OPUS version 7.8 (Bruker Optics Ltd., United Kingdom). All measurements were 
done in triplicate. 
 
3.2.3.3. Powder X-Ray Diffraction  
A scanning range of 3º < 2θ < 30º, using a step scan mode with a step width of 0.01º and 




3.2.4. FDM feedability testing: 
Feedability of the extruded filaments was tested by feeding into the printing head of using 
the aforementioned Makerbot® Replicator 2. Successful extrusion of the polymer through 
the nozzle tip was regarded as successful feeding, making the filament feedable. It should 
be highlighted that the printing quality was not assessed and is out of the scope of this 
study. All filaments were fed at the printer’s default feeding temperature of 230 ºC.  
 
3.2.5. Texture analysis:  
Texture analysis was conducted using a compression method; the filaments were 
compressed axially with a 3.15 mm/sec compression speed, corresponding to the roller 
movement speed of a Makerbot® Replicator 2X (determined by feeding an accurately cut 
10 cm filament into the printer head and measuring the time needed for the filament to 
pass through the printing head). 5 cm long filament pieces were held standing in conical 
end caps to allow bending and to avoid fracturing them with the clamps (Figure 3-2). The 
compression distance was set to 15 mm with a trigger force of 0.05N and data was 
collected during both compression and release.  TA tests were done in triplicate for all 
tested filaments.  
 
3.2.6. Data manipulation and statistical analysis: 
For the compression tests, the varying hardness of the materials dictated that the scaling 
of the flexibility profile (force (N) vs. distance (mm)) plots was not directly comparable 
without data range normalisation. Therefore, data range normalisation was performed 
using the equation: 
 
𝑌𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑
𝑛 =  
𝑌𝑛
𝛴𝑌
 (Equation 3-1) 
     
Where Yn is the nth point on the Y-axis (force). Correlation analysis of the flexibility 
profiles of the pharmaceutical filaments with the data of the commercial filaments was 
conducted using Microsoft® Excel 2016 expanded with the Data Analysis add-on. PCA 
was conducted using IBM® SPSS Statistical Analysis Suite (version 25), with the 
Varimax rotation method, extracting components possessing an eigenvalue ≥ 1, as per 




3.3. Results  
3.3.1. Materials characterisation: 
Figure 3-3 shows the thermograms of Copovidone, Soluplus, Eudragit EPO, ST, and SP. 
All of which were found to have inadequate mechanical properties to be fed into the 3D 
printer (all were found to be too brittle, except formulation ST, which was found to be too 
flexible). The Tg of Copovidone was seen at 107 °C. The Tg of Soluplus was seen at 71 °C. 
The Tg of Eudragit EPO was seen at 45 °C. The Tg of SP was seen at ≈ 40 °C. The Tg 
of formulation ST was not detected.  
 
 
Figure 3-3: DSC thermograms of non-feedable filaments 
 
Figure 3-4 shows the DSC thermograms of the raw materials used in the HPMCAS-based 
formulations. The Tg of HPMCAS was seen at ~120 °C. An endothermic event 
corresponding to the Tm of PEO was seen at ~60 °C, and another endothermic event 
corresponding to the Tm of paracetamol form I (monoclinic form) (130) was seen at 






Figure 3-4: DSC thermograms of raw materials. 
 
Figure 3-4 shows the DSC thermograms of the physical mixes (2nd heating cycle) and 
extruded filaments of HPMCAS based filaments HP10, HP20, and HP30. For the physical 
mixes, the decreased enthalpy of the Tm of PEO, and a decrease in the Tg of HPMCAS 
were observed in the 2nd heating cycle and are summarised in Table 3-2 below:  
 
Table 3-2: Enthalpy of the melting of PEO, and the shifted Tg in the physical mixes of 
formulations HP10, HP20, and HP30. 
Formulation Enthalpy of Tm of PEO Tg 
HP10 4.01 J/g ± 0.04 J/g 110 °C ± 1.53 °C 
HP20 5.20 J/g ± 0.11 J/g 86 °C ± 2.50 °C 
HP30 9.50 J/g ± 0.18 J/g Not seen 
 
In the extruded filaments, the melting of PEO is absent in formulations HP10, HP20, and 
HP30. This result indicates that with 10-30% PEO loading, HPMCAS mixed well with 
PEO after extrusion and the amount of HPMCAS present was sufficient to prevent PEO 





Figure 3-5: DSC thermograms of the HPMCAS based filaments HP10, HP20, and HP30 
 
When increasing the PEO content to above 30%, clear melting of phase-separated 
crystalline PEO can be identified (Figure 3-6). Using the melting enthalpy values of the 
PEO melting in the HP filaments and the enthalpy value of the pure PEO (obtained from 
the DSC results of pure PEO), it is possible to estimate the degree of crystallinity of PEO 
in the filaments. HP90 and HP70 have 56.3% and 51.5% crystallinity, respectively, which 
is much higher than the 30.8% for HP40. This indicates that in high PEO content filaments 
(HP70 and HP90) the continuous phase is the semi-crystalline PEO. This contrasts with 
low PEO content filaments (HP10-HP30) that has the HPMCAS as the continuous phase. 
For HP40, as the contents of HPMCAS and PEO are close, it is reasonable to expect that 
there is no clear a continuous phase which would contribute the significant mechanical 




Figure 3-6: DSC thermograms of formulations HP40, HP70, and HP90 
 
For the drug loaded physical mixes, a small melting endotherm at ~169 ºC can be seen 
corresponding to the melting of paracetamol. A small melting endotherm of PEO was 
detected in the thermogram of the HP30D filament, suggesting the existence of some 
phase separate, semi-crystalline PEO in this drug-loaded filament. The Tm of paracetamol 
was not seen in any of the drug-loaded filaments, suggesting the formation of an 
amorphous solid dispersion of paracetamol. The Tg values of the drug-loaded filaments 
could not be identified. The DSC thermograms of the drug-loaded formulations can be 




Figure 3-7: DSC thermograms of drug loaded filaments and their physical mixes 
 
ATR-FTIR and PXRD were carried out to further confirm the amorphous nature of the 
filaments and investigate any possible molecular interactions between the polymers and 
additives. Figure 3-8 and shows the ATR-FTIR spectra of paracetamol, PEO, and 
HPMCAS, as well as the filaments.  
 
 




Across the whole FTIR spectrum, the sharp bands of crystalline paracetamol are absent 
and a broad peak at 3321 cm-1 which corresponds to the N-H stretching of paracetamol in 
its amorphous state can be seen in all drug-loaded filaments. Furthermore, the 
paracetamol peak at 808 cm-1, corresponding to the out-of-plane bending of a para-
substituted aromatic ring, documented to be particularly indicative of the crystal packing 
of the monoclinic form of paracetamol (111,146), was notably absent in the spectra of the 
filament. The drug-loaded filaments showed no observable change in the carbonyl peak 
of HPMCAS indicating that there is neither hydrogen bonding nor dipole-dipole 
interactions between the polymer and drug. This absence of hydrogen and dipole-dipole 
interactions suggests that the mechanism of stabilisation of this solid dispersion is kinetic 
stabilisation (78). 
 
The PXRD patterns of the milled filaments shown in Figure 3-9 confirm the fully 
amorphous nature of all drug-loaded filaments, as no peaks corresponding to neither PEO 








3.3.2. Filament feedability tests: 
Pure polymer filaments Eudragit EPO, HPMCAS, copovidone, and Soluplus were found 
to be too brittle and would fracture inside the printing head whenever feeding was 
attempted. Formulations ST, SP, and HD (plasticised with Tween 80, PEG, and 
paracetamol, respectively) were also found to not be feedable. SP and HD were found too 
brittle to be fed, while ST was too flexible and would coil inside the print head. Increasing 
the contents of the plasticizers (20% of Tween 80 for ST and 40% of PEO for HP40) led 
to over-plasticization. The ST and HP40 filaments were found to be overly flexible and 
would coil up inside the feeding zone and would not thread through into the melting zone 
of the printing head. The rest of the pharmaceutical filaments were successfully fed 
through the FDM printer. The feedability test results are summarized in Table 3-3.  
 
























3.3.3. Texture Analysis screening tests: 
TA tests were used to obtain the force-distance curves of the filaments under axial 
compression. The force curves were normalised as shown in Equation 3-1 to obtain a 
comparable scaling of the flexibility profiles. Normalised Force vs. Distance curves were 
then plotted to compare the behaviours of different filaments.  
 
Figure 3-10 shows the TA plot of the non-feedable filaments. All the tested filaments were 
found to fracture during the test, which appears in the flexibility profile as a sudden drop 
of Force down to 0. As can be seen in Figure 3-10, Copovidone was the most brittle of 
the materials, fracturing immediately without bending. Soluplus and Eudragit EPO were 
slightly more malleable; neither filament fractured at peak axial force but rather bent 
slightly before fracturing. Plasticised filaments HD and SP, and the pure HPMCAS 
filament were yet more malleable and bent considerably before fracturing. However, all 
filaments shared a characteristic fracture pattern, with the aforementioned bending being 
negligible in comparison to the feedable filaments.   
 
 
Figure 3-10: Flexibility profile plots of non-feedable filaments 
 
Of all the non-feedable filaments, filaments ST and HP40 could not be tested using TA as 
both filaments were too floppy and would collapse under their own weights rather than 
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stand up straight between the two holsters attached to the texture analyser probe (Figure 
3-11). 
 
Figure 3-11: non-testable filament. Shown: filament HP40. 
 
Figure 3-12 shows the flexibility profiles of the commercial filaments ABS, HIPS and 
PVA commercial filaments. Notably, none of the three commercial filaments fractured 





Figure 3-12: Flexibility profile plots of commercial filaments. 
 
Figure 3-13 shows the flexibility profiles of the in-house extruded feedable filaments. 
Similar to the commercial filaments, none of the in-house extruded filaments that were 





Figure 3-13: Flexibility profiles of in-house melt-extruded filaments. A: placebo filaments, B: 
drug-loaded filaments. 
 
Using this data, it is possible to group filament behaviour in order to examine the 
correlation between the flexibility profile and the feedability of the filaments tested 
directly using the FDM printer. The ST and HP40 filaments were too flexible to be placed 
in the TA rig (as illustrated in Figure 3-11). The rest of the non-feedable filaments all 
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shared a characteristic brittle fracture pattern, with sudden discontinuation of force on the 
filament after reaching a peak fracture force. These filaments fractured immediately at 
the maximum force, showing no bending, plastic, or elastic deformation to accommodate 
the increased strain. Within the non-feedable filaments, Eudragit EPO, PVPVA64 and 
Soluplus exhibited much sharper fracture and lower strain-bearing ability than HPMCAS, 
HD and SP. This is evident by the longer travel distance of the probe before the fracture 
of the HPMCAS, HD and SP filament.  
 
Despite seeming random at first glance, the flexibility profiles of the feedable filaments 
all share a characteristic bending deformation after the maximum strain bearing point is 
reached. When the TA probe was returning to the start position, the filaments were able 
to partially recover and straighten within the rig even though they had lost some of their 
stiffness. Of the feedable filaments, filament HP10 was notably the only filament to 
fracture during TA. However, filament HP10 did exhibit substantial bending after 
reaching peak tension force and only fractured after being bent considerably by the texture 
analyser probe. Therefore, its recorded fracture pattern was found to considerably differ 
from the sharp brittle fracture patterns exhibited by non-feedable filaments.  
 
3.3.4. Correlation Analysis: 
The correlations between the flexibility profiles (the normalised area under the force-
distance curves) of each in-house filaments and each of the three commercial FDM 
printable filaments, ABS, dissolvable filament and PLA, were generated and listed in 
Table 3-4. This correlation can be treated as the quantification of the level of similarity 
between the flexibility profile of the in-house pharmaceutical filaments and the 
commercial printable filaments. The higher the correlation score, the more similar were 
the tested filament to the commercial filament.  
 
As seen in Table 3-4, for most of the filaments, the correlation scores to the three 
commercial filaments vary. This is not surprising as the correlation scores of the flexible 
profiles of the three commercial filaments also vary indicating there are some differences 
in their flexible profiles. The correlation data were further analysed by taking the mean 








where Cx is the correlation score with commercial filament x. Overall, all the in-house 
filaments that passed the feedability test had a mean correlation score above 0.5; whereas 
the filaments that failed the feedability test all had a mean correlation score below 0.5. 
Furthermore, the correlation scores of plasticised filaments were higher than those of non-
plasticized filaments indicating that plasticisation improves the flexibility of the filaments.  
 
Table 3-4: Correlation analysis of the flexibility profiles of in-house extruded filaments against 
commercial filaments 
Filament ABS HIPS PLA Mean Rounded mean score 
HPMCAS 0.38 0.64 0.18 0.40 0 
Mowiflex 0.76 0.69 0.74 0.73 1 
PEO 0.92 0.71 0.82 0.82 1 
PVPVA64 -0.08 0.22 -0.12 0.01 0 
Soluplus -0.56 0.40 -0.75 -0.30 0 
Eudragit EPO -0.70 0.30 -0.79 -0.40 0 
EUD 0.94 0.65 0.88 0.82 1 
HD 0.32 0.60 0.18 0.37 0 
HP10 0.85 0.82 0.67 0.78 1 
HP10D 0.96 0.53 0.94 0.81 1 
HP20 0.94 0.70 0.87 0.84 1 
HP20D 0.90 0.48 0.95 0.78 1 
HP30 0.95 0.77 0.89 0.87 1 
HP30D 0.91 0.40 0.94 0.75 1 
HP70 0.70 0.73 0.51 0.65 1 
HP90 0.81 0.81 0.74 0.79 1 
SP 0.49 0.63 0.28 0.47 0 
 
3.3.5. Principal Component Analysis: 
PCA is a multivariate statistical technique that, from a data table containing observations 
describing a multitude of inter-related variables, can extract key information which is 
represented as functions of “Principal Components”. Similarities between the 
observations can be represented by plotting the variables on a map referred to as a space 
plot (171). PCA was performed to further explore the relationship between the flexibility 
profiles of the filaments and their feedability. As the correlation scores of the Dissolvable 
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filament with the other commercial filaments are low, the dissolvable filament was treated 
as an outlier and was not included in the PCA. For the PCA, the normalised full force-
distance curves were used the analysis. Principal Component 1 shows an eigenvalue of 
10.13, Principal Component 2 shows an eigenvalue of 3.57, Principal Component 3 shows 
an eigenvalue of 1.51, while all other principal components show an eigenvalue < 1. By 
applying the Kaiser Rule, the first three principal components were extracted.  
 
Figure 3-14 shows the loadings plot of Principal Components 1, 2, and 3. The filaments 
aggregated on the plot into five clusters. The feedable filaments aggregated into three 
clusters, the first containing ABS, PVA, HP10D, HP20D, and HP30D. The second 
contains filaments HP10, HP20, HP30, EUD, and PEO. The third cluster contains 
filaments Mowiflex, HP70, and HP90. The three clusters are closely aggregated together 
and can be looked at as a single macro-cluster. 
 
Figure 3-14: Loadings plot of the PCA conducted on the flexibility profiles of all tested 
filaments. 
 
The fourth cluster contained filaments SP, HD, and HPMCAS, which are the filaments 
that showed some strain-bearing ability in the TA tests but still fractured as the result of 
compression (Figure 3-10). This cluster of slightly deformable brittle filaments is closely 
positioned to the macro-aggregated cluster of feedable filaments. Although the filaments 
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in this cluster are not feedable, they exhibited some potential and with formulations 
modification such as adding plasticisers they can be feedable. HPMCAS is an example. 
The fifth cluster contains the highly brittle and non-feedable filaments of Eudragit® EPO, 





3.4. Discussion  
3.4.1. Intrepretation of the Texture Analysis Flexibility Profile: 
The data presented in Section 3.3.3. suggests that examining the whole of the TA 
flexibility profile may be necessary to extrapolate information about the feedability of the 
filament. As discussed in Section 3.3.3., the characteristic attribute of non-feedable 
filaments was the brittle fracture pattern exhibited by all the tested filaments (Figure 3-
10). Feedable filaments, on the other hand, were notable for their capacity to recover post-
deformation.  
 
Figure 3-15 shows an example of a flexibility profile combined with photographs of the 
filament at critical points in the profile. At the beginning of a TA test, the straight filament 
received the compression forces, with the continuous movement of the TA probes towards 
each other, the forces born by the filament continuously increase. At a critical point in the 
applied force, the filament reaches the Euler point at which an infinitesimal lateral force 
will cause bending. This is the bending point highlighted in Figure 3-13. After this, the 
applied force acts to both compress the filament and to further bend the filament at the 
weakened bend point which leads to the complex TA profile pattern of this stage of the 
test as seen in the flexibility profiles of the feedable filaments (Figures 3-11 and 3-12). 








Despite the previous argument, fracturing of a feedable filament was observed in filament 
HP10. The fracturing behaviour of said filament was notably different to that of the brittle 
fracture patterns exhibited by the non-feedable filaments, seeing as its Flexibility Profile 
exhibited more of the characteristics of a feedable filament, rather than a non-feedable 
filament, as shown in Figure 3-16, which highlights the key characteristics of the 
Flexibility Profiles of a non-feedable filament, a fracturable feedable filament, and a non-
fracturable feedable filament.  
 
 
Figure 3-16: highlighting the main features of the Flexibility Profile of a non-feedable filament 
(HPMCAS). A feedable filament that can fracture (HP10), and a feedable filament that does not 
fracture (HP10D) 
 
A more detailed discussion of the fracturing pattern of filament HP10 and how it is 
different from the non-feedable filaments is presented in the upcoming section 3.4.2.  
 
An important factor one must consider when interpreting the Flexibility Profile is the fact 
that it is of a qualitative nature. The absolute amount of force a filament can bear before 
bending or fracturing does not appear to correlate with its feedability. Figure 3-17 shows 
the untreated Texture Analysis curve of a feedable filament (ABS), against a non-feedable 
filament (Eudragit), as well as the filament that showed the highest strain-bearing force 
prior to bending (Mowiflex). Both ABS and Mowiflex showed a maximum strain-bearing 
force of < 20 N, despite the fact that ABS is a commercial, feedable filament, while 
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Eudragit EPO is a non-feedable, brittle filament. Conversely, Mowiflex, a feedable 
filament, showed strain-bearing bearing forces higher than all of its non-feedable 
counterparts, with a strain-bearing force up to 100 N. Even without area normalisation, 
the patterns outlined in Figure 3-16 can still be clearly observed for all three filaments 
(bending and recovery for Mowiflex and ABS vs. the brittle fracture pattern exhibited by 
Eudragit EPO) regardless of the absolute force exerted. Further indicating that the 
“pattern” exhibited by the filament during TA provides more information about the 
feedability of the filament, with absolute quantitative values such as maximum force offer 
little to no help in terms of predicting feedability. This conclusion aligns with what has 
been previously reported in the literature by Ponsar et al. (177) and Borujeni et al. (179), 
in which Young’s Modulus was found to be of little relevance towards predicting the 
feedability of filaments, further suggesting that this phenomenon is of qualitative nature.  
 
Figure 3-17: Flexibility profiles of Mowiflex, Eudragit EPO, and ABS. Showing absolute force 
rather than Area Normalised Force 
 
3.4.2. Correlation between mechanical properties and feedability: 
This study is aimed to develop a screening method to speed up the formulation 
development of FDM printable solid formulations. To achieve good printability, the FDM 
filaments first need to exhibit good feedability to allow the smooth and continuous 
delivery of the filaments to the heating zone of the printing head. As previously discussed, 
the feeding mechanism employed by FDM printers involves mechanical pushing of a 
filament held between two counter-rotating gears. In situations where the filament being 
fed is too brittle to bear the mechanical strain generated from the compression and 
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pushing, this is likely to cause the filament to fracture, discontinuing the force that is 
propelling the filament forward, causing a block in the printing head. If it is too ductile it 
will deform when being passed forward and again block the head. 
 
When HME is used in the fabrication of traditional solid dosage forms (i.e. tablets), the 
extrudates produced often undergo particle size reduction, to produce powders or granules 
with a suitable particle size for pharmaceutical processing (i.e. compression) (103). 
Unsurprisingly, brittle extrudates are more suitable in that regard, as brittle materials 
require less time and energy to be milled or granulated as opposed to ductile/flexible 
materials (182). Therefore, most pharmaceutically relevant polymers that are suitable for 
HME often yield brittle extrudates that readily fracture, and while this makes such 
polymers suitable for traditional pharmaceutical applications of HME, it renders those 
polymers unsuitable for FDM implementation.  
 
From the TA test, it is clear that there are two groups of non-feedable polymers, both 
exhibiting brittle fractures, but differ in whether they show any strain bearing ability. The 
addition of plasticisers allows for an increase in the strain bearing ability of the filaments. 
As an example, pure Soluplus filament exhibited no strain bearing capacity in the TA test, 
whereas the addition of 10% PEO (SP) shifted the flexibility profile to the group 
exhibiting some strain bearing capacity, which is attributable to the plasticisation effect 
of PEG. Plasticisers used in the formulation of pharmaceutical blends for FDM printing 
include triethyl citrate, triacetin, various grades of polyethylenes (PEG and PEO), Tween 
80, and glycerol (16,18,43,44,54). Over-plasticisation of filaments was observed to also 
cause a feeding defect; filaments HP40 and ST were found to coil inside the printing head 
when feeding was attempted. Those filaments possess little-to-no rigidity and would 
readily deform when any force is applied, with their texture being more similar to a fabric 
than to thermoplastic polymers. This indicates that the appropriate level of plasticisation 
is vitally important. The non-feedability of the over-plasticised filaments is because they 
readily deform inside the printing head making them unable to thread through the melting 
zone for deposition. This lack of rigidity sits in stark contrast to feedable filaments which 
are pliable enough to bend and deform on handling, but retain their original shape when 
force is released.  
 
HPMCAS was selected as the platform polymer for drug loading and plasticization 
screening because, although the filament itself was not feedable, its flexibility profile 
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displayed some strain-bearing properties comparable to those of plasticised Soluplus (SP). 
The addition of 10% PEO was found to readily transform the filament into a feedable one. 
Furthermore, the addition of 10% paracetamol to the filament significantly changed its 
fracture pattern from a brittle fracture to a slightly more ductile fracture (Figure 3-16). 
This can be attributed to the plasticisation effect of the drug on the polymer. This is also 
supported by the fact that although HP10 did fracture (but was still feedable), filament 
HP10D did not, suggesting that the addition of 10% paracetamol further increased the 
strain-bearing ability of the filament.  
 
 
Figure 3-18: Impact of plasticisation on the flexibility profiles of HPMCAS-based formulations. 
 
Filaments HP10, HP20, HP30, HP20D, and HP30D were all found to be feedable, 
suggesting that, at least for HPMCAS, there is a wide margin available for plasticiser 
loading without unduly influencing the mechanical properties. Increasing the PEO 
loading to 40% rendered the filament unfeedable (HP40), which most likely is due to the 
significant phase separation of HPMCAS and PEO as indicated by DSC (Figure 3-6). 
Inversely, filaments HP70 and HP90 were found to be feedable. The high PEO loading in 
comparison to HP10, HP20, and HP30 means that the filaments are most likely PEO-
based with the HPMCAS being the second material in the matrix. This is further 
supported by the colour difference; HP10, HP20, and HP30 all had the characteristic pale 
yellow colour of hot-melt extruded HPMCAS (163), while filaments HP70 and HP90 
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were coloured identically to a PEO filament. Based on these results, it is reasonable to 
hypotheise that in the case of HPMCAS-PEO blends, the existence of a continuous phase 
(either HPMCAS or PEO) as the matrix is important to maintain the mechanical strength 
of the filaments.  
 
3.4.3. Using flexibility profile towards screening 
In terms of screening, the TA test was designed to simulate the conditions inside the 
printing head as closely as possible, the speed of compression was set to 3.15 mm/sec, 
which matches the speed of feeding inside the printer. Tested filaments were found to 
exist in either one of three categories; brittle filaments, string-like filaments, and pliable 
filaments. Brittle filaments are filaments that fracture during the analysis. String-like 
filaments are filaments could not be tested due to them being too flexible to maintain a 
vertically suspended straight beam shape and would collapse under their weight. Pliable 
filaments are filaments that would deform due to compression by the texture analyser, but 
recover when the force is removed.  
 
It should be noted that the aforementioned categories do not have clearly defined 
boundaries, but are rather like a spectrum. Filaments SP, HD, and HPMCAS, despite 
being brittle filaments, did exhibit some pliability before fracturing. Inversely, filament 
HP10 did fracture during TA, but the predominating mechanical property it exhibited was 
pliability.  
 
A high correlation between the feedable in-house filaments and the commercial filaments 
was observed. All feedable filaments displayed correlation scores > 0.50 with the 
commercial filaments, indicating the significance of the relationship between the 
flexibility profiles of the filaments and their feedability. However, no observations were 
made that indicate feedability existing as a spectrum property of the filaments (i.e. no 
filaments were found to be “more feedable than others”). Feedability of the filaments is 
a Boolean value, being either true or false. The TA data is a curve which is then normalised 
and sorted into categories by statistical analysis. The normalisation procedure used in the 
analysis removes differences in the absolute values of force applied. Mowiflex is feedable 
but notably much stiffer than all other tested materials, with the minimum required force 
for deforming Mowiflex being 120 N. The higher stiffness of Mowiflex filaments does 
not affect feedability and suggests that provided the shape of the overall flexibility profile 
follows the acceptable trend, the filament will be feedable regardless of the absolute 
 
85 
mechanical properties. To further simplify the analysis, rounding the mean correlation 
scores of each filament to the nearest integer (values < 0.5 are rounded down to 0, while 
values > 0.5 are rounded to 1) produces a method (Table 3-4) that simply sorts the 
filaments into feedable with a score of 1 (True) and non-feedable filaments with a score 
of 0 (False).  
 
PCA was used as a qualitative statistical method to sort the different filaments using their 
flexibility profiles into feedable and non-feedable filaments. As seen in Figure 3-14, three 
clusters were observed in the rotated space plot of the filament flexibility profiles. The 
feedable and non-feedable filaments are well separated. Interestingly a cluster containing 
filaments that can be easily tuned to be feedable (referred in the Figure 3-14 as ‘tunable’ 
filament) is also isolated. Using HPMCAS as an example, as demonstrated in Figure 3-
18, with the addition of a plasticiser, the non-feedable polymers and polymer blends 
(HPMCAS and HD) in this cluster can be transferred into feedable filaments (HP10 and 
HP10D). This data demonstrates that the flexible profile obtained from the TA test can be 
correlated to the feedability and used to predict the potential of the FDM printability of 






Mechanical properties of the HME filaments are an important property determining the 
processibility for FDM 3DP. By measuring the flexibility, one of the most directly 
relevant mechanical properties of the HME filaments, this study described the 
development of a simple method for screening the feedability and subsequent printability 
of HME filament for FDM printing. A wide range of filaments prepared using 
pharmaceutical polymers and excipients were tested to validate the method. The method 
described was able to accurately and reproducibly separate feedable and non-feedable 
filaments. Furthermore, coupled with PCA, more insights were gained in the aspects of 









Chapter 4  
Investigating the impact of printing temperature 
and printing speed on pharmaceutically-







When characterising FDM printed objects, the non-pharmaceutical literature is largely 
concerned with the surface roughness and tensile strength of the fabricated objects 
(40,50–53). In pharmaceutical applications, when the FDM printed objects are intended 
to be used as dosage forms, achieving precise and highly reproducible dimensions and 
weight is critical. However, to date, there is no debate on whether the fundamental design 
of these prototype-building FDM printers is suitable for pharmaceutical manufacturing.  
 
In the FDM printing process, the quality of the printed object is the result of a complex 
interplay between the properties of the printing material and the settings of the machine 
(both adjustable and non-adjustable), as shown in Figure 1-7. For the printer used in this 
work, the machine adjustable parameters are print speed; extrusion temperature; build 
plate temperature, and layer thickness. These represent the main variables in the FDM 
printing process. Temperature will affect the material properties, in particular, its 
rheological properties (183). These, in turn, will determine the flow out of the printing 
head, often known as melt flow, which is one of the factors investigated in this study, and 
the spread on the build plate which may then affect the reproducibility and dimensional 
precision of the printed object. Under some circumstances, high temperature may increase 
the fluidity of the printing material and cause unstable layer deposition (in the work 
presented herein, temperatures high enough to cause this phenomenon were temperatures 
greater than 120 °C). At the other extreme, low temperatures may cause reduced flow in 
the print head, resulting in a blockage or a flow rate too small to print adequately at some 
printing speeds (in the work presented herein, 70 °C was the only temperature low enough 
to cause insufficient polymer flow). Obviously, the range of temperatures at which a 
polymer can be printed without suffering from unstable layer deposition or insufficient 
polymer flow depends on the thermal and rheological properties of that particular polymer. 
Rheology also affects flow after deposition on the build plate. In this chapter, the 
interaction of the machine adjustable parameters and the print material rheological 
properties (as indicated by the melt flow index), and their effect on the reproducibility 
and adherence to design specification of the printed object are investigated. We note that 
some research suggests that computational factors such as slicing (the process by which 
the computer-generated 3D model is translated into movement instructions for the printer 
motors) algorithms could play a significant role in the overall quality of the printed object 
(48,49). However, computational parameters are outside the scope of this work, which is 
restricted to exploring the relevant physical parameters.  
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Furthermore, the ‘levelling’ of the printer build plate, a calibration process carried out to 
ensure that the distance between the printing head and the build plate is constant across 
the printing area should be performed to ensure the reproducible quality of the printed 
objects. It has been reported (54) that, for a machine of the same make and model as the 
one used herein, the outcome of this process could be operator dependent, indicating that 
the printing outcome may be irreproducible between operators. We report below on our 
examination of this problem.  
 
Polycaprolactone (PCL) is one of the very few polymers approved for pharmaceutical use 
that are suitable for FDM without further plasticisation (43,180). PCL was used as the 
model polymer to investigate the effect of material and process parameters on the quality 
of printing. In the course of the work, it was noted that the first deposited layer tended to 
have different morphology to the layers above. A phenomenon which we have dubbed 
The First Layer Effect (FLE). Apart from the variables discussed above, the surface 
properties of the build plate may affect the first layer so the printing behaviour on different 
surfaces was also investigated. This is expected to have great importance for selecting the 
best build plate lining that allows the most suitable adherence of the printing material to 
the build plate during the building process and provides the easy peel-off of the object 
after the complete production of the printed dosage forms.   
 
The work presented in this study summarises an investigation on the impact of FDM 
process parameters (printing speed and printing temperature) and how they affect the 
perceived quality attributes of a 3D printed dosage form (weight, weight uniformity, 




4.2. Materials and methods 
 
4.2.1. Materials: 
Materials used in this study were PCL (both as commercial filaments, and as a powder 
for HME), and acetylsalicylic acid (ASA). 
 
4.2.2. Preparation of drug loaded filaments by HME: 
Three drug loaded PCL filaments containing 5%, 10%, and 15% (w/w) ASA were 
prepared using HME. For each batch of the filament, the powder mixes were accurately 
weighed then thoroughly mixed using a mortar and pestle before extrusion. Extrusion was 
performed at 100 °C with a screw rotation speed of 100 RPM. All formulations were 
cycled in the extruder for 5 minutes to ensure homogeneous mixing of ASA and PCL 
before being flushed out. 
 
4.2.3. FDM 3D printing of commercial filaments and drug-loaded filaments: 
The solid dosage form used in this study was a film with the 25 mm in width, 25 mm in 
length, and 0.6 mm in thickness. The film is made up of 3 layers with a layer thickness of 
0.2 mm. The film is comprised of 31 identical rods (rod dimensions: 0.4 mm wide, 0.2 
mm thick, and 25 mm long). The design of the film is shown in Figure 4-1. The Film was 
designed using Blender software and was then exported as an STL file. The STL file was 





Figure 4-1: Macroscopic (left), light microscopy image (right), and the computer-generated 
image of the STL file (bottom) design of the 3D printed film. 
 
Twelve sets of different printing experiments were conducted, each varying either one of 
three factors (nozzle temperature, build plate temperature, and printing speed), as seen in 
Table 4-1. Five films were printed using each set of printing parameters. Each printed 
film was weighed and the dimensions of the films were then accurately measured using a 
digital calliper. Printing of the drug-loaded filaments was performed using a nozzle 












Nozzle Temperature (°C) Platform Temperature (°C) Printing Speed (mm/sec) 
100 30 30 
100 30 90 
100 30 160 
110 30 30 
110 30 90 
110 30 160 
120 30 30 
120 30 90 
120 30 160 
100 45 30 
100 45 90 
100 45 160 
 
4.2.4. Melt Flow Index measurements: 
The melt flow index (MFI) of the filaments was measured using an adaptation of the ISO 
1133-1 standard method (184). The printing head of the MakerBot® Replicator 2X was 
detached from its roller feeding zone and used to melt the filaments. A piston attached to 
a metal weight of 80 g was used to propel 2 cm slices of the filament through the nozzle 
(Figure 4-2). The filament melt flowing from the nozzle was collected at specified time 
intervals and weighed. The mass of the polymer (in milligrams) extruded per second was 
regarded as the MFI of the polymer. Using this adapted method maintains the gravimetric 
flow of the polymer melt that is characteristic of standard MFI measurements, but over 
the relevant capillary diameter of the printing nozzle. The MFI measurements for PCL 





Figure 4-2: Illustration for the method adapted for measuring the melt flow index for different 
materials 
 
The quantity (in milligrams) of material deposited per second during an actual FDM 
printing process is defined in this study as the FDM-MFI. The FDM-MFI values of the 
PCL filaments were measured at three different printing speeds (30 mm/sec, 90 mm/sec, 
and 160 mm/sec) over a range of processing temperatures (70-130 °C). For both MFI and 
FDM-MFI measurements, the rate of deposition of the objects was then expressed as 
weight deposited per unit time (mg/min). 
 
4.2.5. Levelling of the build plate of the printer: 
Two investigations of the platform levelling were performed. Inter-person calibration: the 
platform was levelled by two operators, then six square films were printed and their 
weights and dimensions quantified. Same person inter-day calibration: the platform was 
levelled by the same operator on two different days; then, a set of six squares were printed 
and their weights and dimensions were quantified. The object used for calibration was a 
simple square design with an edge length of 10 mm and a thickness of 1 mm printed using 
standard printer settings at 100 ºC. The printed squares were accurately weighed and 
measured with a digital calliper. The measured values were compared via an Independent 
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Sample T-Test, the null hypothesis being there is no significant difference in the weight 
and dimensions of the films when different operators levelled the printer. 
 
Levelling was conducted as per the standard printer levelling procedure outlined in the 
user manual of the printer (39). The card supplied with the instrument was placed between 
the nozzle and the build plate at various positions around the build plate and the levelling 
screws were adjusted until the card can just slide between the build plate and the nozzle. 
 
4.2.6. Printing on different surfaces  
The FLE was further investigated by printing the PCL films on three different surfaces, 
Kapton® (polyimide) Tape, aluminium, and glass. Aluminium and glass were secured to 
the build plate using double-sided adhesive tape, to ensure that there was no movement 
of the test surface during printing. All of these printing experiments were conducted using 
a nozzle temperature of 100 °C and a printing speed of 90 mm/sec. The build plate was 
levelled following the protocol described in section 4.2.5. before each printing attempt. 
 
4.2.7. Characterization of printed solid dosage forms 
Microscopic images were acquired using a Linkam Imaging Station, equipped with a 
Linkam MDS600 heating/cooling stage (Linkam Scientific Instruments, Tadworth, 
United Kingdom). Image analysis (dimensions measurements) was conducted using 
LINK software version 1.0.5.9 (Linkam Scientific Instruments, Tadworth, United 
Kingdom) to measure the road widths of the 3D printed objects.   
 
ATR-FTIR spectroscopy and DSC were used to characterise all materials used in this 
study. ATR-FTIR was conducted using a scanning range of 4000 cm-1 – 600 cm-1. DSC 
was used to characterize the pure materials (PCL commercial filament, PCL powder, and 
ASA powder), the physical mixes, and extruded filaments. PCL powder was characterised 
using a heat-cool-reheat method with a range from 20 ºC to 120 ºC, followed by cooling 
to -90 ºC, then reheating to 120 ºC.  ASA powder and physical mixes of all three 
formulations were scanned using a heat-cool-reheat method; samples were tested over a 
range of 20 ºC to 150 ºC, then cooled to -90 ºC, and then reheated to 150 ºC. All extruded 
filaments were characterized using a heat-cool-reheat method using a temperature range 
of -90 ºC to 150 ºC. A heating/cooling rate of 10 ºC/min was used for all experiments. All 
samples were equilibrated for 3 minutes at either 20 ºC or -90 ºC at the start of each 




4.2.8. Statistical Analysis 
Independent sample T-tests were conducted using Microsoft Excel (version 2016) 
expanded with the statistical data analysis add-on.  
 
Summed Standard Deviation (SSD) was calculated as follows: For each value of 
temperature (T) and speed (S), the normalised standard deviations (P’) of the measured 
parameters weight (M), length (L), width (W), thickness (D), and road width (R), were 








)𝑻,𝑺    (Equation 4-1)   
  
Where 𝑷𝒊 is the value of the measured parameter at a fixed value of S and T and 𝜎𝑖
𝑝
 is its 
standard deviation. These were summed as shown in equation 2. 
 











𝑹]𝑻,𝑺    (Equation 4-2) 
 
Principal Component Analysis (PCA) was conducted on all the measured responses using 
IBM® SPSS statistics (version 25). Following the Kaiser rule, only principal components 
with an eigenvalue ≥ 1 were extracted (n = 2), yielding a total explained variance of 
82.15% (Principal Component 1: 57.77%. Principal Component 2: 24.38%). The 
unrotated components matrix showed no factor that could be explained solely by either 
principal component (coefficient < 0.4), therefore, Varimax rotation was conducted such 
that each factor is solely described by a single principal component. The loadings plot 
was used to extract variable scores for each of the two factors (printing temperature, and 
printing speed), the scores were imported into Microsoft Excel and used to generate a 




4.3. Results  
4.3.1. Material characterisation: 
4.3.1.1. Differential Scanning Calorimetry 
Drug incorporation can often cause changes to the printability of polymeric filaments, in 
most cases due to the plasticisation effect of the drug when a molecular dispersion is 
formed between the drug and the polymer. Three levels of drug loading were used to 
create filaments that were either true molecular dispersions or supersaturated with the 
crystalline drug in the filaments. DSC and ATR-FTIR spectroscopy were used to 
characterise the physical state of the ASA in the filaments prepared by HME.  
 
Figure 4-3 shows the DSC thermograms of PCL (both powder and commercial filaments) 
and pure ASA powder.  The Tg of PCL was seen at approximately -64 °C in both the 
powder and commercial filaments. Tm onset was seen at approximately 53 °C, with the 
peak midpoint at 59 °C for the commercial filament, and 57 °C for the powder.  Tm of 
ASA was seen at 141 °C. 
 
Figure 4-3: DSC thermograms of ASA, PCL commercial filament, and PCL powder 
 
For the powder mixtures (Figure 4-4), the Tm of ASA was not seen during the first heating 
cycle in neither the 5% nor the 10% ASA-to-PCL ratios. In the 15% ratio, an endothermic 
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event occurring at approximately 135 °C was seen. During the second heating cycle of 
the powder mixtures, significant changes in the glass transitions were observed; the Tg of 
the 5% was seen at -70.74 °C, the Tg of the 10% mixture was seen at -63 °C, and the Tg 
of the 15% mixture was seen at -55 °C. A depression in the Tm of PCL was also seen in 
the second heating cycle of the powder mixtures. The magnitude of this Tm depression is 
notably inversely proportional to the %ASA within the mixture. 
 
Figure 4-4: DSC thermograms of the PCL-ASA powder mixtures. A: first heating cycle. B: 
second heating cycle 
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Figure 4-5 shows the DSC thermograms of the ASA-PCL melt-extruded filaments. In the 
5% melt-extruded filament, the Tg of PCL was seen at -64 °C. The Tg of PCL was seen at 
-61 °C in both the 10% and 15%. Notably, an endothermic event was seen in the DSC of 
the 15% filament at approximately 80 °C. 
 
Figure 4-5: DSC thermograms of melt-extruded PCL-ASA filaments. 
 
4.3.1.2. Attenuated Total Reflectance – Fourier Transform Infrared 
Spectroscopy 
Figure 4-6 shows the ATR-FTIR spectra of PCL, and ASA (both as a crystalline powder 
and a melt), and the ASA-PCL formulations. Absorption bands characteristic of PCL 
include the C=O stretching at 1725 cm-1, C-O stretching at 1293 cm-1, and the C-OH 





Figure 4-6: ATR-FTIR spectra of the melt-extruded filaments and their raw materials. 
 
Bands characteristic to crystalline ASA are the C=O stretching peaks at 1749 cm-1 and 
1679 cm-1, corresponding to the carboxyl groups in the acetate and salicylate moieties 
comprising the structure of ASA, aromatic C=C stretching at 1606 cm-1, and a strong 
doublet peaking at 1306 cm-1 and 1294 cm-1, likely corresponding to C-O stretching of 
the acetate moiety, and a strong peak at 1184 cm-1 corresponding to the C-OH stretching 
of the salicylate moiety. In the ASA melt, the carboxyl band at 1679 cm-1 was shifted to 
1683 cm-1, the C=C benzene stretch was shifted to 1603 cm-1, the doublet at 1306 cm-
1/1294 cm-1 morphed into a broad singlet peak centred around 1288 cm-1. The C-OH peak 
was shifted to 1179 cm-1. 
 
The spectrum of the 5% formulation was dominated by PCL bands. The C=O stretching 
band of PCL was seen, albeit shifted to 1722 cm-1. The C=C stretching of the benzene 
ring in ASA and the C-O stretching of PCL are also visible, without any shifts. A broad 
C-OH peak was seen, centred around 1165 cm-1, the shape and the significant broadening 
of this peak suggests that it consists of the merged C-OH peaks of PCL and ASA.  
 
In the 10% formulation, ASA bands are more prominent. The carboxyl stretching peaks 
of ASA can both be seen, without any shifts from those seen in crystalline ASA. The C=C 
stretching peak at 1606 cm-1 is more prominent. The C-O doublet which was absent in 
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the 5% is now clearly visible, with the peak at 1290 cm-1 being shifted to 1294 cm-1. 
Furthermore, the C-OH peak of ASA is now clearly visible, having shifted to 1182 cm-1, 
this peak also notably has a shoulder, which is absent from the peak in crystalline ASA 
but is present in the spectrum of the ASA melt.  
 
The spectrum of the 15% showed all the characteristic peaks of both ASA and PCL very 
clearly. The C=O stretching peaks of both ASA and PCL are very prominent, the two C=O 
stretching bands of ASA can be seen at 1686 cm-1 and 1751 cm-1. The C=O stretching of 
PCL can be seen at 1723 cm-1. Similar to the 10% formulation, the C-O doublet is visible 
at 1306 cm-1, with the peak previously seen at 1290 cm-1 having shifted to 1294 cm-1. The 
C-OH stretch of ASA was seen at 1185 cm-1, albeit with much broader and clearly defined 
shoulder, likely caused by merging with the C-OH peak of PCL. 
 
The results indicate the formation of a molecular dispersion of ASA in PCL at 5% drug 
loading, whereas both the 10% and 15% formulation contain a crystalline fraction of ASA. 
The shifted peaks of the C-O and C-OH groups indicate the molecular interaction of ASA 
and PCL via hydrogen bonding at the carboxyl groups, as seen in Figure 4-6.  
 
4.3.2. Impacts of build plate levelling: 
It has been previously reported in the literature that the levelling of the build plate of 
MakerBot® printers causes a significant difference in the weights of the 3D printed objects 
when conducted by different operators (54). In an attempt to prevent this discrepancy 
from misattributing other findings of this work, two investigations of the platform 
levelling were performed. Inter-person calibration: the platform was levelled by two 
operators, then six square films were printed and their weights and dimensions quantified. 












Table 4-2: Effect of levelling by different operators on the weight and dimensions of the printed 
objects. RSD: Relative standard deviation ((𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 ⁄ 𝑀𝑒𝑎𝑛) × 100). 
Operator I 
n Thickness (mm) Length (mm) Width (mm) Weight (mg) 
1 1.09 9.92 10.01 110.6 
2 1.04 10.03 10.10 114.6 
3 1.07 10.00 10.16 113.4 
4 1.05 10.00 10.09 111.0 
5 1.10 9.91 10.02 109.8 
6 1.05 9.99 10.20 111.0 
RSD 2.25% 0.48% 0.74% 1.65% 
Operator II 
n Thickness (mm) Length (mm) Width (mm) Weight (mg) 
1 1.03 10.05 10.16 107.7 
2 1.08 10.05 10.23 112.6 
3 1.04 10.06 10.13 111.1 
4 1.06 10.05 10.20 112.5 
5 1.04 9.96 10.18 108.7 
6 1.06 9.94 10.10 110.1 
RSD 1.71% 0.53% 0.46% 1.8% 
Independent Sample T-Test 
P-Value (Length) P-Value (Width) P-Value (Thickness) P-Value (Weight) 
0.223 0.101 0.127 0.137 
 
For the same person inter-day calibration, the platform was levelled by the same operator 
on two different days; then, a set of six squares were printed and their weights and 
dimensions were quantified. The object used for calibration was a simple square design 
with an edge length of 10 mm and a thickness of 1 mm printed using standard printer 








Table 4-3: Inter-day variation in levelling on the weight and dimensions of the printed objects. 
RSD: Relative standard deviation ((Standard deviation⁄Mean)×100). 
Day 1 
n Thickness (mm) Length (mm) Width (mm) Weight (mg) 
1 1.09 9.92 10.01 110.6 
2 1.04 10.03 10.10 114.6 
3 1.07 10.00 10.16 113.4 
4 1.05 10.00 10.09 111.0 
5 1.10 9.91 10.02 109.8 
6 1.05 9.99 10.20 111.0 
RSD 2.25% 0.48% 0.74% 1.65% 
Day 2 
n Thickness (mm) Length (mm) Width (mm) Weight (mg) 
1 1.02 10.08 10.11 108.7 
2 1.04 10.09 10.12 108.4 
3 1.07 10.03 10.14 105.2 
4 1.03 10.06 10.11 107.9 
5 1.02 10.03 10.08 104.5 
6 1.04 10.06 10.14 109.7 
RSD 1.83% 0.25% 0.23% 1.93% 
Independent Sample T-Test 
P-Value (Length) P-Value (Width) P-Value (Thickness) P-Value (Weight) 
0.004 0.213 0.04 0.006 
 
 
4.3.3. Impacts of melt flow of the printed materials: 
The Melt Flow Index (MFI), is defined by the ISO standard 1133-1 as “the mass of the 
molten polymer, in grams, that flows through a capillary of a specific diameter in 10 
minutes” (184). The MFI of a filament is often cited as one of the key factors defining 
the success of an FDM printing process (43,180,185). The MFI is highly associated with 
the thermal viscosity of the filament materials at a certain printing temperature (183). 
Therefore, MFI measurements (which describe the amount of PCL deposited due to its 
melt flow) were compared to the amount deposited during FDM printing. The results are 




Figure 4-7: FDM-MFI and MFI (secondary axis) measurements of PCL commercial filament 
 
MFI measurements showed that PCL has a measurable MFI at a temperature of 70 ºC; 
however, the printing of PCL was only possible at this temperature at the lowest speed of 
30 mm/sec. Objects printed at 80 ºC and either 90 mm/sec or 160 mm/sec were distorted, 
with very poor printing quality and erratic melt deposition. Therefore, samples printed at 
70 ºC and 80 ºC were disregarded. This suggests that there is a lower limit to the melt 
flow index below which good quality printing is not possible. 
 
Despite the temperature dependence of rheology seen in the MFI experiments, there was 
a very weak temperature dependence of deposition rates when printed using FDM. This 
implies that over the range of relevant printing temperatures, the change in the melt flow 
of the filament is not too great to significantly impact the amount of material being 
deposited by the print head. The only effect was seen at 70 ºC where printing was only 
possible at a printing speed of 30 mm/s.  This leads to the hypothesis that, provided that 
the operating speed is sufficient to overcome the viscosity of the polymer melt, the 




4.3.4.  Impact of processing conditions on weight uniformity: 
Figure 4-8 shows the weights of the printed films at different processing conditions. At a 
fixed printing speed, increasing the printing temperature caused an increase in the weights 
of the printed grids. The standard deviations of weights does not seem to follow any trends 
either with temperature or printing speed. The largest recorded standard deviation was 
±3.2 mg at 90 mm/sec and 120 ºC. The second largest being ±3.0 mg at 30 mm/sec and 
70 ºC, and the third-largest being ±2.4 mg at 30 mm/sec and 110 ºC. Notably, fixing the 
printing speed at 160 mm/sec yields the narrowest standard deviations, with the smallest 
standard deviation at that speed being ±0.1 mg at 100 ºC, and the largest being ±0.9 mg, 
seen at both 120 ºC and 130 ºC. Even though all the reported standard deviations fall well 
within acceptable limits for weight uniformity specified in the pharmacopoeias, it is worth 
noting that changing the printing conditions was seen to substantially impact weights of 
the printed objects, by as much as 31.3 mg. The lightest printed object weighed 169.1 mg 
(±0.5 mg, printed at 70 ºC, and 160 mm/sec), and the heaviest printed object weighing 
200.3 mg (±1.5 mg, printed at 130 ºC, and 30 mm/sec). 
 
 
Figure 4-8: weights of the 3D printed films 
 
On average, the impact of the printing temperature on melt deposition rate was not as 
significant as printing speed. It appears that it may impact the reproducibility of the 




4.3.5. Impact of processing conditions on dimensional authenticity: 
Figure 4-9 shows the impact that different printing conditions had on the lengths and 
widths of the 3D printed films. Printing at 90 mm/sec and 160 mm/sec yielded objects 
that possessed greater length and lower width than the target (average dimensions being 
25.29 mm ± 0.06 mm x 24.95 mm ± 0.04 mm for 90 mm/sec, and 25.29 mm ± 0.11 mm 
x 24.93 mm ± 0.04 mm for 160 mm/sec), showing no significant difference in dimensions 
between the two conditions. However, printing at 30 mm/sec yielded objects that were 
smaller than the target geometry of 25 mm x 25 mm (with the films being, on average, 
24.68 mm ± 0.06 mm x 24.33 mm ± 0.11 mm). At this speed, no changes in length and 
width relative to changing the temperature were observed. In terms of reproducibility of 
lengths and widths, none of the three printing speeds showed remarkably different results, 
with no significant differences between the standard deviations of dimensions between 
the three printed conditions. 
 
 
Figure 4-9: Impact of processing conditions on the lengths and widths of the 3D printed films 
 
Figure 4-10 shows the impact of printing conditions on object thickness. The thickness of 
the 3D printed objects tended to decrease with increasing temperature for both 160 
mm/sec and 30 mm/sec, going from 0.65 mm ± 0.00 mm at 90 ºC to 0.61 mm ± 0.01 mm 
at 130 ºC when printed at 30 mm/sec, and from 0.65 mm ± 0.02 mm to 0.59 ± 0.01 mm 
when printing at 160 mm/sec. Objects printed at 90 mm/sec had, on average, consistent 
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thickness, independent of printing temperature. Furthermore, printing at 90 mm/sec 
appears to have the most reproducible object thicknesses, with the narrowest recorded 
standard deviation at said speed being ± 0.00 mm, and the widest being ± 0.01 mm (within 
the limits of detection of the digital calliper used).  
 
 
Figure 4-10: Impact of processing conditions on the thickness of 3D printed films 
 
Microscopic imaging of the printed films revealed that the road width of the first layer is 
much larger than that of the subsequent layers, and the width of the first layer appears to 
be correlated to the nozzle temperature. This correlation between first layer road width 
and the reduction of object thickness with increasing temperature suggests that when the 
first layer is deposited on the build plate, the fluid melt spreads sideways, increasing in 





Figure 4-11: The First Layer Effect. 
 
For the commercial printers, the pre-set (target) object parameters are dimensions instead 
of weight. Therefore, it is important to understand the effect of the process parameters by 
comparing the measured printed object dimensions to the target values pre-set by the STL 
file. Despite the source STL file being designed as a square in this study, all the objects 
printed displayed a difference between length and width. To avoid ambiguity, length was 
defined as the dimension parallel to the roads of the first layer, and width as the dimension 
perpendicular to the roads of the first layer. The impact of the printing temperature on the 
dimensions (width, length, and thickness) of the objects are illustrated in Figures 4-9 and 
4-10. For each printing condition, the length of the objects was found to be larger than 
the width of the objects. The printing temperature showed no significant effect on the 
reproducibility of the length and width of the printed films at a fixed printing speed.  
 
4.3.6. Impact of processing conditions on the road width: 
Figure 4-12 shows the average road width of each layer under different printing 
conditions. The top layer is the closest to the nozzle. The platform layer is the bottommost 





Figure 4-12: Impact of processing conditions on the road widths of the printed films 
 
No significant difference was seen between the top and middle layers of the objects, 
regardless of printing conditions. The average road width for the top layer was 347.0 µm 
± 12.00 µm at 30 mm/sec, 345.0 µm ± 15.37 µm at 90 mm/sec, and 323.5 µm ± 25.62 
µm at 160 mm/sec. The average road width for the middle layer was 341.3 µm ± 18.46 
µm at 30 mm/sec, 310.4 µm ± 13.56 µm at 90 mm/sec, 316.8 µm ± 27.45 µm at 160 
mm/sec.  The platform layer displayed a larger road width than the corresponding top and 
middle layers at every printing condition, with the average road width of the platform 
layer being 438.8 µm ± 51.79 µm at 30 mm/sec, 425.8 µm ± 34.56 µm at 90 mm/sec 
436.1 µm ± 68.63 µm at 160 mm/sec.  
 
The road width of the platform layer was also observed to vary proportionally to printing 
temperature. There was a notable decrease in the average road width of the first layer at 
different printing temperatures; at 30 mm/sec, the road width increased from 402.1 µm ± 
12.9 µm at 90 ºC to 517.5 µm ± 26.0 µm at 130 ºC. At 90 mm/sec, the road width increased 
from 420.5 µm ± 19.1 µm at 90 ºC to 465.2 µm ± 14.9 µm. At 160 mm/sec, the road width 
increased from 422.0 µm ± 35.7 µm at 90 ºC to 554.0 µm ± 55.9 µm at 130 ºC. Due to 
the platform layer being the first layer constructed during the fabrication of the object, 
this phenomenon has been dubbed The First Layer Effect (FLE). This spreading effect is 
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assumed to be caused by the nature of the interaction of PCL with the surface of the 
Kapton® tape. Therefore, printing was attempted on different surfaces.  
 
 
Figure 4-13: Road widths of the first layer when printing on different platform surfaces. 
 
Printing on different surfaces yielded different spreading amounts (Figure 4-13). Building 
on glass was found to yield the narrowest average road width (322.3 µm ± 13.03 µm). 
Building on aluminium was found to yield the widest road width (419.8 µm ± 22.00 µm). 
The increased spreading with temperature when printing on Kapton® is likely due to 
decreased viscosity of PCL at higher temperatures allowing it to flow more prior to 
solidifying.  
 
When printed at higher temperatures (> 110 °C) PCL was found to bind strongly to the 
Kapton® tape. When printed at lower temperatures (i.e. 80 °C – 100 °C), the PCL films 
were easily removed. However, no sticking to aluminium or glass was observed. This is 
most probably caused by weak interactions between PCL and Kapton® at higher 
temperatures.  
 
4.3.7.  Impact of drug incorporation 
It would be expected that a drug-polymer molten solution would exhibit different 
spreading behaviour when printed on the surface since the incorporation of the drug 
would be expected to alter the physical properties of the mix (99). This was investigated 
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by printing ASA-loaded PCL filaments at a median condition of 100 °C and 90 mm/sec. 




Figure 4-14: First layer road width of drug loaded and placebo filaments printed at 90 mm/sec 
and 100 °C 
 
No significant difference was seen in the nozzle and middle layer between the three drug-
loaded filaments and the placebo filament. However, there is a significant increase in the 
average road width of the first layer that was brought about by incorporation of ASA in 
PCL; printing at 90 mm/sec and 100 °C showed an increase in the first layer road width 
from ≈ 390 µm to > 600 µm. This is likely due to the presence of ASA in the PCL matrix 
decreasing the viscosity of the melt, allowing for a greater extent of spreading before the 
road completely solidifies. No significant difference was seen between the three drug-
loaded formulations, this could be attributed to the ASA-PCL melt reaching the maximum 
possible wettability it can achieve on Kapton® before it solidifies, regardless of drug 
loading. Notably, the drug-loaded objects exhibited greater sticking to the platform than 
their placebo counterparts, requiring very careful peeling off the platform with a razor 




4.3.8. Statistical Analysis 
The SSD scores for all printing conditions can be seen in Figure 4-15. The processing 
parameters 120 °C and 90 mm/sec yielded the lowest SSD while 130 °C and 160 mm/sec 
yielded the highest SSD. Objects printed at 90 mm/sec notably had lower SSD scores for 
every single temperature than their counterparts printed at 30 mm/sec and 160 mm/sec. 
The SSD scores represent a figure of merit which can be used to select a set of printing 
conditions which will give minimal overall variability.  
 
 
Figure 4-15: SSD scores of printability of all tested conditions. 
 
Figure 4-16 shows the loadings plot of the measured responses in rotated space. Principal 
Component 1 (PC1) was found to describe object mass, road width, length, width, and 
the printer deposition index, corresponding to 57.77% of the total variance. Principal 
Component 2 (PC2) was found to describe object thickness, and first layer width, 
corresponding to 24.38% of the total variance. Object thickness and the first layer effect 
were found to correlate more strongly with printing temperature than with printing speed. 
Object mass, length and width, and the FDM-MFI were found to vary more significantly 
in response to change in printing speed rather than printing temperature. Therefore, one 
may extrapolate that PC1 may be redubbed the speed axis, as it describes variance 
introduced due to change in printing speed. Similarly, PC2 may be named the temperature 
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axis as the variables it describes are those that alter more significantly in response to 




Figure 4-16: Loadings plot in rotated space. (FLW: first layer width. RW: road width). 
 
Length, width, mass, FDM-MFI, and road width were all described by the speed axis. 
Length, width, and FDM-MFI being anti-correlated to mass and road width, with the 
former three loading positively, and the latter negatively, indicating that length, width, 
and the FDM-MFI are directly correlated to printing speed, while mass and road width 
are inversely correlated.  
 
Figure 4-17 shows the biplot obtained when case scores were projected onto the loadings 
plot shown in Figure 4-16. The X-axis, denoting the scores of the cases against PC1, 
unsurprisingly separates the cases into three clusters relative to printing speed, with three 
clusters showing clear separation between the 30 mm/sec set, followed by 90 mm/sec, 





Figure 4-17: Biplot projecting the scores of the studied cases onto the response loadings. 
 
The Y-axis, which shows the scores loadings relative to PC2 (the temperature axis) 
describes quality parameters which are influenced by printing temperature (object 
thickness, and the FLE). While the clusters do not appear to offer any meaningful metric 
towards either parameter at first glance, closer observation reveals that both object 
thickness and FLE are not described within each cluster, but rather between the clusters. 
With respect to object thickness, looking at objects printed at the same temperature (i.e. 
90 ºC), the one printed at 160 mm/sec was the thickest, followed by the object printed at 
30 mm/sec, with 90 mm/sec coming in third. Similarly, with respect to FLE, of the objects 
printed at 100 ºC, the one printed at 160 mm/sec had the largest FLE, followed by the one 
printed at 30 mm/sec, followed by the one printed at 90 mm/sec. This inter-cluster pattern 
was found to apply to all the observed cases. Furthermore, the 90 mm/sec cluster was the 
most centred cluster with respect to the four quadrants of the biplot, indicating that 90 





4.4.1. Material characterisation:  
The DSC thermograms of the ASA-PCL physical mixtures suggest that the mechanism 
by which ASA is incorporated into PCL is via thermal dissolution. This is evidenced by 
the absence of the melting of ASA in both the 5% and 10% physical mixtures during the 
first heating cycle, but the existence of a significant difference in both the Tg and the Tm 
of PCL between the formulations in the second cycle. The depressed Tm of ASA was seen 
in the 15% physical mix at approximately 135 °C but was not seen in the second cycle. 
ASA appears to have an antiplasticisation effect on PCL, as evidenced by the increase in 
the Tg of PCL per ASA concentration in the physical mix. The Tg of ASA was presumably 
seen at -33 °C during the second heating cycle. However, it should be noted that, due to 
ASA rapidly degrading beyond its melting point, it is difficult to ascertain whether the 
detected transition belongs to ASA or to a related compound to which ASA degrades.  
 
The thermogram of the 5% formulation showed no signs of crystalline ASA within the 
matrix. Furthermore, the ATR-FTIR spectrum of the 5% filament showed a clear shift in 
the C=O stretching band of PCL from 1725 cm-1 to 1722 cm-1, and the C-OH peak shifted 
from 1163 cm-1 to 1165 cm-1. Furthermore, the C-O stretch at 1293 cm-1 was notably a 
weak singlet peak, unlike the strong doublet seen in crystalline ASA. The absence of 
peaks characteristic to crystalline ASA in the ATR-FTIR spectrum, coupled with the 
absence of the Tm of ASA in the thermogram strongly suggests ASA is molecularly 
dispersed in the PCL matrix. The shift in the C=O and C-OH peaks of PCL point towards 
hydrogen bonding at the carboxyl groups as the main ASA-PCL interaction maintaining 
the solid dispersion.  
 
The endothermic event seen at 80 °C in the thermogram of the 15% filament likely 
corresponds to the depressed melting endotherm of ASA. The absence of any significant 
difference in the glass transition and melting endotherm of PCL in the 10% and the 15% 
formulations further supports that the continuous phases of the two formulations are 
similar, indicating that the thermal event seen at 80 °C is crystallised ASA. The ATR-
FTIR spectra of the 10% and 15% filaments both display the C-O doublet previously seen 
in the spectrum of crystalline ASA. However, the peak at 1290 cm-1 has shifted to 1295 
cm-1 in the 10% filament, and to 1294 cm-1 in the 15% formulation. The C-OH peak seen 
in crystalline ASA at 1184 cm-1 was seen in the 10% peak at 1182 cm-1. This indicates 
that both the 10% and 15% formulation contain a crystalline fraction of ASA, which was 
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not seen in the 10% thermogram possibly due to detection limits of the DSC. The shifted 
peaks of the C-O and C-OH groups still indicate that the molecularly dispersed fraction 
of ASA is maintained by hydrogen bonding at the carboxyl groups. The saturation 
solubility of ASA in PCL is likely somewhere between 5% and 10%. 
 
4.4.2. Validation of build plate levelling:  
An article published by Melocchi et al. previously reported the existence of significant 
variation on the weights and dimensional accuracy of FDM printed objects when the 
printer platform was levelled by different individuals, and even by the same individual on 
different occasions (54). Therefore, minor validations of platform levelling operation 
were conducted (Tables 4-2 and 4-3). This was coupled with the use of an independent 
sample T-Test to compare the weights and dimensions yielded when the printer is levelled 
by different operators. As can be seen in Table 4-2, the levelling of the printer by different 
operators had no significant impact on the weight uniformity, nor the dimensional 
consistency of the 3D printed objects. However, as shown in Table 4-3, a significant 
difference was observed (most importantly in weights of the printed objects) when the 
printer was levelled by the same operator on two different days. 
 
Both our findings and what was reported by Melocchi et al. serve to highlight the operator 
dependence of the calibration of this model of printer which can be a potential problem 
in this design of the printer if it is used for printing pharmaceutical standard products. The 
current method employed by the printer to level the build plate is very subjective; The 
instructions for levelling the platform of a MakerBot® Replicator 2 used in both studies 
read “tighten the three knobs under the build plate until a thin piece of paper can just 
slide between the nozzle and the platform with some friction” (39).  Relying on the 
operator’s judgment as ‘suitable friction’ between the nozzle tip and levelling card. While 
this may be adequate for printing large commercial prototype objects, it is unlikely to be 
a suitable ‘calibration’ method for pharmaceutical printing of oral solid dosage forms 
where high printing precision is required. Therefore, we conclude that the contradictions 
between what was previously reported by Melocchi et al., and what is presented herein 





4.4.3. Impact of processing conditions on the perceived quality attributes of 3D 
printed objects.  
Optimisation of printing temperature, and by extension the melt rheology of the polymers, 
is regarded as a key significant factor to optimize for FDM formulation design (43,185). 
Initially, MFI studies (Figure 4-7) were conducted to attempt to determine the rationale 
behind manufacturer-recommended printing temperatures from a melt-flow perspective. 
The commercial PCL filament tested unsurprisingly exhibited pseudoplastic melt flow 
that is characteristic of thermoplastic, polymeric materials (183). However, no 
noteworthy change in FDM-MFI was observed at, or near the manufacturer recommended 
printing temperature.  
 
As can be seen in Figure 4-7, plotting the MFI of PCL commercial filament against its 
FDM-MFI at different speeds shows the fundamentally different behaviour exhibited by 
random melt flow in comparison to printing. The FDM-MFI, being an adaptation of ISO 
MFI standard, yields a largely exponential curve with temperature. The MFI standard 
method, as well as the adapted version described herein, rely on a weight being pulled by 
the influence of gravity to propel the polymer melt through the orifice. Which dictates 
that the object will always be accelerating downwards by a factor of 9.8 m/sec2 minus the 
resistance to flow exerted by the polymer melt. However, FDM printers propel the 
filament through the use of a stepper motor at a constant rate. Furthermore, as can be seen 
in Figure 4-8, weights of the 3D printed films were not found to correlate with printing 
temperature. And, as seen in Figure 4-7, FDM-MFI was not found to be influenced by 
temperature, but rather by printing speed, leading to the conclusion that, provided the 
selected printing temperature allows for the flow of the polymer melt, printing 
temperature does not significantly impact the properties of objects printed via FDM. This 
is further supported by considering the engineering of the FDM printer. The printing head 
utilises a stepper motor to drive the filament forward. As can be seen in Equation 4-3 
below, the torque of a stepper motor is a function of the current flowing through the motor 
multiplied by its intrinsic torque constant (186).  
 
𝑇𝑜𝑟𝑞𝑢𝑒 = 𝐾𝑇 ∗ 𝑖     (Equation 4-3) 
   
Where KT is the torque constant of the motor, and i is the current. In other words, the 
torque is independent of the weight/resistance to motion of the material the motor is 
attempting to push. The load on the stepper motor in the 3D printer is the temperature-
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dependent resistance to flow exerted by the polymer melt. Which explains the 
temperature-independence of the FDM-MFI observed in this study.  
 
An engraving on the back of the stepper motor driving the 3D printer used in this study 
identified its make and model to be a Moons’ MS17HD4P6038 (Moons’ Electric Co. Ltd., 
Shanghai, China). The datasheet of the motor was retrieved from the website of the 
manufacturer (187), from which Figure 4-18, the torque-speed curve of the motor, was 
obtained. As can be seen in Figure 4-18, operating the motor at higher speeds yields lower 
torque values. The magnitude of this decrease tends to a plateau at higher operating speeds 
(hereinafter referred to as the steady torque region). Notably, the increase in the FDM-
MFI from 30 mm/sec to 90 mm/sec was much larger than the increase in FDM-MFI from 
90 mm/sec to 160 mm/sec. Which is likely due to the high operating speeds (90 mm/sec 
and 160 mm/sec) occurring near or on the steady torque region of the motor. Furthermore, 
attempted printing at 70 °C was notably only successful at 30 mm/sec, this is likely due 
to it being the only speed at which the motor possesses sufficient torque to overcome the 
viscosity of the PCL melt at that temperature.  
 
 
Figure 4-18: Torque vs. speed curve of the Moons’ MS17HD4P6038 stepper motor used by the 
Makerbot® Replicator 2 
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Per every printing condition, the printer was found to yield highly reproducible weights 
(Figure 4-8). With the largest recorded standard deviation being 3.2 mg for objects printed 
at 120 °C and 90 mm/sec. While this falls well within general pharmacopoeial standards, 
simply modifying the printing speed caused the printed film to increase in weight by 
nearly 20 mg in some cases. If FDM is to be utilised in personalised medicine, careful 
screening of the printing parameters, and choosing the appropriate conditions to match 
the target dose is of utmost importance (4).  
 
As shown in Figures 4-9 and 4-10, none of the objects printed in this study matched the 
theoretical dimensions dictated by the STL file. While none of the objects created in this 
study matched the theoretical dimensions, no significant difference was seen in printing 
at 90 mm/sec and 160 mm/sec, printing at 30 mm/sec, however, yielded objects that were 
significantly different from the other two printing speeds.  
 
4.4.4. The First Layer Effect 
A significant difference in road width was seen between the platform layer and the two 
subsequent layers. This effect was found to be temperature-dependent, with the road 
width of the platform layer being directly correlated with the printing temperature. 
Notably, no significant difference was seen between the middle layer and the top layer 
regardless of printing temperature, nor printing speed. 
 
This spreading effect is assumed to be caused by the surface wettability of the Kapton® 
tape. Printing on different surfaces yielded different spreading amounts, as can be seen in 
Figure 4-13. However, there was a notable difference in the stickiness of the PCL printed 
films to the different surfaces; PCL was found to bind strongly to the Kapton® tape and 
was very difficult to remove, particularly when printed at higher temperatures (> 110 °C). 
When printed at lower temperatures (i.e. 80 °C – 100 °C), the PCL films were easily 
retrieved off the platform. However, almost no sticking to aluminium nor glass was 
observed. This points towards the existence of two factors influencing this behaviour. The 
first being the wettability of the surface. The temperature-dependent spreading and the 
sticking of the objects to the Kapton® tape at elevated temperatures are probably due to 
the formation of PCL-polyimide interactions at elevated temperatures, yielding greater 




4.4.5. Statistical Analysis 
The data above demonstrated the quality of the printed dosage form is a result of the 
complex interplay between different processing and materials factors. These factors also 
often interact such that varying the level of factors concurrently has a greater impact over 
a perceived measure of goodness than varying either parameter individually. Furthermore, 
while one can measure particular properties of the 3D printed object (such as weight, 
dimensions, road width, etc.) to be utilised as measures of goodness for parameter 
selection, this remains a non-straightforward process. Mainly because processing 
conditions that appear to produce a more favoured object when observing one measure of 
goodness fail when another measure of goodness is considered (i.e. weight v.s. 
dimensional authenticity). Therefore, it is clear that there exists a need for an overarching 
method for selecting the optimum printing conditions which will produce the objects with 
the greatest overall quality. For this purpose, a measure of goodness to determine the 
printing conditions which will produce objects with the highest overall printing 
reproducibility was conceived. Said conditions are those that will yield the minimum 
Summed Standard Deviation (SSD) score. This proposed SSD can be calculated by first 
normalising, then summing the standard deviations of each measured value at each 
condition. As previously mentioned, objects printed at 90 mm/sec had lower SSD scores 
for every single temperature than their counterparts printed at 30 mm/sec and 160 mm/sec. 
Suggesting that 90 mm/sec is the optimum printing speed for this filament.  
 
While the SSD provides a quick method to determine the optimum printing conditions 
for a given filament, further statistical analysis techniques can be used to extract more 
information about the process parameters and how they interact to influence the process. 
Therefore, PCA was conducted as an exploratory data analysis tool to investigate the 
interplay between the different perceived quality parameters.  
 
Observing the measured variables as described by the loadings plot (Figure 4-16) allows 
for a more overarching look at how printing speed and temperature both influence 
perceived quality attributes, as well as how the quality attributes relate to one another. 
Object thickness and first layer width load opposite to each other on the temperature axis, 
suggesting the two are anti-correlated. This suggests that the spreading of the first layer 
not only increases its road width but also decreases road height in the Z-axis. Furthermore, 
first layer width loads positively, while thickness loads negatively on the axis, indicating 
that wider road widths are brought about by higher temperatures while greater object 
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thickness is a result of lower printing temperature. Therefore, a conclusion can be drawn 
that printing at higher temperatures leads to a more drastic FLE, while printing at lower 
temperatures leads to thicker objects.  
 
The length/width vs. road width correlation is an interesting one as it gives insight into 
the operation of the feeding motors, as well as printer accuracy; the anti-correlation 
between road width and printing speed suggests that at higher printing speeds, the printer 
is not feeding sufficient material to keep up with the demands of the higher printing speed, 
leading to the deposited road to be tugged as the print head is moving, stretching it thinner 
(leading to a decrease in road width) and longer (leading to an increase in length/width). 
This argument relating printing speed and feeding speed suggests that, at higher print 
speeds, the printer is not providing enough material feed to faithfully replicate a print at 
lower speeds. Therefore, objects printed at higher speeds should have less mass than their 
lower speed counterparts. This was found to be true as mass loaded negatively on the 
speed axis, and was found to be anti-correlated to length, width, and FDM-MFI. The latter, 
which was found to increase relative to speed (Figure 4-7) was unsurprisingly found to 
load positively on the speed axis. This inverse correlation between printing speed and 
object mass further supports the argument presented in section 4.4.3. regarding the 
printing motor torque-speed relationship. The clustering pattern seen in the biplot in 
Figure 4-17 further supports the argument presented prior relating printing speed to object 
mass and dimensions, as the leftmost cluster, falling on the “largest mass” quadrant of the 
biplot belonged to the 30 mm/sec, then 90 mm/sec, which was then followed by 160 
mm/sec, the “widest dimensions” set. Notably, there is less separation between the latter 
two sets than between 30 mm/sec and 90 mm/sec, which strongly mirrors the FDM-MFI 
results displayed in Figure 4-7. 
 
Of the three clusters, the 90 mm/sec group appears to show the least variance relative to 
the change in printing temperature. Indicating that that printing speed further minimizes 
the significance of printing temperature. This sits in agreement with the result obtained 
from the SSD displayed in Figure 4-15, in which printing at a speed of 90 mm/sec yielded 
the lowest SSD, regardless of printing temperature, indicating that higher reproducibility 
is achieved when printing at 90 mm/sec. Therefore, one may extrapolate that, for the PCL 
filament used herein, printing at 90 mm/sec offers the most predictable and reproducible 





The results of this study demonstrated the significant impacts of the processing 
parameters on the weights and dimensions of the 3D printed dosage forms. For the printer 
used in the study, the printing speed exhibited more profound effects than the printing 
temperature on the weight uniformity and dimension authenticity of the printed dosage 
forms. Printing temperature and the build plate surfaces contribute significantly to the 
FLE. For pharmaceutical applications, the control of such impacts should be thoroughly 
understood as it can impact the performance of the printed formulation. These results 
brought to the conclusion of that careful engineering for a pharmaceutically-suitable 
FDM 3D printer should be treated as a priority for making the shift of FDM 3D printing 
from proof-of-concept to industrial application. The use of summed standard deviations 






Chapter 5  
Infill density and its impact on drug release 
kinetics from oral solid dosage forms prepared 








Infill density is a manipulable parameter in FDM 3D printing (26,68,125,128). The term 
defines the ratio of the volume of free space to the volume of deposited roads within the 
3D printed object. Traditionally, even if the infill is set to 0%, the printed object appears 
to be a completely solid composite (26).  This is due to the roof and floor layers, which 
are printed at 100% infill regardless of the user input, presumably to maintain an attractive 
surface finish. The roof and the floor serve to provide a more aesthetically attractive 
surface finish to the object, as well as provide structural support to strengthen the object. 
For the make of printer used herein, the default roof and floor thickness are 0.8 mm each. 
When printing with default settings, any fabricated object will always possess a roof and 
a floor, each having a thickness of 0.8 mm and an infill density of 100%, regardless of 
what infill the user has instructed the printer to use (39). An example of this would be the 
article presented by Goyanes et al., in which they 3D printed 4-aminosalicylic acid (4-
ASA) and 5-aminosalicylic acid (5-ASA) loaded polyvinyl alcohol (PVA) tablets at three 
infill densities (90%, 50%, and 10%). However, the photographs presented in their article 




Figure 5-1: 3D lower infill 5-ASA tablets with intact floors and roofs, showing no 
differences in external geometries. Figure retrieved from Goyanes et al. (26) 
 
Although the infill density of the roof and the floor cannot be changed, the thickness of 
the roof and floor are customisable, and may even be set to 0 mm, thus allowing the entire 
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object to be fabricated to the infill density which the user has instructed the printer, and 
exposing the internal microstructures of infill region of the printed dosage form.  
 
Some previous articles have briefly investigated the effect that manipulation of infill 
density has on drug release properties, albeit not exhaustively. In the aforementioned 
article by Goyanes et al. (26), Goyanes reported no significant difference in release rates 
of the three 5-ASA formulations. However, the 10% infill formulation of 4-ASA showed 
some enhanced release over its 50% and 90% counterparts. However, no significant 
difference was seen between 50% and 90%. Goyanes concluded that the use of infill 
density may be a useful parameter to consider when aiming to modulate the drug release 
rate from a 3D printed dosage form.  
 
Ibrahim et al. printed metformin-loaded PVA filaments at 10% infill, the tablets were then 
perforated with either one or two piercings along the diameter to “increase their surface 
area”. Drug release studies were then conducted to compare the performance of the 
perforated tablets against tablets left without perforation. Release studies showed no 
significant difference between the three designs (128).  
 
Clark et al. printed small, thin-layered carvedilol-systems by photo-initiated 3D inkjet 
printing (37), of which two variants (the mesh and the ring geometries) can be considered 
infill variants (only those two objects had the same external diameter). No significant 
difference was seen in the drug release rate of the two infill variants. Clark reported that 
the dosage forms swelled during drug release studies. 
 
Kyobula et al. used thermal inkjet printing to print fenofibrate-loaded beeswax tablets 
with honeycomb-pattern infill at different infill densities (36). Of the six infills 
investigated, the four lower density infill formulations showed no significant differences 
in drug release between one another but were significantly faster than a higher infill 
formulation, and the 100% infill formulation. Kyobula reported observing no swelling 
nor erosion from the system, making the release mechanism entirely diffusion-based. 
 
Lamichhane et al. printed both closed (with roof and floor) tablets at 25%, 50%, and 75% 
infill, and open tablets (at 25% and 50% infill) of HPMC-loaded pregabalin (188). Closed 
systems showed no significant difference in drug release rate between any of the three 
formulations, while open systems showed a significantly faster release rate for the 25% 
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infill tablet. The open system tablet (25% infill) was tested against a commercially 
available product (Lyrica™), no significant difference in release rate was observed 
between the printed tablet and the marketed product, likely because the characterisation 
results presented showed the drug to be at least partially phase-separated as crystals in the 
matrix. Due to both the 3D printed formulation and the punch-pressed commercial tablets 
containing crystalline pregabalin, the rate of drug release is going to be limited by the 
dissolution rate of the drug crystals present in both, rendering the dissolution rates similar 
between the 3D printed formulation and the commercially available product.  
 
As outlined prior, there appears to be conflicting evidence about the feasibility of using 
infill density as means to manipulate drug release. While it is clear that the infill – release 
rate relationship is only applicable in open systems (i.e. tablets printed without floors and 
roof), due to the exposed internal structure increasing the available surface area. 
Investigations into the effect of infill density on the drug release rate show what is 
seemingly conflicting reports on the effect of infill density on drug release rate. The 
previously mentioned article by Kyobula et al. (36) showed no effect of infill between 
four different infills, yet displayed a significant effect between a low infill tablet, a high 
infill tablet, and a 100% infill tablet. Yet, the aforementioned findings reported by Clark 
et al. (37) showed no significant difference between the two tablets which can be 
considered to be infill variants. This suggests that there appears to be a maximum 
threshold that the infill density may be reduced to, that, once crossed, induces little to no 
effect on the drug release rate. One factor which has not been accounted for is the 
distortion of the 3D printed tablets during dissolution, due to matrix-media interactions 
(swelling, erosion, relaxation, etc), which may alter the shape of the tablet, altering the 
impact of infill density.  
 
This study investigated the impact of infill on drug release properties of a 3D printed 
object under swelling, and erosion conditions (by varying pH of the dissolution media), 
and under a combination of both conditions in which the tablets were placed for two hours 






5.2. Materials and methods:  
5.2.1. Materials:  
The filament used in this investigation is filament HP10D whose constituents have been 
previously outlined in section 3.3.2., containing 81% of HPMCAS w/w, 9% PEO w/w, 
and paracetamol at 10% w/w. 
 
5.2.2. Methods: 
5.2.2.1. Preparation of filaments by Hot-Melt Extrusion (HME) 
Extrusion was conducted at a screw speed of 100 RPM and a temperature of 155 °C. 
Materials were cycled in the extruder for 5 minutes before flushing to ensure homogeneity 
along the filament. The melt was flushed at a screw speed of 35 RPM onto a conveyer 
belt. The diameter of the extruded filaments was measured using a digital calliper, 
sections of the filament falling outside the range of 1.6 mm ± 1 mm were discarded.  
 
5.2.2.2. Printing of tablets 
Tablets were printed in the shape of a cylinder (dimensions: 10 mm diameter, 2 mm 
thickness) at a layer thickness of 0.2 mm, corresponding to 10 layers per tablet. Roof and 
Floor Thickness were set to 0 mm to allow for the exposure of the internal structure of 
the 3D printed objects. The cylinder shape was designed using Microsoft 3D Builder 
software (version 16.1) and was then exported as an STL file. The STL file was printed 
using MakerBot® MakerWare (version 3.8.0). 
 
 
Figure 5-2: Photographic (Top) and microscopic (bottom) images of the 3D printed 
tablets. Left to right: 100% infill, 75% infill, and 50% infill. 
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Three batches of tablets were printed, at three different infills: 100% infill, 75% infill, 
and 50% infill (Figure 5-2), using the default hexagonal infill pattern. All batches were 
printed using a nozzle temperature of 175 °C onto an unheated build plate.  
 
The microscopic images shown in Figure 5-2 belong to the same samples shown in the 
photographic images in that figure. However, the reflective light microscope used to 
obtain the photographic images could only clearly capture the topmost layer. Therefore, 
some macroscopic distortions visible in the photographs may not be apparent in the 
microscopic images.  
 
5.2.2.3. Material Characterisation 
The materials used were characterised by DSC, ATR-FTIR, and PXRD as described in 
sections 3.2.3.1., 3.2.3.2., and 3.2.3.3., respectively.  
 
5.2.2.4. Drug content uniformity in the filament 
Filament content uniformity measurements were conducted by taking three samples every 
5 cm of weights 8 – 15 mg each along the relevant length of the filament, which were 
then dissolved in pH 6.8 Phosphate Buffer Saline (PBS) overnight. Drug content was 
analysed by UV–Visible Spectroscopy (Perkin-Elmer lambda 35, USA) at a wavelength 
of 242 nm. Homogeneity testing was conducted in triplicates.  
 
5.2.2.5. In vitro drug release studies  
In vitro drug release testing was conducted using a standard Caleva 8ST dissolution 
apparatus (Caleva Ltd., Dorset, United Kingdom). Table 5-1 outlines the conducted 
dissolution experiments. The temperature of the dissolution bath was maintained at 37 ºC 
± 0.5 ºC. For all experiments, 5 mL were withdrawn from the dissolution media at 
predetermined time points and were then promptly replenished with fresh dissolution 
media. Drug content was analysed using a UV–Visible spectrophotometer (Perkin-Elmer 
lambda 35, USA) at a wavelength of 242 nm (55). All dissolution tests were conducted 
with a rotation speed of 50 RPM. All reported measurements were conducted in triplicates.  
 
For the drug release experiments conducted at pH 1.2, the volume of the dissolution media 
was limited to 750 mL to maintain the same hydrodynamic environment as the drug 
release experiment conducted under pharmacopoeial conditions (2 hours in 750 mL of pH 
1.2 media, followed by 6 hours in pH 6.8 PBS, which is a pharmacopoeial standard 
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method for delayed-release/gastro-resistant formulations such as the one presented herein 
(189)).  
  
Table 5-1: List of performed dissolution experiments 
Apparatus Dissolution Media 
Paddle 900 mL of pH 6.8 phosphate buffer saline (PBS) 
Basket 900 mL of pH 6.8 phosphate buffer saline (PBS) 
Basket 750 mL pH 1.2 acidic media 
Basket 750 mL of pH 1.2 media for two hours, tablets were then transferred to 900 mL of pH 6.8 PBS 
 
5.2.2.6. Swelling experiments 
Measuring swelling rate using weight change on water intake was not possible due to 
water being entrapped between the pores of the 3D printed objects, particularly the 75% 
infill formulation. Attempting to release the entrapped water by tapping the tablets on a 
tissue caused the destruction of the tablets. Therefore, swelling experiments were 
performed on a two-layer mesh 3D printed using the same formulation. The mesh was 
designed using Microsoft 3D builder to be a perfect square of length size 15 mm, and a 
pore size of 400 µm. The printed meshes possessed an average mass of 4.5 mg ± 0.16 mg. 
Printing of the meshes was conducted using the same conditions used for printing the 
tablets, as outlined in section 5.2.2.2. 
 
The swelling rate measurements were conducted by placing the meshes in a Petri dish, 
submerged in 100 ml of pH 1.2 media in a shaking incubator rotating at a speed of 50 
RPM. The Petri dish was retrieved at predetermined intervals and the mesh was imaged 
using a Linkam Imaging Station (Linkam Scientific Instruments, Tadworth, United 





Figure 5-3: the apparatus used for measuring the swelling of the polymer matrix. 
 
The swelling rate was approximated by measuring the decrease in the pore area of the 
mesh as a function of time. Pore area was measured using the GNU Image Manipulation 
Program (GIMP) version 2.10.6. Drug release rates from the 3D printed meshes was 
also measured on a further set of three meshes. At each time point, 5 mL were 
retrieved from the dissolution media and promptly replaced with 5 mL of fresh 
dissolution media to maintain sink condition.  
 
All reported measurements were done in triplicates  
 
5.2.2.7. Dissolution kinetics model fitting:  
In an attempt to gain an understanding of the underlying drug release mechanism, all the 
obtained drug release profiles were fitted to the Korsmeyer – Peppas power law. The 









Where Mt /M∞ is the fraction of drug released at time t, k is the release rate constant, and 
n is the Peppas coefficient, an exponent whose value describes the underpinning drug 
release mechanism (190,191). A notable constraint of this model is that the fitting is valid 
for cases where Mt /M∞ ≤ 0.6, exclusively. In this study, the limits of n used were the 
ones for cylindrical systems, as described by Ritger and Peppas (190), and are 
summarised below in Table 5-2.  
 
Table 5-2: Values of the Peppas Coefficient (n) and the corresponding implied drug 
release mechanism. Table adapted from Korsmeyer et al., (192), and Ritger & Peppas 
(190)  
n-value Drug release mechanism 
0.45 Fickian diffusion 
0.45 < n < 1.00 Anomalous transport 
1.00 Zero-order release 
n > 1.00 Super Case II transport 
 
The drug release mechanism was also investigated using the first-order model (193):  
 
𝑀𝑡 = 𝑀∞ ∗ (1 − 𝑒
−𝑘𝑡)   (Equation 5-2) 
 
Where Mt is the amount of drug released at time t, M∞ is the amount of drug released as t 
approaches infinity. Unlike the Korsmeyer – Peppas model, which restricts the fitting to 
the first 60% of the drug release curve, fitting to the first-order model can be conducted 
to the entire drug release curve.  
 





5.3.1. Characterisation of the 3D printed tablets: 
The average drug content in the filament was found to be 9.3 mg ± 0.24 mg, with no 
significant differences in drug content along the length of the extruded filament (Figure 
5-4).   
 
 
Figure 5-4: Drug content uniformity along the length of the filament.  
 
Mass of the 100% infill tablets was 123.73 mg ± 2.35 mg. Mass of the 75% infill tablets 
was 76.77 ± 9.76 mg. Mass of the 50% infill batch was 64.03 mg ± 3.95 mg. The 75% 
infill tablets weighed, on average, 62.0% of the 100% infill tablets. The 50% infill tablets 
weighed, on average, 51.7% of the 100% infill tablets.   
 
5.3.2. In vitro drug release studies:  
5.3.2.1. Drug release testing in pH 1.2  
Figure 5-5 shows the drug release rate of the three different infill batches in pH 1.2 acidic 
media. The 50% infill batch possessed the fastest release rate under acidic conditions (~ 
47% in 8 hours), followed by the 75% infill batch (~ 30% in 8 hours). The 100% infill 





Figure 5-5: Release profile of the three infill batches at pH 1.2. 
 
The tablets remained intact for the duration of the experiment, microscopic imaging of 
the tablets at the end of the experiment showed that the roads comprising the tablets had 
swelled significantly during the experiment (Figure 5-6). The swelling behaviour of the 
formulation is further discussed in Section 5.3.3. and Section 5.4.2.2.  
 
 
Figure 5-6: Microscopic images of the 3D printed tablets after 8 hours in pH 1.2 media. 
Left to right: 100% infill, 75% infill, 50% infill 
 
5.3.2.2. Drug release testing in pH 6.8:  
Drug release in buffer media (pH 6.8 PBS) was conducted as per USP apparatus II 
(paddle) (188). However, the 50% infill and the 75% infill tablets were observed to float 
during the experiment. So the dissolution profiles were reacquired using the basket 




Figure 5-7 shows the drug release rates of the three infill batches in pH 6.8 PBS using the 
paddle apparatus, the 50% infill batch possessed the fastest release rate, reaching 100% 
release in 90 minutes, followed by the 75% infill batch, which reached 100% release in 
120 minutes, with the 100% infill batch being the slowest releasing, reaching ~ 100% 




Figure 5-7: Release profile of the three infill batches in pH 6.8 PBS using the paddle 
apparatus 
 
Figure 5-8 shows the drug release rates of the three infill tablets in pH 6.8 PBS using the 
basket apparatus. The release rate was found to be considerably slower than what was 
observed using the paddle method, with the 50% infill and 75% infill formulation 
requiring 240 minutes to reach 100% drug release. The release rate of the 100% infill 









5.3.2.3. Drug release testing under buffer change conditions:  
Testing the dissolution rate of the 3D printed tablets under buffer change conditions was 
conducted as per the United States pharmacopoeial specifications for the testing of enteric 
release formulations (189); tablets were placed in 750 mL of pH 1.2 media for two hours, 





Figure 5-9: Release profile of the three infill batches under buffer change conditions 
conducted using the basket apparatus (top), with the first 120 minutes magnified to a 
separate graph (bottom). 
 
As can be seen in Figure 5-9, the portion of the drug release study conducted in pH 1.2 
followed the same trend as what was presented prior in Figure 5-5. The portion of the 
curve observed following the media change was significantly different from what was 
previously observed under similar conditions (basket method at pH 6.8 PBS).  Both the 
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50% and 75% infill formulations required ~ 360 minutes to achieve 100% release. The 
100% infill formulation required 420 minutes to achieve 100% release.  
 
An additional set of three tablets of each infill were placed in 750 mL of pH 1.2 acidic 
media, then retrieved after two hours and imaged using a light microscope (Figure 5-10). 
 
 
Figure 5-10: Microscopic images of the 3D printed tablets after 2 hours in pH 1.2 
media. Left to right: 100% infill, 75% infill, 50% infill 
 
5.3.2.4. Dissolution kinetics model fitting: 
The significant differences observed in the behaviour of the 3D printed tablets at different 
pH (exclusively swelling with no observed erosion at pH 1.2, vs. complete erosion at pH 
6.8) strongly suggest a change in mechanism on changing the dissolution media. 
Therefore, dissolution kinetics modelling was conducted in an attempt to categorise the 
drug release mechanisms involved at different pH. The Korsmeyer – Peppas model was 
conceived as a model to describe diffusion mechanisms from non-swellable polymers 
(190). It is, nonetheless, commonly used to describe drug release from erosion-mediated, 
and swellable systems (24,194,195). While it is a useful semi-empirical metric, it has 
notable limitations which may lead to misattribution. Therefore, it is important to explore 
fitting to other models as well. As mentioned previously, the present work used the 
Korsmeyer – Peppas model and the first-order release model.  A discussion of the release 
kinetics model fitting, as well as the aforementioned limitations of the Korsmeyer – 
Peppas model are presented in section 5.4.3.  
 
Table 5-3 shows the results of the curve fitting of the drug release rates of the 3D printed 




Table 5-3: Results of fitting the drug release curves obtained from the 3D printed tablets 
to the Korsmeyer – Peppas model and the first-order model. *: dosage form released > 
60% drug content in under 15 minutes; fitting was not possible. 
 50% infill 75% infill 100% infill 
Basket Apparatus – pH 6.8 
First-order 
model 
R2 0.991 0.999 0.996 




R2 0.997 0.999 1.000 
Rate constant (k s-n) 2.128 ± 0.228 2.544 ± 0.136 2.305 ± 0.074 
Peppas Coefficient (n) 0.742 ± 0.028 0.738 ± 0.015 0.688  ± 0.008 
pH 6.8 using the paddle apparatus 
First-order 
model 
R2 0.999 0.997 0.999 







Rate constant (s-n) 3.14 2.15 
Peppas Coefficient (n) 0.83 ± 0.026 0.80 ± 0.033 
Basket Apparatus – pH 1.2 
First-order 
model 
R2 0.989 0.989 0.969 
Rate constant (k s-1) 
0.0037 ± 
0.0004 




R2 0.989 0.999 0.987 
Rate constant (k s-n) 1.039 ± 0.195 0.630 ± 0.034 1.591 ± 0.216 
Peppas Coefficient (n) 0.628 ± 0.033 0.628 ± 0.009 0.404 ± 0.024 
fitting the first 120 minutes of the buffer change release experiments 
First-order 
model 
R2 0.997 0.997 0.993 
Rate constant (k s-1) 0.018 ± 0.001 0.017 ± 0.001 0.018 ± 0.001 
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R2 0.996 0.996 0.996 
Rate constant (s-n) 2.048 ± 0.247 1.499 ± 0.181 1.164 ± 0.140 
Peppas Coefficient (n) 0.513 ± 0.028 0.513 ± 0.030 0.513 ± 0.028 
Post buffer change 
First-order 
model 
R2 0.857 0.877 0.926 
 Rate constant (k s-1) 0.0045 ± 0.001 0.0030 ± 0.001 0.0008 ± 0.0001 
 
As previously discussed, the drug release profiles experiments in pH 6.8 were conducted 
using both the basket and the paddle apparatus. For the drug release profiles acquired 
using the basket apparatus, good fits were achieved with both the Korsmeyer – Peppas 
power law and the first-order release model. The n-value for all three formulations was 
in the range of 0.45 < n < 0.89, which is usually associated with the release mechanisms 
dubbed anomalous transport. Plots of the curve fit models can be seen in Figures 5-11 and 
5-12 
 
For the drug release experiments conducted using the paddle apparatus, Figures 5-13 and 
5-14 show the curve fit plots. Curve fitting of the 50% infill formulation to the Korsmeyer 
– Peppas model was not possible because the tablet had released > 60% of its drug content 
in under 15 minutes. Therefore, the number of available sampling points was insufficient 
to allow for a good fit to be achieved, and the aforementioned Mt /M∞ ≤ 0.6 constraint 
does not allow for extending the region of the curve used. Similar to what was observed 
with the basket apparatus, good fits were achieved with both the Korsmeyer – Peppas 
power law and the first-order release model. The n-value for all three formulations was 





Figure 5-11: fitting the release rates (at pH 6.8, basket apparatus) of the 3D printed 




Figure 5-12: fitting the release rates (at pH 6.8, basket apparatus) of the 3D printed 







Figure 5-13: fitting the release rates (at pH 6.8, paddle apparatus) of the 3D printed 





Figure 5-14: fitting the release rates (at pH 6.8, paddle apparatus) of the 3D printed 
formulations to the first-order release model. 95% confidence interval marked. 
 
The 50% infill formulation had a first-order release rate constant of 0.0093 sec-1 under 
basket conditions, and a first-order release rate constant of 0.073 sec-1 under paddle 
conditions, corresponding to an 87% decrease of the release-constant when using the 
basket apparatus compared to the paddle apparatus. The 75% infill formulation had a first-
order constant of 0.0125 sec-1 with the basket apparatus, and 0.025 in the paddle apparatus, 
corresponding to a 50% decrease in release rate when using the basket apparatus. No 




Figure 5-15: Drug release rates from the 3D printed tablets in pH 6.8, showing the 
release rate difference between experiments conducted with the paddle apparatus vs. the 
basket apparatus. 
 
A noteworthy observation is, for the case of the 50% infill and the 75% infill tablets, there 
was a significant decrease in the drug release when the release experiments were 
conducted using the basket apparatus instead of the paddle apparatus. As can be seen in 
Figure 5-15, both the 50% infill and 75% infill formulations had a faster drug release rate 
with the paddle apparatus than their counterparts studied using the basket apparatus. This 
difference in release rate is also visible in the release rate constants achieved with the 
model fitting.  
 
Similar to the release profiles obtained in pH 6.8, the drug release profiles obtained in pH 
1.2 media were fitted to both the Korsmeyer – Peppas model and the first-order model. 
Table 5-5 summarises the obtained results. The 50% and 75% infill formulations had an 
n-value = 0.45 < n < 0.89. The 100% infill formulation had an n-value of 0.404 ± 0.024. 
Figures 5-16 and 5-17 show the curve fits for Korsmeyer – Peppas and the first-order 




Figure 5-16: fitting the release rates (at pH 1.2) of the 3D printed formulations to the 




Figure 5-17: fitting the release rates (at pH 1.2) of the 3D printed formulations to the 
first-order model. 95% confidence interval marked. 
 
Figure 5-18 shows the fitting of the 120 minutes of the buffer change release experiments 
to the Korsmeyer – Peppas, and the first-order model. The obtained fits did not differ 
significantly from the fits obtained from the experiments conducted in pH 1.2 for 8 hours 
presented above, particularly the first 120 minutes of it. Similar to all the other observed 
cases herein, the n-value corresponding to the Peppas coefficient fell in the range of 0.45 









Figure 5-18: fitting the first 120 minutes (buffer change conditions) of the release rates 
of the 3D printed formulations to the Korsmeyer-Peppas model. 95% confidence interval 
marked. 
 
Figure 5-19 shows the curve fits of the first 120 minutes of the buffer change drug release 
experiment to the first-order release model. For the portion of the curve following the 
buffer change, fitting due to the Korsmeyer – Peppas model was not possible due to the 
aforementioned restriction of 60% upper bound for model validity. Fitting to the first-






Figure 5-19: fitting the first 120 minutes (buffer change conditions) of the release rates 
of the 3D printed formulations to the first-order model. 95% confidence interval marked. 
 
 
Figure 5-20 shows the drug release curves of the drug release experiments conducted 






Figure 5-20: fitting the release rates of the buffer change release experiments (following 
buffer change) to the first-order release model 
 
All three of the curves had an R2 value < 0.95. Furthermore, as can be seen in Figure 5-
20, there is a notable overall positive skew in the residuals, suggesting that the first-order 
model does not adequately describe the release mechanism in this particular case.  
 
5.3.3. Swelling and drug release from the 3D printed meshes:  






Figure 5-21: Drug release rate vs. polymer swelling rate. 
 
Drug release rate from the meshes reached a plateau at ~70% release (300 minutes). 
Maximum polymer swelling was reached after ~200 minutes, the pore size having 
decreased by ~40%. The onset of the plateau of drug release appears to have occurred 
concurrently with the polymer reaching maximum swelling. Furthermore, much like their 
tablet counterparts, the grids remained intact throughout the entirety of the experiment, 
with no polymer erosion observed. Unsurprising, since HPMCAS, the primary matrix 
former of this formulation is an enteric polymer and is well-documented to have little-to-





5.4.1. Characterisation of the melt-extruded filaments: 
As previously discussed in section 3.3.1., the results obtained from DSC, ATR-FTIR, and 
PXRD strongly suggest that PAC is molecularly dispersed in the HPMCAS-PEO carrier 
matrix. This, coupled with the uniformity of drug content along the lengths of the melt-
extruded filaments strongly indicate that any observable differences in release rates are 
going to be solely due to the impact of the print geometry as opposed to the solid state of 
the drug.  
 
The yellow-to-brown discolouration observed in the filaments and printed tablets (Figure 
5-2) can be attributed to either the natural discolouration HPMCAS is susceptible to when 
undergoing thermal processing (163). However, it is possible that the observed 
degradation is due to the oxidation of paracetamol. Oxidation of paracetamol is 
documented to yield a red-orange discolouration due to the release of ammonium ions 
(196). The assay of drug content in the filament (Figure 5-4) suggests that somewhere 
between 4.6% to 9.4% of paracetamol was lost during processing. While some of the lost 
drug is probably due to paracetamol powder being lost during transfer, one cannot rule 
out the possibility of the thermal oxidation of paracetamol during thermal processing.  
 
5.4.2. In vitro drug release studies:  
5.4.2.1. Drug release in pH 6.8 
When the drug release profiles were acquired using the paddle apparatus, the drug release 
rates were proportional to the infill density, with the 50% infill formulation being the 
fastest releasing, followed by the 75% infill, then the 100% infill formulation. On 
replicating the experiment using the basket apparatus. The release rates of both the 50% 
infill and the 75% infill were found to decrease significantly from the paddle counterparts. 
However, the 50% infill formulation was found to have a significantly faster release rate 
than the 100% infill formulation under those conditions.  
 
The significant difference seen between the basket and the paddle is likely due to the 
differences in flow dynamics between the two apparatus, with the latter exerting greater 
shear on the tablets, and (as evidenced by the absence of any significant differences 




Figure 5-22: tablets in the dissolution bath during the release experiment conducted at 
pH 6.8 using the paddle apparatus. The tablet (marked) is shown swimming around the 
bath due to the shear applied by the paddle on the dissolution media 
 
Photographs of the tablets during the release experiments with the paddle apparatus show 
the tablets being moved around the dissolution bath by the action of the paddle rotation 
(Figure 5-22). The basket apparatus, on the other hand, differs from the paddle in two 
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ways, the first being the fact that the basket confines the tablet within it, restricting the 
motion of the tablet during the dissolution experiment, and secondly, the basket apparatus 
is a thin cylinder that sits directly in the centre of the dissolution bath, and thus has much 
lower capacity to move the dissolution media than the much longer paddles. Therefore, 
the torque of rotation is much higher with the paddle apparatus than with the basket 
apparatus (Figure 5-23), due to the effective distance of the paddle apparatus being much 
longer than that of the basket.  
 
 
Figure 5-23: Graphical representation of the dissolution apparatus (cross-section) 
showing the effective distance available to shear the dissolution media by both the 
paddle (left) and the basket apparatus (right) 
 
In the paddle apparatus, where the tablets are allowed to flow freely through the bath, the 
solvent movement around and through the open cavities of the lesser infill tablets yielded 
greater polymer-media interactions, resulting in the significantly faster drug release rates 
compared to when the tablets were confined to the basket apparatus. The 100% infill 
tablets, having no open internal structures, exhibited no significant difference between 
the paddle apparatus and the basket apparatus, since solvent motion is restricted only to 
the external surface of the tablet. This suggests that the drug release rate from open 3D 
printed systems is highly dependent on the hydrodynamics of the environment in which 
the dissolution is taking place (197,198). 
 
5.4.2.2. Drug release in pH 1.2 and the impact of swelling:  
The drug release rate of the three infill variants (50% infill, 75% infill, and 100% infill) 
followed a trend that was proportional to their infill density, with the 50% infill 
formulation being the fastest-releasing, followed by the 75% infill formulation, with the 
100% infill formulation being the slowest of the three. This is likely due to the differences 
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in the surface areas of the three formulations, with the 50% and 75% infill tablets having 
greater surface areas to allow for drug diffusion.  
 
One observation that was of interest is the fact that the roads comprising the tablets were 
observed to swell significantly throughout the 8 hours over which the release experiment 
was conducted (Figure 5-6). This swelling rate was approximated semi-quantitatively 
using the microscopic method outlined prior in section 5.2.2.6. The observed swelling 
rate of the grid structures cannot be readily extrapolated to the tablets, due to the 
significant differences in geometry, and the hydrodynamic environment of the dissolution 
media. However, if one were to consider the observed swelling in the context of drug 
release rate from the grids, it may provide some context to the swelling rates of the 3D 
printed tablets if viewed in light of their observed release rates. An estimation that is not 
too far-fetched, as the grids and the tablets are fabricated from the same formulation.  
 
Of the 3D printed grids, the most notable observation is that the drug release required 
roughly the same time to reach a release plateau as the time required for maximum 
swelling to be achieved (~200 minutes). This suggests that there may be a correlation 
between the polymer swelling rate and drug release rate.  
 
Observing the drug release rates from the 3D printed tablets shows that all three infills 
appear to be tending towards a drug release plateau (~300 minutes in the 50% infill, and 
~180 minutes in the 75% infill formulation), with the exception of the 100% infill 
formulation which is maintaining a steady plateau of drug release from the onset of the 
experiment. Examining this observation in the context of the release-swelling correlation 
observed with the 3D printed grids (Figure 5-21) suggests that this tendency towards a 
plateau may be related to the swelling of the polymer in pH 1.2. This swelling-release 
correlation can be explained by either of two hypotheses, both of which are discussed in 
the subsequent paragraphs.  
 
The first hypothesis as to why drug release is hindered by swelling is due to the effect 
swelling has on the surface area available for drug diffusion; the filled internal 
microstructure of the 100% infill tablet allows very little room for the swelling of the 
roads of the tablet. Similarly, the 75% formulation has a lower spatial allowance to 
accommodate swelling than the 50% infill formulation, therefore, it arrived at its 
“maximum” swelling faster than the 50% infill formulation. Both the tablets and more 
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noticeably the grids were observed to curl up significantly during the experiment, which 
indicates that the swelling is anisotropic. The fact that the formulation exhibits anisotropic 
swelling dictates that swelling will decrease the surface area of the pores within the tablets, 
as opposed to altering the aspect ratio of the tablets as a whole. The anisotropy of the 3D 
printed formulations is discussed further in section 5.4.2.4.  
 
 
Figure 5-24: 3D printed grids post-dissolution, showing contortion due to anisotropic swelling 
 
The second hypothesis explaining why drug release is hindered by swelling relates to the 
rate of drug liberation from the polymeric matrix. It is evident from the absence of dose 
dumping in the release rates of the three formulations (particularly the 100% infill 
formulation) that drug release from the polymer matrix is rate limited by the rate of 
polymer hydration. In such situations, the distance the dissolution media must travel to 
liberate a drug molecule increases as more drug is released. Polymer swelling during 
dissolution indicates solvent entrapment within the polymer matrix, which introduces a 
gradient through which the liberated drug molecules must first diffuse to be released from 
the tablets.  
 
Verifying that the 50% and 75% infill formulations actually tend to steady plateau of drug 
release requires conducting the release experiments to completion. However, 
extrapolating from the behaviour of the 100% infill formulation, and the 3D printed grid 




In the drug release studies conducted under buffer change conditions, in which the tablets 
were allowed to swell in pH 1.2 media for 2 hours, then transferred to pH 6.8 PBS were 
then conducted to determine whether this swelling effect would have a significant impact 
on the release rate in situations similar to the pH changes expected an in-vivo scenario in 
which the formulation will likely travel from gastric pH to intestinal pH.  
 
5.4.2.3. Drug release under buffer change conditions 
 As discussed in the previous section, drug release under buffer change conditions was 
conducted to determine whether the swelling of the polymer roads in acidic conditions 
was significant enough to negate the impact of the greater surface area of the lesser infill, 
open tablets. Microscopic images of the tablets after 2 hours in pH 1.2 media (Figure 5-
10) showed some swelling over the 2-hour period. This experiment was performed to 
determine whether that swelling had an impact on the drug release rates of the 3D printed 
tablets.  
 
A significant decrease in drug release was observed in the buffer change release studies 
compared their pH 6.8 PBS counterparts (Figure 5-25) for all the three infill formulations. 
The overall decrease in the release rates of the formulations in the buffer change 
experiments is most likely due to the low, diffusion-controlled release of HPMCAS in pH 
1.2 media causing a “lag phase” in the drug release, one which is not seen in curves 
obtained in pH 6.8, resulting in the perceived overall decrease in drug release rate.  
 
Similar to what was observed in other cases, the 50% infill formulation consistently had 





Figure 5-25: drug release profiles of the three infill formulations in pH 6.8 (basket 
apparatus) vs. their release profiles in buffer change (BC) conditions. 
 
5.4.2.4. Reproducibility of drug release from the 100% infill formulation 
Of all the release experiments conducted, the release curves obtained for the 100% infill 
formulation in pH 6.8 PBS using the paddle apparatus (Figure 5-7) notably exhibited a 
much wider standard deviation than any of its counterparts, showing an average standard 
deviation of ±11.79%, and a maximum standard deviation of ±19.78%.  
 
The observed deviation is far greater than is to be expected of sampling error. The 
standard deviation at the last time point (480 minutes; the point at which the tablet has 
completely dissolved) is ±3.41%, at which point the possible causes of deviation are due 
to human and machine error as the tablets have dissolved completely and there is no more 
discrepancy to be observed due to drug release rate differences between the three 
replicates. This indicates that the relatively wide deviation between the 100% infill 
replicates at those conditions are due to genuine sample-to-sample differences.   
 
Plotting the separate drug release curves of the three replicates of the 100% infill 
formulation separately shows three distinct curves, each with a different release rate 
(Figure 5-26). This was not observed when separating the replicates of the 50% infill 




Figure 5-26: Release curves of the 100% infill formulation at pH 6.8 using the paddle 
apparatus, with the three replicates plotted separately 
 
In the 50% infill formulation (Figure 5-27A), the observed discrepancies between the 
three replicates are two notable drops in drug release at t=30 minutes (Replicate 3) and 
t=60 (Replicate 2), which cannot be real observations as the amount of drug released 
cannot decrease. The observed drops in amounts of drug release may be due to accidental 
over-dilution on replenishing the dissolution media.  
 
In the 75% infill formulation (Figure 5-27B), the plots of the three replicates appear to be 
largely similar, except for Replicate 3 possessing a slower release rate. 
 
Estimates the release half-life (T50) of the three different infill formulations based on the 
graphs of the separate replicates are shown in Table 5-4.  
 
Table 5-4: T50 of each replicate of the three infills formulations at pH 6.8 using the paddle 
apparatus 
Formulation Replicate 1 Replicate 2 Replicate 3 
100% infill 30 minutes 50 minutes 60 minutes 
75% infill 40 minutes 30 minutes 30 minutes 
50% infill 7 minutes 12 minutes 12 minutes 
 
158 
The difference in T50 between the three replicates of the 100% infill formulation is much 
larger than its lower infill counterparts. Furthermore, each replicate forms a smooth curve 
with no random scattering of sampling points, suggesting that 100% infill formulation 
has indeed exhibited three different drug release behaviours under those conditions. 
 
 
Figure 5-27: Release curves of the 50% infill formulation (A) and the 75% infill formulation (B) 





A possible explanation for this phenomenon may be due to the build-up and dissipation 
of thermal potential energy in the tablet during printing. The pre-processing for 3D 
printing is HME, which is well documented to align the polymer chains parallel to the 
direction of motion within the extruder (163,199). In printing, the polymer is first passed 
through the heated nozzle at the constant rate of the printing speed, with the direction of 
motion being parallel to that during extrusion. The aligned polymer chains are then 
deposited onto the build plate and must instantaneously be deflected at a 90° angle so that 
the road rests on the build plate (200). Once a road is deposited, it rapidly cools down 
with heat being transferred to the surrounding environment by convection (201). 
Concurrently, a new road is being deposited, forming a contact point with the prior, and 
similarly begins cooling down by transferring heat to the environment and exchanging 
heat with the neighbouring road (153,202).  
 
For the tablets described herein, the 50% and 75% infill tablets have every single road 
exposed to air, making the surface area available for cooling much larger than that of the 
100% infill tablets (Figure 5-28). Due to the aforementioned stressing and alignment 
during printing, this rapid cooling is hypothesised to cause anisotropic alignment of the 
polymer chains as they cool down too rapidly to relax and re-entangle post-printing.  
 
 
Figure 5-28: a sketch representing heat flow(q) while the tablets are cooling during, and post-
printing 
 
In 100%, roads which happen to be deposited in the inner sections of the object are 
restricted to exchanging heat with the neighbouring roads as they are isolated from the 
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external environment. This dictates that the 100% infill tablets will cool down at a slower 
rate than their lesser infill counterparts. Furthermore, the stresses forced on the melt, as 
well as the thermal gradient arising from the variability of heat transfer due to the majority 
of the roads being isolated from the air will dictate that roads in different regions of the 
tablet will cool down at different rates from one another, and thusly will possess different 
degrees of entanglement between the polymer chains as no two roads have been allowed 
to relax under similar conditions. This results in the build-up of thermal stress in the tablet. 
Residual thermal stress in 3D printed objects fabricated by FDM is a well-documented 
phenomenon (153,200–204). 
 
When observed under polarised light, the 50% and 75% infill tablets exhibited light 
scattering diffraction (Figure 5-29). Seeing as DSC, PXRD, and FTIR data showed no 
evidence of crystallinity within the formulations and factoring in that the tablets were 
placed whole (2 mm thickness) on the microscope stage, it is unlikely that the observed 
light scattering is due to the presence of crystals within the formulation, which suggests 
that the observed light diffraction is due to the anisotropic alignment of polymer chains 
within the matrix of the tablets (205,206). This anisotropy was not observed in the 100% 





Figure 5-29: Polarized light microscopy images of the (A) 50% infill, (B) 75% infill, and (C) the 
100% infill formulations. 
 
Keeping the two lesser infill tablets isothermal at 100 ºC for 10 minutes caused the 
birefringent light scattering patterns to disappear (Figure 5-30). This observation strongly 
supports the argument presented prior relating to forced polymer chain entanglement and 
relaxation during printing; the anisotropy observed in the lesser infill batches may be 
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attributed to the system cooling rapidly, preventing the polymer chains from relaxing after 
the forced extrusion/printing alignment, while the hypothesised lower thermal gradients 
in the 100% infill tablets would allow some degree of polymer relaxation before the 
system drops to below its glass transition, forming a largely isotropic matrix. 
 
 
Figure 5-30: the 50% infill (A) and 75% infill (B) tablets after being heated at 100 ºC for 10 
minutes 
 
The argument presented prior shows that the 100% infill formulation is cooling at a slower 
rate and unevenly, compared to the 50% infill and 75% infill formulations. It is possible 
that the uneven cooling causes microscopic fractures to develop within the matrix of the 
100% infill formulation. Such fractures are exaggerated when subjected to the high shear 
conditions of the paddle apparatus (as discussed in section 5.4.2.1.), causing pieces of the 
tablet to break off, thus causing the observed differences.   
 
While one cannot dismiss the possibility that the observed discrepancy in the release 
profiles of the 100% infill tablets is due to the heterogeneity of the PEO content within 
the tablets causing varying hydrophilicity inside the tablet matrix, the thermal-history 
dependant anisotropy strongly supports the chain entanglement hypothesis. Furthermore, 
release rate discrepancies of this magnitude are commonly reported with FDM printed 
dosage forms, even in cases where the filament had been prepared via the soaking method 






5.4.3. Dissolution kinetics model fitting:  
The use of the coefficient of determination (R2) to determine the goodness of fit when 
fitting dissolution data to a mathematical model is a commonly practised method in the 
literature (18,24,36,194,195,207). By that metric, good fits were achieved for all the 
release curves (R2 > 0.99) to both the Korsmeyer – Peppas model and the first-order 
release model, with the exception of the fitting the latter 6 hours of the simulated in-vivo 
release studies (Table 5-8), for which R2 < 0.95 for all three formulations.   
 
The Korsmeyer – Peppas model is a popular method for categorising drug release profiles 
(24,36,70,194,195). It does, however, have known limitations. The model, as originally 
described by Ritger and Peppas, was intended to be only applied to describe diffusion-
mediated (whether Fickian or non-Fickian) drug release of non-swellable systems (190). 
It is, nonetheless, often used to investigate the drug release kinetics of systems which are 
known to swell. Another limitation is that the model is only valid to describe drug release 
up to 60% of the dosage form content, leaving the latter 40% of the release profile 
completely unaccounted for, which is a significant portion to discard. Furthermore, while 
the Peppas coefficient (n) can clearly describe Fickian diffusion (n = 0.5 (sheets) or n = 
0.45 (cylinders)), and zero-order (n = 1), the mechanism which Ritger and Peppas dubbed 
“anomalous transport” seemingly has little correlation with any actual physical 
phenomenon, as the anomalous transport mechanism is seemingly suitable to describe 
both non-Fickian diffusion, and erosion-controlled release.  
  
Sunil et al. used the Korsmeyer – Peppas model, among others, to describe the release of 
indomethacin from a sucrose-fatty acid ester carrier matrix (194), achieving good fits (R2 
≥ 0.98) to all of nine formulations reported. Sunil et al. did note observing swelling with 
some of the reported formulations (attributed to their pregelatinsed starch content). The 
formulations. Paradoxically, the formulations reported by Sunil et al. achieved equally 
good fits to the Hixson-Crowell model, the Higuchi model, the zero-order release model, 
and the first-order release model. The Peppas coefficients (n-values) reported were 







Table 5-5: kinetic model fitting of formulations T1 through T9 as reported by Sunil et al. 
Table recreated from Sunil et al., (194) 
Model Zero Order First-order Higuchi Hixson-
Crowell 
Pepas 
Batch R2 K0 R2 K R2 R2 R2 n 
T1 0.990 1.56 0.998 0.028 0.979 0.928 0.995 0.771 
T2 0.991 1.587 0.958 0.024 0.931 0.915 0.979 0.858 
T3 0.982 1.687 0.944 0.023 0.893 0.888 0.986 0.881 
T4 0.977 1.66 0.984 0.049 0.990 0.985 0.997 0.719 
T5 0.979 2.10 0.983 0.051 0.992 0.968 0.996 0.610 
T6 0.938 2.13 0.976 0.087 0.993 0.997 0.991 0.552 
T7 0.937 2.07 0.982 0.072 0.994 0.993 0.984 0.532 
T8 0.935 2.97 0.992 0.083 0.998 0.973 0.999 0.560 
T9 0.934 3.05 0.999 0.099 0.998 0.990 0.995 0.573 
 
Maswadeh et al. (195) and Sagar et al. (70) reported results not unlike those reported by 
Sunil. Maswadeh reported on a formulation of ciprofloxacin microspheres whose release 
rates achieved good fits to the first-order release mode, the zero-order release model, 
Higuchi model, Hixson-Crowell, and the Korsmeyer-Peppas model. The n-values 
reported by Maswadeh were indicative of Fickian diffusion. Sagar, on the other hand, 
reported achieving good fits to the zero-order model, the Higuchi model, and the 
Korsmeyer – Peppas model when modelling the release rates of voriconazole-loaded 
Soluplus formulations. Sagar notably did not report the values acquired from the Peppas 
coefficient, and presented the Korsmeyer – Peppas model fit as a function of 
log(cumulative drug release %) vs. log(time), so there may be merit to approaching those 
reported results with some scepticism, despite the findings aligning with what is 
commonly reported in the literature.   
 
Khaled et al. similarly used the Korsmeyer – Peppas power law to fit the release profiles 
of 3D printed formulations of HPMC-loaded guaifenesin (24). Khaled et al., similarly 
reported achieving good fits (R2 = 0.99) with the Korsmeyer – Peppas model. Despite 
reporting observing swelling during the formulation, the n-value reported by Khaled was 
0.44, which their work attributed to Fickian diffusion, as per the Peppas coefficient values 
outlined in Table 5-2.  Khaled et al. also reported achieving similarly good fits to the first-




For the formulations presented herein, the release mechanism for release profiles acquired 
in pH 1.2 presumed to be non-Fickian diffusion; diffusion since the tablets remained 
perfectly intact during the experiment, and is presumed to be non-Fickain due to the 
swelling-release correlation discussed prior; Fickian diffusion is diffusion that occurs 
when the rate of polymer relaxation is much larger than the rate of solvent diffusion time. 
While non-Fickian diffusion occurs when polymer relaxation time happens at a similar 
rate to solvent diffusion time (208). According to the Peppas coefficient, the dominant 
release mechanism of the 50% infill and 75% infill tablets in pH 1.2 is anomalous 
transport. The 100% infill formulation had an n-value of 0.404 ± 0.024. Cases in which n 
< 0.45 were not accounted for in the works of Ritger and Peppas (190) and subsequent 
expansions (191,209). One may take this n-value to mean Fickian diffusion due to its 
proximity to 0.45. However, the same data set achieved good fits with the first-order 
model (Figure 5-16). Furthermore, the 100% infill tablets arise from the formulation as 
the 50% infill and 75% infill tablets, therefore, a change in the release mechanism is not 
expected. This leads to the conclusion that the observed value of 0.404 ± 0.024 is serving 
to highlight an issue with the Korsmeyer – Peppas model. It is probable that the true 
Peppas coefficient of this sample set is > 0.45, which was not observed due to the fitting 
being conducted on the mean release rate of three 100% infill replicates, without 
accounting for the standard deviations between the three replicates. 
 
In the pH 6.8 drug release experiments, the tablets were visually seen to erode to 
completion when drug release was conducted at that pH. Polymer erosion is documented 
to be a time-dependent, first-order process (210). Fitting to the first-order release model 
achieved good fits, indicating that the drug release from the tablets at pH 6.8 follows first-
order kinetics. Fitting to the Peppas coefficient similarly achieved good fits, and yielded 
values of n in the range of 0.45 < n < 0.89, which, in the case of cylindrical geometries 
(190,192), are commonly associated with anomalous transport. However, as previously 
discussed, the first-order model has the advantage of allowing one to use the entirety of 
the release curve, while the Korsmeyer – Peppas equation omits the latter 40% of the 
release curve. Furthermore, little is known about what physical mechanism the term 
“anomalous transport” represents, and in the results reported herein, the term can be used 
to describe two physically different drug release mechanism (the diffusion-based release 




For the buffer change release studies, the first 120 minutes (conducted at pH 1.2) were 
unremarkable, showing little difference from their counterparts acquired at that pH over 
8 hours. The region of the curve acquired at pH 6.8 was remarkably different from its 
counterparts acquired solely in buffer media. The curve did not appear to follow a first-
order release model. Therefore, it is possible that the swelling of the polymer matrix over 
the earlier 2 hours influenced the release mechanism. Looking closely at Figure 5-9, if 
one were to account for the error bars, it is entirely possible to fit a straight line through 
the buffer portion of the curve. Considering the underlying physical phenomena; that 
portion of the curve describes drug release from polymeric materials whose polymer 
chains were allowed to expand by the action of the solvent uptake and swelling in the 
earlier region of the curve. This spreading of the polymer chains grants greater solvent 
access through the polymer chains than what would have been achieved otherwise if the 
tablets were not allowed to swell prior (i.e. the case of drug release profiles acquired at 
pH 6.8 exclusively). This increase in the solvent access through the polymer will result 
in a change in the drug release mechanism, and although polymer erosion was observed, 
it is likely happening independently of the drug release in this particular case. However, 
due to the few available sampling points, the release mechanism for this curve only be 




This study investigated the effect of varying the infill density on the drug release rates 
and kinetics of 3D printed oral solid dosage forms. For tablets printed at 50% and 75% 
infill, enhancement in dissolution rate proportional to the infill density was seen when 
drug release was conducted in the paddle apparatus, but was not seen when the experiment 
was reproduced using the basket apparatus. This was attributed to be due to the 
differences in fluid dynamics between the low-shear basket apparatus, and the 
comparatively high-shear paddle apparatus. This observation suggests that for such open 
systems, one needs to carefully consider the in-vivo environment in which they are 
expected to perform. For oral dosage forms, the hydrodynamic environment inside the 
gastrointestinal tract is not realistically mirrored by the “tablets rotating in a bowl” 
paradigm imposed by the pharmacopoeial dissolution bath (197). Therefore, it is easy to 
see situations in which the in-vivo performance of a 3D printed dosage form may be 
overestimated due to the difference in hydrodynamics between the in-vivo environment, 
and the in-vitro environment used as a reference during dissolution development.  
 
Swelling of the polymer was observed to have an effect on drug release rate; the rate of 
drug release was found to be proportional to the rate of swelling, up to the point at which 
the tablets reached the maximum possible swelling, at which point drug release stagnated, 
likely due to the tablets reaching steady-state diffusion. It is worth noting that the 
“maximum possible swelling” observed was different for each infill variant, despite all 
infill variants coming from the same formulation. This was attributed to the fact that the 
lower the infill of a tablet, the more room is available for the roads to swell. Tablets with 
a higher infill density had less room to accommodate road swelling and thus reached their 
maximum possible swelling faster than the lower infill counterparts.  
 
The results outlined prior indicate the importance of careful considerations of the 
geometry of the 3D printed tablet. Different geometries of the same formulation do not 
perform equivalently. The a priori equation of infill density to the surface area, while true, 
does not account for the observed effects of hydrodynamic flow, and polymer swelling. 
3D printed dosage forms require not only careful formulation design, but also careful 
geometric design, one which accounts for properties of the polymer, and the environment 





Chapter 6  








The presented work was an exploration of the critical process parameters of FDM, 
investigated from a pharmaceutical perspective to determine the feasibility of FDM as a 
method to fabricate pharmaceutical solid dosage forms. As was discussed in Chapter 1, 
3D printing process parameters can be generally grouped as being either machine 
parameters, process parameters, or material parameters. Said parameters were observed 
to have complex interactions that affect the final properties of the 3D printed dosage form.  
 
6.1.1. Impact of material properties on the properties of 3D printed objects:  
The primary limiting parameter to be overcome was observed to be the mechanical 
properties of the material comprising the filament (Chapter 3). Regardless of how suitable 
the thermal properties of a polymer are for 3D printing, FDM printers dictate that any 
material used must fall within a very narrow margin of suitable mechanical properties. If 
said properties are not met, the filament will block the feeding motors and stop the 
printing process, without the material ever even arriving at the melting zone to begin the 
polymer deposition process.  
 
The effect of polymer melt flow was investigated and was found to have only a secondary 
effect on the properties of the 3D printed object. As discussed in Chapter 4, properties of 
3D printed objects were not found to vary as significantly on changing printing 
temperature (and by extension, the random melt flow of the polymer), than on changes 
with printing speed. Polymer melt flow was, however, observed to strongly correlate with 
a printing distortion phenomenon we have dubbed the First Layer Effect (FLE). This 
effect was found to have an influence on the thickness of 3D printed objects.  
 
As shown with the design geometries presented in Chapter 5, 3DP allows for the creation 
of porous solid dosage forms by varying a process parameter known as infill density. This 
porous design allows for an increase in surface area that can modulate drug release. 
However, as was observed with the formulation present, polymer swelling during 
dissolution may negate the effect of pore inclusion in the design, hindering the drug 
release rate. Under acidic conditions, the formulation reported in Chapter 5 had a 
diffusion-based drug release mechanism that is rate-limited by the polymer swelling rate. 
The reported study investigated the same formulations at three similar geometries (three 
infill variants). The three formulations ranged from no space between the printed roads 
(at 100% infill) to > 900 µm of space between every two parallel roads. The observed 
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trend in drug release was that the lesser the distance between the roads of the 3D printed 
tablet, the faster it reaches steady-state diffusion, which was attributed to the polymer 
having greater room available for swelling in the more open tablets, leading to the 
conclusion that polymer swelling can influence drug release rate from 3D printed tablets, 
subject to the geometry of the object.  
 
Section 6.2.1. discusses possible methods for overcoming material limitations which were 
observed in this work. However, if one were to apply the use of FDM in its current form, 
material (both polymer and API) properties must be carefully selected to meet the 
requirements of the current iteration of FDM. The primary limitation to be addressed is 
the issue of the mechanical flexibility of the polymer; careful tuning of the mechanical 
properties of the filament via plasticisers must be conducted to ensure the filament would 
not fracture or coil during printing. Another important factor to consider is the thermal 
stability of the API. As was observed in Chapter 5, there is a strong possibility that 
paracetamol may have underwent thermal oxidation during processing, causing the 
brownish discolouration observed in the filament. Formulation of filaments for FDM 
dictates that the drug/polymer blend is thermally processed twice (once during HME, and 
a second during printing) to produce the final dosage form. Drugs and polymers which 
are thermolabile make poor candidates for FDM, and any drugs to be formulated for FDM 
must be thoroughly investigated for thermal stability (via TGA, both via heat cycling amd 
being held isothermal at the processing temperature) to ensure that the drug remains stable 
during processing. The third factor to consider when formulating filaments for FDM is 
the melt rheology of the polymer. Melt flow, however, as discussed previously and in 
Chapter 4, is a secondary factor, and does not impact printing as significantly as other 
process parameters.   
 
6.1.2. Impact of machine parameters on the properties of 3D printed objects  
For the make of the printer used herein, machine parameters such as nozzle diameter, 
filament diameter, and motor step size are hardware pre-sets and could not be varied 
without significant modifications of the printer. 
 
Platform levelling, while not a “true” machine parameter, it is a user-manipulated 
calibration process. As was discussed in Chapter 4, the subjectivity of the platform 
levelling process was found to cause significant deviations when the same operator 




6.1.3. Impact of process parameters on the properties of 3D printed objects 
Chapter 4 was an in-depth exploring of the impact of processing parameters on the 
properties of the 3D printed dosage forms. A complex interaction relating printing speed, 
dimensions, mass, and object road width was discovered. A notable inverse correlation 
between printing temperature and object mass was observed, suggesting that for larger 
scale operations, there may be a compromise between dosing accuracy and throughput.  
 
A design limitation of the 3D printer, relating to the nature of operation of the stepper 
motors utilised in the printer, dictated a “lower limit” on the suitable printing temperature. 
For higher printing speeds, printing at lower temperatures is not possible due to the 
inverse correlation between the rotation speed and the output torque of the utilised motors. 
 
6.1.5. General conclusion 
Perhaps the greatest shortcoming of the currently available versions of FDM lies in the 
feeding mechanism. As discussed in Chapter 3, the filament-based mechanism currently 
employed by 3D printers restricts the library of materials available for pharmaceutical use 
to only those which possess adequate mechanical properties. Formulating filaments that 
possess the suitable mechanical properties requires extensive use of plasticisers which 
raises the cost and complexity of the formulation, and raises stability concerns as 
excessive plasticisation of the formulation can decrease the kinetic stability of an 
amorphous solid dispersion (158). Furthermore, the use of stepper motors to drive the 
feeding rollers was also shown to cause an issue relating to dosing accuracy. Thermal 
processing of pharmaceutical materials carries a great risk of inducing thermal 
degradation and keeping the operating temperature the barest minimum is often desired 
when thermally processing pharmaceutical formulations. If this strategy were to be 
employed in P3P, it would restrict the printing to only the lowest speeds, yielding a 
compromise between thermal stability and throughput.  
 
3DP carries with it great prospects for the pharmaceutical industry, the previously 
highlighted freedom it allows for may usher in the next generation of pharmacotherapy; 
patient-tailored medicaments with precisely engineered drug release characteristics. 
However, the aforementioned limitations in mechanical properties (and by extension, 
formulation choices), and the stability-throughput compromise leads one to conclude that 
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for serious pharmaceutical applications, 3DP can only be properly investigated with a 




6.2. Future Outlooks 
6.2.1. Overcoming materials limitations: 
As previously discussed, the current biggest limitation against pharmaceutical adaptation 
of FDM is the restriction of the feeding mechanism. The formulation of a filament suitable 
for FDM is a complex process. This complexity may be the reason why the soaking 
method for filament drug loading continues to see use despite its inadequate drug loading 
capacity (128,178,211). The restriction imposed by the feeding mechanism led to the 
conclusion that, as it stands, filament-based FDM is not fit for pharmaceutical 
applications. Attempts at re-engineering the feeding mechanism have been conducted, the 
most notable of which is the Arburg® Freeformer Droplet Extrusion 3D printer (212). 
This 3D printer is similar to FDM in that it is a polymer melt deposition process. However, 
it is notable for having a unique feeding mechanism that is adapted from injection 
moulding. The feedstock of the 3D printer utilises pellets, which are propelled through 
the melting zone by single screw melt extruder. The polymer melt is then deposited in the 
nozzle cavity and then injected droplet-wise on the build plate. (Figure 6-1) 
 
 





To date, this printer has not been used in a pharmaceutical context. A comparative study 
similar to what was presented in Chapter 4, comparing a conventional FDM printer with 
the Arburg® Freeformer is perhaps a logical next step. It is clear from the filament-free 
design that this printer can accommodate a wider library of materials due to the absence 
of mechanical restrictions. But an investigation of its precision is needed before 
considering it for serious pharmaceutical applications.  
 
6.2.2. Overcoming machine limitations:  
As previously discussed, the Makerbot® Replicator 2 FDM 3D printer has been treated 
as a the de facto “standard” 3D printer for pharmaceutical use. It is obvious that the printer 
is not fit for purpose. The issue with build plate levelling discussed in Section 4.4.2. and 
more thoroughly investigated by Melocchi et al. (54) can potentially introduce significant 
variability in the printed dosage forms.  
 
The need to manually level the build plate arises from the design of the Makerbot® 
Replicator 2 3D printer, namely the fact that during printer operation, the build plate does 
not remain stationary, but rather moves in the Z-axis to accommodate the subsequent layer 
once the former has been printed. This design of FDM printers is what is known as a 
Cartesian FDM Printer (213), named so for possessing three motors, each of which moves 
along one axis of the 3-dimensional Cartesian coordinate plane; two motors that move 
the print head in the X and Y axes, and a third that moves the build plate in the Z-axis.  
 
An alternative design of FDM 3D printers called the delta design exists (213). Delta 3D 
printers opt for using a stationary build plate. Delta FDM printers still utilise three motors, 
but in this case all three motors are restricted to moving in the Y-axis exclusively (Figure 
6-. The motors are all connected to the printer head, and offset between the location of 
the three motors at any given time is what moves the print head in 3D space.  
 
All currently available Delta FDM 3D printers still utilise a filament feeding mechanism, 
but they possess the advantage of eliminating the need for levelling the build plate, greatly 
reducing variability that may arise in the 3D printed object due to the subjectivity of 




Figure 6-2: a Delta FDM 3D printer. Image obtained from all3DP.com (213) 
 
A second machine limitation that is critical to overcome is the inability to access the inside 
of the print head for cleaning. Appendix 1 reports an experiment in which calcium 
carbonate salt was incorporated into melt-extruded filaments of HPC. While the filament 
was successfully printed. Repeated use of the filament caused the building up of salt 
deposits inside the nozzle which led to the print head being completely blocked. All 
attempts to clean the nozzle through purging with other polymers or rinsing with solvents 
were unsuccessful, and the entire print head assembly had to be replaced entirely. This 
raises great concerns about the Good Manufacturing Practices (GMP) compliance of 
FDM. It is imperative that any equipment intended to be used for pharmaceutical 
manufacturing be easy to clean. Simply purging the printer nozzle with material prior to 
a print is not sufficient to demonstrate that the innards of the nozzle are thoroughly clean 
and do not contain any contaminants from a previous print. The only way to overcome 
this cleaning limitation is for a print head design in which the innards of the print head, 
including the nozzle, may be accessed for washing and scrubbing.  
 
6.2.3. Generating a deeper understanding of FDM process parameters:  
Process parameters, unlike machine and material parameters, are those which allow for 
the greatest degree of freedom. As such, it would be false to assume the existence of 
“process limitations”. Rather, there is still a need for a deeper understanding of FDM 
process parameters, and how changing process parameters can influence the properties of 
3D printed solid dosage forms.  
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Infill density, as an FDM process parameter, offers unprecedented control over the shape 
and morphology of oral solid dosage forms. Those ‘open systems’ which can be produced 
by printing at low infill density display a more complex drug release behaviour than what 
has been previously observed with traditional dosage forms.  
 
The impact of the fluid dynamics on the release rate from 3D printed tablets observed in 
Chapter 5 is one of interest. As previously mentioned, the dissolution bath apparatus does 
not necessarily reflect physiological conditions. The novel capabilities offered by FDM 
(such as open tablets) make it yet even more challenging to extrapolate meaningful 
expectations of in-vivo performance based on what was seen in-vitro. A study comparing 
the in-vitro-in-vivo correlation (IVIVC) of an FDM printed dosage form vs. a 
traditionally manufactured dosage form is perhaps necessary to gain an understanding of 
the magnitude of this effect. The two standard apparatuses for investigating drug release 
rates in a dissolution bath are the paddle and basket apparatuses. Neither apparatus 
accurately mimics the hydrodynamic environment inside the stomach as the peristaltic 
movement has a different effect on fluid movement than a motor rotating a paddle or a 
basket. Open tablet geometries, such as those presented in Chapter 5, have exposed 
internal structures (roads), such open systems permit solvent flow through the tablet, 
rather than restricting it to the surface of the tablet as is the cases with traditional solid 
dosage forms. Obviously, the rate drug release will be significantly altered by the rate of 
solvent flow through the tablet, leading to significantly different drug release rates when 
the same formulation is investigated under different environments, as was observed in 
Chapter 5. The complex nature of drug release due to this solvent wash-through effect 
makes it exceedingly difficult to confidently extrapolate information about the in-vivo 
performance of open 3D printed tablets based on their in-vitro drug release. Drug release 
from open 3D printed dosage forms is a complex multivariate issue, that is influenced by 
several different variables like the BCS class of the drug, polymer swelling and/or erosion, 
the geometry of the 3D printed tablet, and the hydrodynamic environment in which 
dissolution is taking place. And although drug release kinetics model fitting may provide 
some useful metrics relating to drug release rate, more advanced modelling techniques 
(like computational fluid dynamics modelling) should be explored as means to attempt to 






6.2.4. Future prospects of pharmaceutical FDM 3D printing:  
As it stands, the current greatest hurdle standing against real clinical applications of FDM 
as a pharmaceutical manufacturing tool is an engineering issue, rather than a 
pharmaceutical one. Many an example of proof-of-concept formulations has been 
reported and discussed throughout this work. However, until a fit for purpose FDM printer 
is available, we do not foresee FDM being used in a clinical setting, regardless of the 
abundance of literature demonstrating viable proof-of-concept formulations.  
 
Sections 6.2.1. and 6.2.2. discussed currently available engineering solutions, each of 
which individually solves one of the issues bottlenecking actual commercial applications 
of FDM, namely the feeding issue, and the build plate levelling issue. A pharmaceutical 
FDM printer must incorporate design cues from both to be a fit-for-purpose printer. A 
third consideration for such a fit-for-purpose printer is ease of cleaning. It is beyond the 
scope of this writing (and beyond the capacity of the author) to design and propose a print 
head system whose innards can be accessed for cleaning. It is, however, paramount that 
any future research into pharmaceutical applications of FDM start by designing such a 
print head, which can be then incorporated into a Delta axes system, whose feeding 
mechanism is more friendly towards pharmaceutically-relevant materials.  
 
With the availability of a printer that is functionally (and regulatory) suitable for the 
production of pharmaceutical solid dosage forms. Extensive work should be conducted 
into understanding how the complex geometries which can be produced by FDM affect 
the clinical performance of the produced dosage forms. As discussed in Chapter 5 and in 
Section 6.1.3., the complex geometries which can be produced by FDM mark an 
uncharted territory in pharmaceutical dosage forms. Extensive research into the 
dissolution and bioavailability of the geometrically complex 3D printed dosage forms 
will be necessary to understand how to best leverage the advantages of FDM and translate 
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Incorporation of insoluble salts in the filament 










The rising interest in P3P is mainly due to the prospects it offers in addressing the dosing 
personalisation challenge currently faced by the pharmaceutical industry (4). However, 
the two largest patient demographics who require robust dosing personalisation are 
incidentally the two demographics often regarded as being the least capable of handling 
oral solid dosage forms: paediatric patients and geriatric patients.  
 
The purpose of this experiment was to develop a 3D printable formulation that can rapidly 
disintegrate either ex-vivo (by reconstitution prior to administration), or in the mouth. 
The rationale behind this design is to target patient groups who may have difficulty 
swallowing solid dosage forms, paediatric and geriatric patients. To this end, sodium 
bicarbonate (NaHCO3) was chosen as a disintegration enhancing material. The 
hypothesised mechanism in which NaHCO3 would induce the disintegration of a 3D 
printed dosage form is by compromising the structural integrity of the roads comprising 
the printed object, causing the collapse of the 3D structure upon hydration. 
Hydroxypropyl cellulose (HPC) was chosen as the main matrix-forming polymer because 
the polymer has been reported to yield mechanically suitable filaments without the need 






A1.2. Materials and methods 
A1.2.1. Materials: 




A1.2.1.1. Preparation of filament: 
The HPC-NaHCO3 filament was prepared by HME using an extrusion temperature of 
130 °C. The formulation was prepared at two ratios: 95%:5% (HPC:NaHCO3). 
 
Prior to extrusion, the NaHCO3 was milled using a ball mill at 30 oscillations per second 
for 5 minutes, to ensure that the particle size was smaller than the 400 µm printer nozzle.  
 
A1.2.1.2. 3D printing 
3D printing was attempted at 130 °C, 135 °C, and was successful at 140 °C. The STL file 
used for printing this formulation was the 10 mm diameter x 2 mm thickness cylinder 
described in section 5.2.3. Layer thickness was set to 0.2 mm.  
 
A1.2.1.3. Scanning Electron Microscopy 
SEM, coupled with elemental analysis, was conducted to determine the homogeneity of 
distribution of NaHCO3 particles in the filament.  
 
A1.2.1.4. Laser Diffraction 
Laser diffraction was conducted to determine the particle size of NaHCO3 both as 
purchased and post-milling.  
 
A1.2.1.5. Texture Analysis 
Texture analysis of both pure HPC filament, and the HPC + NaHCO3 filament were 
conducted as per the method outlined in Chapter 3. The flexibility profiles of ABS, 
Mowiflex, and formulation HP10 were used as positive controls. The flexibility profiles 




A1.3. Results and discussion 
A1.3.1. Filament feedability testing: 
Figure  A-1 shows the Loadings Plot of the filament feedability testing. Both the pure 
HPC filament and the filament loaded with 5% NaHCO3 clustered with the Mowiflex 
filament, indicating that both filaments possess suitable mechanical properties to be 
deemed feedable.  
 
 
Figure A1-1: PCA loadings plot showing the feedability of the HPC-based filament. 
HPC5Bicarb: filament loaded with 5% NaHCO3. 
 
Table A1-1 shows the rounded correlation scores for the HPC-based filaments with all the 
control filaments. Similar to the results extracted from the loadings plot. The flexibility 
profiles of both HPC-based filaments were found to correlate with those of feedable 
filaments (ABS, Mowiflex, and HP10), and not correlate with the non-feedable, brittle 
filaments.  
 
Table A1-1: Rounded correlation scores of the tested filaments 
Tested filament  ABS Eudragit 
EPO 
Mowiflex Soluplus Copovidone HP10 
HPC + NaHCO3  1 0 1 0 0 1 







A1.3.2. Particle size analysis of the sodium bicarbonate:  
Figure A1-2 shows the laser diffraction pattern of the NaHCO3 as purchased. The smallest 
10% of particles possessed a particle size ≤ 21.58 µm, the median particle size was ≤ 
80.63 µm. At the 90th quartile was ≤ 810.79 µm. Notably, the diffractometer issued a 
warning that the presence of coarse particles exceeding the quantification limit of the 
diffractometer was detected. Suggesting that the true average particle size distribution of 
the NaHCO3 powder is much larger than what was possible to quantify.  
 
 
Figure A1-2: particle size distribution of unprocessed NaHCO3 powder. 
 
The presence of coarse particles exceeding the nozzle diameter of the printer is not desired 
as it will lead to blockages of the printer nozzle. Furthermore, NaHCO3 is to be suspended 
as is in the matrix of the HPC, therefore, a finer particle size distribution is desired to 
allow for homogeneous dispersion of the salt particles within the matrix. Therefore, the 
NaHCO3 powder was milled using a ball mill at a frequency of 30 oscillations per second, 
for 5 minutes. Figure A1-3 below shows the particle size distribution of the milled powder.  
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As can be seen in Figure A1-3, the 10th quartile of particle size distribution was ≤ 7.01 
µm.  The median particle size was ≤ 41.48 µm, and the 90th quartile was ≤ 98.43 µm. 
With 100% of the particles possessing a particle size smaller than 200 µm. This was 
deemed appropriate for the purpose of this experiment, as 100% of the particles were 
smaller than the nozzle diameter (400 µm). 
 
A1.3.3. Scanning Electron Microscopy: 
Figure A1-4 shows the SEM images of the pure HPC polymer. Both the surface and the 
cross-section of the pure HPC filament. The morphology of the filament was largely 
unremarkable, with the exception of some visible cracking in the cross-section of the 
polymer, which is assumed to be a scar caused by the razor blade used to expose the cross-
section.  
 
Figure A1-4: Surface (right) and cross-section (left) SEM images of pure HPC filament. 
 
Figure A1-5 shows the surface and cross-section SEM images of the NaHCO3-loaded 
HPC filament. There is a notable increase in surface roughness compared to the pure HPC 
filament shown in Figure A1-4. Deposits of what appears to be a crystalline material are 
also visible on the surface of the polymer and in the cross-section. Furthermore, cavities 
that are clearly different from the razor scarring mentioned prior are clearly visible in the 
cross-section of the polymer. Those cavities were likely formed during HME due to 
expelled moisture from the polymer reacting with a fraction of the NaHCO3, expelling 




Figure A1-5: Surface (top) and cross-section (bottom) SEM images of HPC filament in which 
5% NaHCO3 has been incorporated. 
 
To clearly visualise the uniformity of distribution of the NaHCO3 within the matrix, 
elemental mapping for carbon and sodium was conducted. The surface mapping images 
can be seen below in Figure A1-6. The locations of the crystalline deposits previously 
mentioned correspond to the locations in which sodium was detected, indicating that the 
majority of said crystalline deposits are NaHCO3 salt crystals. Furthermore, some sodium 
was detected on the outline of the aforementioned cavities in the matrix. This supports 
the previous hypothesis that the pockets were brought about by the reaction between 
NaHCO3 and water present due to residual moisture. The presence of sodium in the 
vicinity of the air pockets indicates that that is a location in which the water-bicarbonate 
reaction has taken place, and sodium detected is actually sodium carbonate (Na2CO3), 






Figure A1-6: Elemental analysis mapping for carbon (left) and sodium (right) within the matrix 
of the filament (bottom) 
 
A1.3.4. Disintegration time testing:  
Figure A1-7 shows a picture of the tablet printed using the 5% NaHCO3 filament. To test 
the disintegration ability of the tablet, the tablet was placed in a 10 ml syringe, distilled 





Figure A1-7: 3D printed HPC-NaHCO3 tablet. 
 
This method of testing was used to mimic a real-life situation in which the tablet would 
be used by a patient, as the purpose of the formulation is to have the tablet be disintegrated 
ex-vivo prior to administration. The tablet was indeed found to disintegrate, taking 
approximately 9 minutes until it disintegrated sufficiently to be injected from the syringe 
into a glass vial (Figure A1-8).  
 
 
Figure A1-8: HPC-NaHCO3 tablet post-disintegration 
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On attempting to replicate the results of this experiment, printing a pair of two more 
tablets for replication was planned. However, upon attempting to print a set of tablets to 
replicate the experiment, the printer nozzle was found to be severely clogged. Attempts 
to unblock the nozzle using sufficiently thin needles, flushing with ABS, and even rinsing 
with water were attempted with no success. The nozzle had been so severely blocked that 
it had to be replaced. Unfortunately, this replacement required swapping the entire print 
head assembly. This severe blockage is assumed to be due to deposits of NaHCO3 






The disintegration time for the trialled tablet was just over 9 minutes, which much longer 
than what is expected of a rapidly disintegrating formulation to achieve in order to be 
convenient for the patient. However, while anecdotal evidence of the sole trialled tablet 
suggests that with optimisation of the formulation, a rapidly disintegrating FDM-printed 
tablet may be achievable, replication of the results achieved was not possible, it, therefore, 
remains unclear whether the formulation trialled can reproducibly perform as reported.  
 
The presence of the insoluble NaHCO3 salt in the formulation led to a nozzle block that 
could not be resolved without undergoing an expensive replacement of the print head. 
This leads to either of two hypotheses: the first is that the particle size (100% of particles 
< 200 µm) was still much larger than what can be realistically processed through a 400 
µm nozzle. The second is that printing of filled polymers is simply not possible due to 
particle build up in the nozzle. There is clearly a need to investigate this further, as the 
incorporation of insoluble inorganic solids like salts or clays is a commonly used 
pharmaceutical formulation tactic for enhancing the performance of some dosage forms. 
However, further investigation of this phenomenon was not possible. Repairing the 
blocked nozzle required purchasing a new print head assembly (£350), and the delivery 
time for the new print head was two months. Investigating the blocking phenomenon was 
deemed too severe a fiscal gamble should such experiments lead to yet another blocked 
nozzle. The observations presented herein are intended to advise against printing using 
filled polymers until this build up and blockage phenomenon has been thoroughly 






Drug release rates from the acetylsalicylic acid-








Chapter 4 presented an investigation into the quality parameters and limitations of FDM 
as a tool for the manufacture of pharmaceutical dosage forms. The polymer used for that 
investigation was PCL. As part of that investigation, PCL was loaded with either 5%, 
10%, or 15% ASA, to investigate the impact of drug loading on the FLE. On publishing 
that experiment (173), the addition of an investigation of the drug release rate from the 
3D printed grids was recommended by the reviewers. While it is in the views of the author 
that the drug release studies have no experimental context in the scope of the aims of what 
was presented in Chapter 4, they were nonetheless conducted but were excluded from the 





A2.2. Materials and methods 
A2.2.  In-vitro drug release studies: 
ASA release studies from the 5%, 10%, and 15% loaded 3D printed grid films were 
conducted using the United States Pharmacopoeia (USP) apparatus II (paddle) using a 
revolution rate of 50 RPM. The grids were placed in 750 mL of pH 1.2 simulated gastric 
fluid for 2 hours, then transferred to 900 mL of pH 6.8 phosphate buffer saline. 
Determination of amount of ASA released was conducted using a Perkin Elmer Lambda 
35 UV/Vis spectrophotometer (PerkinElmer, Inc., Waltham, MA, United States) at a 
wavelength of 265 nm (214). 
 
A2.3. Results and Discussion: 
Figure A2-1 shows the in vitro drug release rates for the 5%, 10%, and 15% ASA-loaded 
formulations in PCL. A significant difference in the release rate of the 5% formulation 
compared to its higher loading counterparts was observed. Both the 10% and 15% 
formulation achieved ~100% release in under 300 min. The 5% drug-loaded formulation, 
however, had released only ~30% of the drug after 8 h. As previously discussed, the 5% 
drug-loaded formulation was the only formulation in which the ASA was molecularly 
dispersed within the matrix of PCL, while both 10% and 15% drug-loaded contained 
phase-separated crystalline ASA. This is further evidenced by the aforementioned 
differences in release rate. PCL is a biodegradable polymer that is commonly used for 
implantable, long-term release formulations (123). It is insoluble in aqueous media and 
only degrades over time via hydrolysis of its ester linkages in physiological conditions. 
In the 5% drug-loaded formulation, the ASA is molecularly dispersed within the polymer, 
thus the drug release relies on the slow diffusion of ASA molecules from the PCL matrices 
and the polymer degradation. On the other hand, the 10% and 15% drug-loaded 
formulations contain phase-separated crystalline ASA which can dissolve much faster. 





Figure A2-1: In vitro drug release profiles of FDM printed PCL films containing 5%, 10%, and 
15% ASA. 
 
